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Preeclampsia is a pregnancy disorder that greatly impacts maternal and fetal/neonatal health and 
wellbeing.  This case-control candidate gene association study investigated endoglin pathway 
genetic variation and its association with preeclampsia.  Tagging single nucleotide 
polymorphisms (tSNPs) in ENG, TGFβ1, TGFβR1, ALK1, and TGFβR2 were genotyped with 
iPLEX® and TaqMan® in maternal/fetal dyads.  The Prenatal Exposures and Preeclampsia 
Prevention study provided maternal DNA extracted from peripherally collected white blood cell 
pellets, along with umbilical cord serum we used for fetal DNA extraction.  Data on 355 white 
(181 cases/174 controls) and 60 black (30 cases/30 controls) women matched on ancestry, age, 
and parity were analyzed.  Separate subgroup allele/genotype/haplotype tests were conducted 
with Chi-square or Fisher’s exact tests.  Binary logistic regression provided odds ratios for tSNPs 
with significant genotype tests.  Analysis of maternal/fetal dyads was not conducted, because 
unlike the maternal samples, the fetal samples did not provide a quality template suitable for 
iPLEX® data collection.   In white women, variation in ENG (rs11792480, rs10121110) and 
TGFβR2 (rs6550005) was associated with preeclampsia.  Allelic frequency distributions in 
rs11792480, rs10121110, and rs6550005 were significantly different among cases and controls 
while genotype distributions of rs10121110 and rs6550005 were further associated with 
preeclampsia (p-values < .05).  For rs10121110, women with the AA genotype were 2.290 times 
more likely to develop preeclampsia compared to the GG genotype (99% CI [1.022, 5.133], p = 
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.008).  ENG haplotype TACGA, which contains rs11792480 and rs10121110 risk alleles, was 
also over-represented in cases (p = .022).  In black women, variation in TGFβ1 (rs4803455, 
rs4803457), TGFβR1 (rs10739778), and TGFβR2 (rs6550005, rs1346907, rs877572) was 
associated with preeclampsia.  Allelic frequency distributions in rs10739778, rs6550005, 
rs1346907, and rs877572 were significantly different among cases and controls while genotype 
distributions of rs10739778, rs4803455, and rs4803457 were further associated with 
preeclampsia (p-values < .05).  For rs4803457, women with the CT genotype were 7.437 more 
times likely to develop preeclampsia compared to the CC genotype (99% CI [1.192, 46.408], p = 
.005).  These results demonstrate that variation in ENG pathway genes is associated with 
preeclampsia, with different genes from the same pathway contributing to preeclampsia in white 
compared to black women.   
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1.0  PROPOSAL INTRODUCTION 
Preeclampsia represents a hypertensive, multi-system pregnancy disorder that is significantly 
associated with maternal and fetal/neonatal morbidity and mortality (National Heart, Lung, and 
Blood Institute [NHLBI] National High Blood Pressure Education Program, 2000).  In 
preeclampsia, shallow trophoblast invasion, insufficient remodeling of the maternal vessels 
perfusing the placenta (Brosens, Robertson, & Dixon, 1967; Brosens, Roberston, & Dixon, 1972; 
Gerretsen, Huisjes, & Elema, 1981; Khong, De Wolf, Robertson, & Brosens, 1981; Zhou, 
Damsky, Chiu, Roberts, & Fisher, 1993; Zhou, Damsky, & Fisher, 1997), and alterations in 
vascular endothelial function (American College of Obstetricians and Gynecologists [ACOG], 
2002) have been well documented.  However, the underlying processes responsible for these 
aberrations have not been fully elucidated and the only curative treatment remains delivery.  As a 
result, it is imperative that scientific research continues to investigate the underlying mechanisms 
contributing to preeclampsia development.  Such research can be utilized to design interventions 
(prevention, detection, treatment) that improve health outcomes of mothers and babies. 
Gene expression studies have identified endoglin (ENG) as a factor potentially involved 
in preeclampsia development (Farina et al., 2008; Kim et al., 2009; Levine et al., 2006; Lim et 
al., 2009; Masuyama, Nakatsukasa, Takamoto, & Hiramatsu, 2007; Nishizawa et al., 2007; Rana 
et al., 2007; Robinson & Johnson, 2007; Romero et al., 2008; Salahuddin et al., 2007; Sitras et 
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al., 2009; Stepan et al., 2008; Toft et al., 2008).  ENG is a co-receptor of the TGF-β family 
(Cheifetz et al., 1992) that is involved in regulation of  trophoblast invasion (Caniggia, Taylor, 
Ritchie, Lye, & Letarte, 1997) and vascular endothelial function (Jerkic et al., 2004; Toporsian et 
al., 2005), two processes disrupted in preeclampsia (Roberts & Hubel, 2009).  Given ENG’s 
biological plausability in preeclampsia development, further research investigating its potential 
role in preelcampsia is warranted and may improve our understanding of preeclampsia.   
1.1 PURPOSE AND SPECIFIC AIMS 
Because investigation of the ENG pathway at the molecular level is needed, this pathway 
specific, candidate gene, nested, case-control research study will:  
1. Investigate variation in maternal genes involved in the ENG pathway for impact on 
development of preeclampsia 
2. Explore variation in maternal/fetal dyad genes involved in the ENG pathway for impact on 
development of preeclampsia 
 The candidate’s broad, long term objective of her program of research is to improve the 
scientific/healthcare community’s knowledge of preeclampsia pathophysiology in an effort to 
reduce the overall morbidity and mortality associated with preeclampsia.  Study findings from 
this proposed disseration research will assist in the achievement of this long term objective.   
Results from this proposed research study may explain variability in susceptibility to 
preeclampsia, increase knowledge of preeclampsia pathophysiology, and assist in the 
development of interventions aimed at the prevention, detection, and treatment of preeclampsia. 
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1.2 BACKGROUND AND SIGNIFICANCE 
Preeclampsia (PE), which is characterized by the development of hypertension and proteinuria 
after 20 weeks’ gestation in a previously normotensive woman, significantly impacts maternal 
and fetal/neonatal morbidity/mortality (ACOG, 2002; NHLBI National High Blood Pressure 
Education Program, 2000).  Complicating 3-5% of pregnancies (Roberts & Cooper, 2001), PE is 
estimated to cost the USA $7 billion annually (Preeclampsia Foundation, 2000-2010).  Potential 
short term maternal complications include placental abruption, disseminated intravascular 
coagulation, cerebral hemorrhage, renal/hepatic failure, and death (NHLBI National High Blood 
Pressure Education Program, 2000) while short term fetal/neonatal complications include IUGR, 
low amniotic fluid levels (ACOG), premature birth, low birth weight, and stillbirth (NHLBI, 
n.d.).  In addition, the development of PE can remotely impact the health of the mother and her 
infant.  Long term maternal complications include elevated cardiac morbidity (Berends et al., 
2008; Brown et al., 2006; Forest et al., 2005) and mortality (Arnadottir, Geirsson, Arngrimsson, 
Jonsdottir, & Olafsson, 2005; Irgens, Reisaeter, Irgens, & Lie, 2001).  For premature infants, 
long term complications include increased risk of cerebral palsy, mental retardation, chronic lung 
disease, and vision/hearing problems (March of Dimes, 2007).  Despite the range of short and 
long term complications, efforts to prevent these sequelae are impeded by the unknown etiology 
of PE.  As a result, interventions are symptom driven and delivery of the placenta is the only 
known cure (Norwitz & Repke, 2010). 
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1.2.1 Rationale for genetic research 
PE is to some extent based on hereditability (Nilsson, Salonen Ros, Cnattingius, & Lichtenstein, 
2004; Skjaerven et al., 2005), which provides justification for candidate gene studies.  In 
daughters born to mothers diagnosed with PE during pregnancy, research has shown that these 
daughters had 2 times the odds of developing PE compared with other women (OR =2.2; 95% CI 
[2.0-2.4]) (Skjaerven et al.).  Research has also shown that when comparing a woman whose full 
sister did not develop PE during pregnancy, a woman whose full sister developed PE during 
pregnancy had 3 times the odds of developing PE during her pregnancy (OR=3.3; 95% CI [3.0-
3.6]) (Nilsson et al.).  Moreover, in sons of mothers diagnosed with PE during their pregnancy, 
the odds of fathering a PE pregnancy in the first pregnancy with their partner has been shown to 
be increased (OR=1.5; 95% CI [1.3-1.7]) (Skjaerven et al.).  Thus, evidence suggests that PE 
may be partly attributed to inheritance. 
1.2.2 Biological plausibility of endoglin (ENG) 
ENG is a membrane bound glycoprotein and co-receptor of transforming growth factor beta 
(TGFβ) (Cheifetz et al., 1992) that modulates TGFβ signal transduction via interaction with 
TGFβ type 1 and 2 receptors (Guerrero-Esteo, Sánchez-Elsner, Letamendia, & Bernabéu, 2002).  
TGFβ ligands first bind to a receptor complex comprised of a type I (e.g., ALK1 and ALK5) and 
type II receptor (TGFβR2).  Once this complex is activated, the cellular signal is transferred to 
the mothers against DPP homologs (SMAD) proteins.  The SMAD proteins transmit TGFβ 
signals from the cell-surface receptors to the nucleus and, as nuclear effectors, are involved in 
5 
 
the regulation of target gene transcription (Lebrin, Deckers, Bertolino, & ten Dijke, 2005; Online 
Mendelian Inheritance in Man [OMIM], 2010; ten Dijke, Goumans, & Pardali, 2008).  
ENG is expressed on syncytiotrophoblasts/transitioning cytotrophoblast cells of the 
placenta (St-Jacques, Forte, Lye, &Letarte, 1994) and appears to be involved in regulation of 
placental trophoblast differentiation/invasion of the uterus during pregnancy (Caniggia et al., 
1997).  In PE, trophoblast cells fail to adequately invade maternal spiral arteries, converting them 
from small muscular vessels to large low resistant vessels.  Without this conversion, arterial 
lumen diameter/distensibility is limited, leading to reduced placental and fetal perfusion 
(Brosens, Robertson, & Dixon, 1967; Brosens, Roberston, & Dixon, 1972; Gerretsen, Huisjes, & 
Elema, 1981; Khong, De Wolf, Robertson, & Brosens, 1981; Zhou, Damsky, Chiu, Roberts, & 
Fisher, 1993; Zhou, Damsky, & Fisher, 1997).  The mechanisms responsible for reduced 
placental and fetal perfusion secondary to abnormal placentation are presently unknown; 
however, ENG’s role in placental implantation lends support to its potential involvement in PE.   
Moreover, research examining placental mRNA levels in women with/without PE has 
demonstrated that first/third trimester placental samples of women who went on to develop PE 
had significantly elevated levels of ENG expression (Farina et al., 2008; Nishizawa et al., 2007; 
Sitras et al., 2009; Toft et al., 2008).  
In addition to abnormal placentation, vascular endothelial function is altered in PE 
(ACOG, 2002).  ENG, which is expressed on vascular endothelial cells (Gougos & Letarte, 
1990), has been shown to be involved in the maintenance of vascular tone via the regulation of 
nitric oxide-dependent vasodilation (Jerkic et al., 2004; Toporsian et al., 2005).  Normally, 
endothelial nitric oxide synthase (eNOS) receives activation signals when the TGFβ1 ligand 
binds to its receptor complex (Venkatesha et al., 2006).  However, a placentally derived, soluble 
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form of ENG (sENG) found to be significantly elevated in the blood of women with PE (Kim et 
al., 2009; Levine et al., 2006; Lim et al., 2009; Masuyama et al., 2007; Rana et al., 2007; 
Robinson et al., 2007; Romero et al., 2008; Salahuddin et al., 2007; Stepan et al., 2008) may 
impair TGF-β1 ligand binding (Venkatesha et al.).  As a result, it is believed that the 
sequestering of TGF-β1 by elevated levels of sENG affects downstream signaling of other genes 
and may contribute to the observed clinical sequelae (Venkatesha et al.). 
Despite these findings, research of the ENG pathway at the molecular level in PE is 
lacking.  A study by Srinivas, Morrison, Andrela, and Elovitz (2010), which explored the 
association of allelic variation in the closely related angiogenic pathway with PE, failed to find a 
significant association between ENG and PE.  Because evaluation of ENG in the context of the 
ENG pathway has not been completed, such an investigation has the potential to explain 
variability in susceptibility to PE, improve understanding of PE, and assist in the development of 
interventions. 
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1.2.3 ENG pathway candidate genes 
The following table lists the ENG pathway genes selected for evaluation in this study along with 
the rationale for their inclusion. 
Table 1. Endoglin Pathway Candidate Genes 
Gene Rationale for Inclusion 
ENG Co-receptor of TGFβ1; involved in regulation of placental trophoblast 
differentiation/invasion and vascular tone (Caniggia et al., 1997; 
Cheifetz et al., 1992; Jerkic et al., 2004; Toporsian et al., 2005)  
 
TGFβ1 Ligand bound by ENG; involved in regulation of proliferation, 
differentiation, and migration of many cell types, including trophoblasts.  
In endothelial cells, downstream signaling leads to eNOS expression 
(Jerkic et al., 2004; Jones, Stoikos, Findlay, & Salamonsen, 2006; 
National Center for Biotechnology Information [NCBI], 2010; OMIM, 
2010; Toporsian et al., 2005; Santibanez et al., 2007); TGFβ1 mRNA 
levels (11 week chorionic villous) significantly higher in women who 
later developed preeclampsia compared to healthy controls (Farina et al., 
2008) 
 
ALK1 
(ACVRL1) 
 
Type 1 receptor of TGFβ1;forms a heterodimeric complex with Type 2 
receptor (TGFβR2); responsible for transmission of TGFβ1 signals; 
interacts with ENG (Guerrero-Esteo et al., 2002; OMIM, 2010; ten 
Dijke et al., 2008) ALK5 (TGFβR1) 
 
TGFβR2 Type 2 receptor of TGFβ1; forms a heterodimeric complex with Type 1 
receptors; responsible for transmission of TGF-β1 signals; interacts with 
ENG (Guerrero-Esteo et al., 2002; OMIM, 2010; ten Dijke et al., 2008)  
 
SMAD1, 2, 3, 4, 5, 6, 
7, 8 
Proteins involved in transmission of TGFβ1 signals from cell-surface 
receptors to the nucleus (OMIM, 2010; ten Dijke et al., 2008) 
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1.2.4 Conceptual framework 
The following figure diagrams the conceptual framework that guided this study, which examined 
the association between the genetic composition of the ENG pathway and the development of 
preeclampsia while accounting for potential covariates (e.g., age, race). 
 
 
 
 
 
 
 
 
Figure 1. Conceptual Framework 
1.2.5 Potential covariates 
The development of multi-faceted disorders, including PE, can be influenced by genetic and 
environmental factors.  Although the proposed pathway specific, candidate gene association 
study will focus on the association between the genetic composition of the ENG pathway and 
susceptibility to/protection from PE, other risks factors may contribute to PE development.  In 
attempt to control for the potential effects of several covariates, healthy controls will be 
frequency matched (1:1) to cases on maternal age, ancestry/race, and parity.  The following table 
provides rationale for matching on maternal age, ancestry/race, and parity. 
Potential Covariates 
 
age, ancestry/race, 
diabetes, obesity, history 
of PE, HTN, parity 
 
Genetic 
Composition 
 
Genes involved in 
ENG Pathway 
Preeclampsia 
 
Susceptibility 
to/protection from PE 
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Table 2. Covariates 
Risk Factor Supporting Literature 
Age PE is more common at extremes of reproductive age (ACOG et al., 2010; Funai, 
Evans, & Lockwood, 2008; London, Ladewig, Ball, & Bindler, 2003) 
 
Primiparous women ≥ 40 are 1.68 times as likely to develop PE compared to 
primiparous women < 40 (note: cohort study failed to control or address 
differences at baseline; e.g., preexisting HTN or diabetes) (Duckitt & Harrington, 
2005) 
 
Multiparous women ≥ 40 are 1.96 times as likely to develop PE compared to 
multiparous women < 40 (note: cohort study failed to control or address 
differences at baseline) (Duckitt & Harrington) 
 
Ancestry PE more likely to occur in African American women (ACOG et al., 2010; London, 
Ladewig, Ball, & Bindler, 2003) 
 
Parity Nearly 2/3rds of PE pregnancies occur in nulliparas (Funai, Evans, & Lockwood, 
2008) 
 
Nulliparous women are 2.91 times as likely to develop PE compared to 
multiparous women (Duckitt & Harrington, 2005) 
 
Note. All citations labeled (Duckitt & Harrington, 2005) are presented as unadjusted relative 
risks 
 
1.2.6 Summary 
Despite decades of research, preeclampsia continues to significantly impact the lives of mothers 
and their fetuses/neonates worldwide.  In order to improve short/long term health outcomes and 
reduce healthcare costs associated with preeclampsia, a more comprehensive understanding of 
preeclampsia’s etiology is needed.  Because previous research has demonstrated endoglin’s 
biological plausibility in the development of preeclampsia, further investigation of endoglin is 
10 
 
warranted.  Given that preeclampsia most likely represents a polygenic disorder, investigation of 
endoglin and other genes in its pathway may generate a more detailed representation of the 
endoglin pathway’s potential role in preeclampsia development. 
1.2.7 Significance and innovation 
This project targets the ENG pathway at the molecular level to investigate the impact of genetic 
variation in the ENG pathway of PE.  This proposed project is innovative in the following ways: 
1. Study of the ENG pathway in PE at the molecular level is novel. 
2. Results from the project will add to the knowledge base of PE pathogenesis, potentially 
resulting in clinically relevant biomarkers of susceptibility to PE and early identification 
of at risk individuals. 
3. The project supports the National Institute of Nursing Research’s (NINR) research 
emphasis of promoting health and preventing disease through identification of 
susceptibility genes for at-risk individuals. 
1.3 PRELIMINARY STUDIES 
The following table lists several milestones that have been achieved since entrance into the BSN 
to PhD program in September of 2007.  All milestones listed support the feasibility and scientific 
merit of the proposed dissertation research project titled “Genomics of Endoglin Pathway in 
Preeclampsia.” 
11 
 
 
Table 3. Milestones 
Milestone Date 
PEPP committee approval of submitted research proposal: granted access 
to de-identified biological samples and data from the PEPP research 
study 
 
January 22, 2009 
Ruth F. Kirschstein National Research Service Award (1F31NR011379) 
for proposed dissertation research (Genomics of Endoglin Pathway in 
Preeclampsia) 
 
July 7, 2009 
Receipt of PEPP de-identified biological samples (maternal DNA 
aliquots, fetal cord serum aliquots, and placental samples are stored in the 
School of Nursing Molecular Genetics Laboratory) 
 
October 2, 2009 
University of Pittsburgh IRB Approval (expedited review) 
 
December 2, 2009 
Sigma Theta Tau International Honor Society of Nursing, Eta Chapter 
Research Award (Genomics of Endoglin Pathway in Preeclampsia) 
 
May 28, 2010 
Renewal of Ruth F. Kirschstein National Research Service Award 
(1F31NR011379): year #2 
 
July 19, 2010 
IRB Renewal Approval 
 
September 16, 2010 
International Society of Nurses in Genetics Research Grant (Genomics of 
Endoglin Pathway in Preeclampsia) 
 
October 13, 2010 
 
1.3.1 DNA extraction 
In addition to these milestones, DNA extraction from the 300 ul fetal serum samples provided by 
PEPP has been initiated.  Using the QIAGEN QiAMP DNA Mini Kit, a total of N = 466 fetal 
samples have been processed as of November 2010.  DNA yield of the extracted samples has 
12 
 
been assessed via Taqman allelic discrimination.  Of the extracted samples tested for DNA 
quality, 92.6% of the samples have passed quality checks.    
1.3.2 Preliminary matching 
Preliminary frequency matching (1:1) of healthy controls to cases (preeclampsia, severe 
preeclampsia, or HELLP syndrome) on maternal age, maternal race, and parity further supports 
the feasibility of the proposed study design.   
1.3.2.1 Matching procedures 
The following procedures were conducted as part of the 1:1 frequency matching.  Controls were 
matched to cases with the same self-reported race (Black/White) and parity. Although the 
majority of controls were matched to cases with the same maternal age, seven controls were 
matched to cases within two years of age due to the lack of healthy women with the same 
maternal age.  One case was excluded from analysis due to the lack of a healthy control subject 
with a comparable maternal age (+/- 2 years), resulting in the matching of 219 healthy controls to 
219 cases.  The majority of healthy control subjects (n = 201) were randomly selected and 
matched to cases (n = 201) for a particular maternal age, race, and parity combination while the 
remaining cases (n = 18) were directly matched with appropriate control subjects (n = 18).   
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1.3.2.2 Preliminary matching results 
Table 4. Preliminary Matching Results 
Characteristic Cases (N = 219) Controls (N = 219) 
Maternal Age (M (SD), years) 
 
27.3 (6.2) 27.4 (6.2) 
Nulliparous (%) 
 
81.3 81.3 
Race 
        White (%) 
Black (%) 
 
85 
 
15 
 
85 
 
15 
 
1.4 RESEARCH DESIGN AND METHODS 
This study will investigate how variation in the ENG pathway may relate to genetic susceptibility 
to/protection from PE using a nested, case/control, candidate gene association design.  De-
identified genetic samples have been obtained from the Prenatal Exposures and Preeclampsia 
Prevention cohort Study (PEPP) and tagging single nucleotide polymorphisms (tSNPs) of genes 
in the ENG pathway will be genotyped and analyzed with respect to the specific aims.  All 
aspects of PEPP have been approved by the University of Pittsburgh and Magee-Womens 
Hospital IRB, including the use of samples/data for genetically-based research.  Permission to 
access these samples was granted by PEPP’s Advisory Committee and IRB approval was 
obtained for this dissertation study.  The timeline for this study, which was submitted to the 
National Institute of Nursing Research as part of the candidate’s F31 2010 grant renewal 
paperwork (1F31NR011379), is included below. 
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 Table 5. Study Timeline 
 
 
 
 
 
 
1.4.1 Setting and sample 
The Prenatal Exposures and Preeclampsia Prevention cohort study (PEPP), which is conducted at 
Magee-Womens Hospital of UPMC (Pittsburgh, Pa), examines factors predisposing women to 
PE via two recruitment approaches.  The proposed study will utilize samples/data collected from 
the first two cohorts.  In PEPP’s first two cohorts, women 14-44 years of age were 
recruited/enrolled during early pregnancy (≤ 20 weeks’ gestation) and followed through 
delivery/postpartum period at Magee-Womens Hospital or they were recruited/enrolled at the 
labor/delivery unit of Magee-Womens Hospital due to a suspected diagnosis of preeclampsia. 
Women with a history of chronic renal disease, hypertension, diabetes, or other disorders that 
increased the risk of preeclampsia were excluded from longitudinal enrollment. Cross-sectionally 
enrolled women found to have the aforementioned conditions were excluded from any analyses 
involving women with preeclampsia and healthy controls.  
Demographic, clinical, and laboratory data were collected by trained interviewers.  
Genomic DNA was extracted from peripherally collected venous blood samples via protein 
Adjusted Timetable For Project Year 1  Year 2  Year 3  
Coursework     
DNA extraction from fetal cord blood samples      
Conduct bioinformatics for SNP selection and 
design custom genotyping panes 
    
DNA dilutions and Whole Genome 
Amplification 
    
Collection of genotyping data      
Analysis of data     
Preparation of manuscripts     
Defend dissertation     
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precipitation from white blood cell pellets. All aspects of PEPP, including the use of 
samples/data for genetically-based research, were approved by the University of Pittsburgh and 
Magee Womens Hospital Institutional Review Board (IRB). Separate University of Pittsburgh 
IRB approval was also granted for this nested study.  PEPP subjects not consenting to future 
genetic evaluation and subjects without a stored genetic sample were excluded from this study. 
1.4.1.1 Phenotype definitions 
Designation of pregnancy outcome is based on review/discussion of clinical data by a clinical 
expert panel.  The case group includes subjects diagnosed with either preeclampsia (PE), severe 
PE, or HELLP syndrome while the control group includes healthy subjects without past medical 
histories. 
1. Cases:  
PE was based on blood pressure (BP), urinary protein, and serum uric acid criteria.  
Hypertension (HTN) = BP ≥ 140 mmHg systolic and/or 90 mmHg diastolic AND an 
increase of BP > 30 mmHg systolic and/or 15 mmHg diastolic after 20 weeks’ gestation, 
which were based on the average of the last five BPs taken in the hospital prior to 
therapeutic intervention (medication; anesthesia) compared to the average BP prior to 20 
weeks’ gestation.  BP abnormalities were to resolve by 12 weeks postpartum.  Proteinuria 
= ≥ 300 mg/ 24hours, ≥ 0.3 protein/creatinine ratio, ≥ 2+ on a random urine specimen, or 
≥ 1+ on a catheterized urine specimen.  Hyperuricemia = serum uric acid concentration > 
1 standard deviation from normal for gestational age.  
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Severe PE = PE + ≥ 1 of the following conditions: (1) systolic BP ≥ 160 mmHg; (2) 
diastolic BP ≥ 110 mmHg; (3) proteinuria ≥ 5 grams/ 24 hours; (4) elevated liver 
enzymes; (5) platelet count ≤ 100,000 
HELLP syndrome = PE + presence of hemolysis, elevated liver enzymes, and low 
platelets 
2. Controls:   
 Women who were clinically evaluated and did not meet the above criteria for PE   
1.4.1.2 Sample breakdown and matching 
The proposed study sample consists of 1473 maternal subjects (n = 225 cases; n = 1248 controls) 
with banked samples, demographic, clinical, and laboratory data.  There are 1027 maternal 
subjects classified as White, 405 classified as Black, 8 classified as Hispanic, 22 classified as 
Asian/Pacific, 2 classified as Native American, and 9 classified as “Other”.  A total of 1493 
fetal/neonatal samples (222 from case pregnancies; 1271 from control pregnancies), along with 
demographic and clinical data are also available (Note: 23 women were enrolled in PEPP for two 
different pregnancies.  A fetal sample from the second enrollment was also provided).   Controls 
will be frequency matched (at least 1:1) to cases on ancestry, maternal age, and parity. Other 
potential confounders and covariates detected in the preliminary analyses will be controlled for 
in the primary analyses. 
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1.4.2 Polymorphism selection for assessment of candidate genes 
Single nucleotide polymorphisms (SNPs) having the potential to be functional based on the 
scientific literature will be included in the assessment of the candidate genes when appropriate.  
Because these SNPs will not fully evaluate a gene, tSNPS for each gene will be selected via the 
HapMap database (www.hapmap.org) in order to fully evaluate the genetic variability of the 
candidate genes with the least number of SNPs.  Promoter regions of the candidate genes will 
also be evaluated within the context of the tSNPs.  Tagging SNP selection criteria includes:  
1. Minor allele frequency ≥ 20% for each tSNP 
2. R2 cutoff  = .80 
3. Caucasian (CEU) and African (YRI) ancestry 
 Due to the dynamic nature of the HapMap database, tSNP selection will be re-evaluated 
immediately prior to the initiation of genotyping efforts. 
1.4.3 Genotype data collection 
The i-PLEX® Gold SNP Assay (Sequenom® Inc, San Diego, CA) will be used for genotype 
data collection by the University of Pittsburgh Genomics and Proteomics Core Laboratories 
(http://www.genetics.pitt.edu/).  Several steps are sequentially followed to determine SNP 
genotypes, whose allelic compositions are differentiated based on differences in molecular mass 
via matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF 
MS) (Sequenom).  This is an appropriate methodology given the number of SNPs to be evaluated 
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and has the advantage of multiplexing therefore reducing assay to assay variability as well as 
reducing costs.  Steps one through four are listed below: 
1. Primer Design: Three primers are designed for each SNP of interest using 
MassARRAY® Assay Design 3.1.  The two amplification primers flank the polymorphic 
site to provide for sample amplification, while the single MassExtend primer lies 
immediately adjacent to allow for allelic discrimination via single base extension.  Assay 
Design software determines how primer sets can be pooled to optimize multiplex 
reactions.  Mass modifications are incorporated in the design of the MassExtend primers 
to maximize the mass differential between primers of different loci within a given 
multiplex pool.   
2. Sample Amplification: Target loci are amplified within the samples by multiplex PCR in 
1X PCR buffer (Qiagen) containing 3.5 mM MgCl2, 25 mMdNTPs, 500 µM each 
forward and reverse amplification primer within the multiplex pool and 2.5 U HotStarTaq 
(Qiagen).  PCR conditions are: 95
o
C for 15 minutes for taq activation followed by 45 
cycles of 94
o
C for 20 seconds, 56
o
C for 20 seconds and 72
o
C for 1 minute.  A single 
extension for 1 minute at 72
o
C completes the PCR reaction. dNTPs and primers are 
removed by incubation with 0.5 U shrimp alkaline phosphotase (SAP) at 37
 o
C for 40 
minutes. SAP is inactivated by incubation at 87
 o
C for 5 minutes.   
3. MassExtend: Excess MassExtend primers corresponding to the loci represented by the 
amplification primers used are pooled.  Higher mass primers are added at a higher 
concentration to adjust for signal drop off during spectra acquisition.  Single base 
extension is carried out in 0.2X iPLEX buffer plus, 1X termination mix (containing mass 
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modified termination nucleotides), 1X iPLEX enzyme and primers at 0.84 μM, 1.04 μM 
and 1.25 μM as appropriate to the relative mass of the primer.  A double cycle 
amplification program performs 40 cycles of denaturation at 94
 o
C for 5 seconds followed 
by 5 cycles of 52
o
C for 5 seconds, 80
 o
C for 5 seconds, back to 94
 o
C for a total of 200 
cycles.  A final extension at 72
 o
C for 3 minutes completes the amplification.  Clean resin 
and water is added to the MassExtend reaction products.  Samples are incubated in clean 
resin at room temperature with mixing for 5 minutes and centrifuged at 3200 x g for 5 
minutes. 
4. Nanodispense, Spectra Acquisition and Analysis: Samples are dispensed to a SpectraChip 
using the MassARRAY® Nanodispenser according to manufacturer’s instructions.  
Spectra chips are loaded into the MassARRAY® analyzer and spectra acquired for each 
sample.  MassARRAY® Typer software uses the known mass of the MassExtend 
primers to identify each locus, and the increase caused by each distinct nucleotide to 
identify the alleles present in the sample. 
1.4.4 Reliability of genotype data and haplotype assignment 
Reliability of genotype data will be evaluated in several steps, with attention focused on 
validation of data for consistency and integrity. Steps include checks comparing expected 
homozygosity to observed homozygosity at each SNP, checks of allele frequencies, 
consideration of genotype call rates, and checks for Hardy-Weinberg Equilibrium consistency. 
Haplotypes will be developed and analyzed in addition to the independent evaluation of each 
SNP.  The HAPLO.CC Function of the HAPLO.STATS Package (Version 1.2.2) of the R 
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Genetics Package (Schaid, Rowland, Tines, Jacobson, & Poland, 2002) will be used to conduct 
2- and 3- SNP moving window haplotype analyses for each candidate gene.  Haploview (Version 
3.32) (Barrett, Fry, Maller, & Daly, 2005) will be used to estimate linkage disequilibrium across 
each candidate gene for both D’ and R2. 
1.4.5 Analysis 
1.4.5.1 Sample size justification 
Quanto version 1.2.4 was used to conduct a power analysis for this genetic association study.  
Information for the following program parameters were entered: (1) SNP minor allele frequency: 
0.2 - 0.5; (2) no environmental influence; (3) additive gene effect due to preeclampsia’s multi-
factorial nature; (4) 1:1 case/control matching based on study design; (5) population risk of 5% 
(Roberts & Cooper, 2001); (6) heritability factor range 0.31 - 0.54 (Nilsson, Salonen Ros, 
Cnattinguis, & Lichtenstein, 2004; Salonen Ros, Lichtenstein, Lipworth, & Cnattingius, 2000); 
(7) α =.05; and (8) two-sided test.  A sample of 225 cases resulted in statistical power ranging 
from 0.9496-0.9999.  Although some assumptions may be incorrect and no correction was made 
for multiple testing, these calculations demonstrate that 225 cases allows for analysis of each 
gene separately for aim 1.  Aim 2 is exploratory in nature; however, with the increased power of 
the TDT approach and the availability of 225 affected maternal/fetal dyads, it is believed that 
data generated will indicate significant associations when they truly exist.   
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1.4.5.2 Preliminary analysis 
Prior to analysis of data generated in relation to the specific aims, descriptive statistics of the 
grouped data (cases and controls) will be computed to describe the data and sample distributions.  
Frequency counts, percentages, modes (for nominally and ordinally scaled variables), and 
medians (for ordinally scaled variables) will be generated to describe categorical variables. The 
range will be used to describe the variability of nominal variables, while the interquartile range 
and semi-quartile range will be used to describe variability of ordinal data.  Means, medians, 
modes, standard deviations, frequencies, percentages, skewness, and kurtosis will be computed 
for all continuous-type ratio variables. 
Grouped data screening procedures will also be employed prior to analysis of the specific 
aims in order to appraise data accuracy, assess missing data, detect outliers, evaluate underlying 
assumptions, transform data, and check the reliability of genotype data.  Data accuracy will be 
appraised via range checking.  If abnormalities are identified, questionable observations will be 
reviewed to determine if the entered values are valid or are due to errors in data entry or chart 
abstraction.  If values are found to be a result of incorrect data entry or chart abstraction, the data 
manager of PEPP will be contacted to obtain the correct values. 
The amount of missing data, patterns of missing data, and the missing data mechanisms 
will be investigated using the Missing Values Analysis (MVA) function in SPSS.  Depending on 
the amount, pattern, and mechanism of the missing data, several options for handling the missing 
data will be considered.  Such options include omission of the variable from analysis, complete-
case analysis, available-case analysis, and imputation.  If possible, regression, expectation-
maximization, or multiple imputation will be utilized to estimate the missing values.  For the 
genetic data, SNPs with a genotype call rate of < 86% will be omitted from analysis (Y. Conley, 
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personal communication, March 31, 2010).  For SNPs included in the analysis, available-case 
analysis will be utilized given that missing genotype values are typically missing completely at 
random.  Furthermore, no attempt will be made to impute genotype values, for it is not clear 
what subject predictors could be used to impute SNP genotypes. 
The grouped data will also be screened for univariate and multivariate outliers.  For 
univariate, categorical outliers, variables with uneven splits among the categories (e.g., 90—10 
for dichotomous variables) will be detected via frequency analysis.  Histograms, boxplots, 
normality probability plots, and detrended expected normal probability plots will be generated to 
assess univariately for outliers for continuous variables.  Z scores will also be computed to 
identify potential univariate outliers and bivariate scatterplots will be generated to assess for 
multivariate outliers.  Data transformations, such as score alterations, will also be considered to 
decrease the influence of outliers.  Any data transformations will be noted in any reports or 
papers.   
Parametric or non-parametric tests (e.g., two-sample t-tests, chi-square test of 
independence, Mann-Whitney U-test) will also be conducted, as appropriate, to compare cases 
and controls on additional continuous and categorical variables in an attempt to identify 
extraneous covariates or possible confounders.  Such variables include income, education, 
delivery method, body mass index (BMI), infant weight, and blood pressure.  Prior to these 
parametric data analyses, assessment of underlying assumptions will first be performed on the 
groups for continuous variables (income, education, BMI, infant weight, blood pressure).  
Measures of skewness and kurtosis will be generated along with frequency histograms with 
normal distribution overlays and the Kolmogorov-Smirnov or Shapiro-Wilk tests to assess the 
assumption of normality.  The assumption of linearity will be evaluated via bivariate scatterplots 
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and Levene’s test will be used to assess for homoscedasticity.  Finally, to fulfill the assumption 
of independent observations, only subject data from a single enrollment in PEPP will be 
analyzed.  However, if the data are found to be non-normally distributed, non-linear, or 
heteroscedastic, data transformations will be attempted to induce normality, enhance linearity, 
and stabilize variances.  If the statistical assumptions remain severely violated, non-parametric 
tests will be used. 
The data will also be screened to assess assumptions related to binary logistic regression, 
which represents the statistical approach to be used to address specific aim #1.  Although some 
assumptions will be evaluated as part of the logistic regression analysis procedure, checks for 
multicollinearity and sparseness of cells will be conducted prior to analysis.  To assess for 
multicollinearity in the predictor variables, tolerance and variance inflation factor conditioning 
indices will be computed.  If multicollinearity is found, an attempt will be made to drop the 
collinear variables or create a new variable that is a function of the collinear variables.  In 
addition, the potential issue related to sparseness of cells in the categorical variables will be 
examined via frequency counts.  If sufficient data within different levels of the categorical 
predictors are found to be lacking, variable categories will be collapsed to limit the sparseness of 
cells.  If cells are unable to be collapsed, such predictors will be omitted from the main analyses, 
limiting such predictors to descriptive analysis. 
Reliability of genotype data will be evaluated in several steps.  Particular attention will be 
focused on validation of the data for consistency and integrity.  These steps include: checks 
comparing expected homozygosity to observed homozygosity at each SNP, checks of allele 
frequencies, consideration of genotype call rates, and checks for Hardy-Weingberg Equilibrium 
consistency (check for genotyping error). 
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1.4.5.3 Aim 1 analysis 
Investigate variation in maternal genes involved in the endoglin pathway for impact on the 
development of PE 
The relationship between the presence or absence of preeclampsia and the presence of 
each allele and/or genotype and/or haplotype will be examined via contingency table analysis 
with chi-square tests of independence and binary logistic regression analysis.  Preeclampsia, a 
binary variable (present or absent), is the outcome of interest.  The independent variables will be 
noted as the presence of one allele or the other of the genotype (allele 1 or allele 2) and the 
presence of one genotype or the other (homozygous for allele one, homozygous for allele 2, or 
heterozygous). 
Initially, chi-square tests of independence will be used to test whether there is a 
relationship between the occurrence of preeclampsia and the presence of each SNP alleles and/or 
genotype and/or haplotype.  Furthermore, because the variables of interest are categorical, binary 
logistic regression models will be fitted to yield unadjusted odds ratios and their 99% confidence 
intervals for each candidate gene SNP(s) separately.  In order to reduce inflation of type 1 error, 
the more conservative 99% CI will be computed.  To control for potential covariate and 
confounding effects, the models will be expanded via hierarchical, multivariate logistic 
regression to yield adjusted odds ratios (99% confidence intervals) and the contribution of 
genetic susceptibility/protection after controlling for covariates.  Identified covariates will be 
entered into the first block and the candidate gene SNP will be entered into the second block. 
After conducting the logistic regression procedures, model fit and satisfaction of 
underlying assumptions will be assessed.  Goodness-of-fit (GOF) will be examined via the 
Hosmer-Lemeshow GOF test.  If any of the identified covariates entered into the model are 
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continuous in nature, the assumption of linearity in the logit will be assessed using Box-Tidwell 
approach and subsequent graphical methods if necessary.  For the Box-Tidwell approach, 
interaction terms (cross-product of an independent variable times its natural logarithm) will be 
created and added to the logistic model.  If the interaction terms are found to be significant, non-
linearity will be further assessed with graphical methods.  The graphical assessment will involve 
the following steps:  
1. Creation of a grouped version of the continuous variable based on quartiles 
2. Dummy coding of the grouped version of the continuous variable 
3. Entering all dummy variables into the regression model simultaneously 
4. Generation of beta coefficients (e.g., log odds) 
5. Plotting of the beta coefficients against the midpoint for the group to assess for linearity. 
Analysis of fitted models will also include residual analysis (identification of outliers in 
solution, influential observations).  If an acceptable model is found, the regression 
coefficients will then be evaluated for statistical significance via the Wald test and the 
likelihood ratio chi-square test. 
1.4.5.4 Aim 2 analysis 
Explore variation in maternal/fetal dyad genes involved in the endoglin pathway for impact on 
development of preeclampsia. 
 Because specific aim #2 involves related dyads (mother/infant), transmission 
disequilibrium testing (TDT) will be used to analyze the genetic data related to specific aim #2.  
TDT is based on the assumption that there is over-transmission of an allele from parents to 
affected offspring and under-transmission of that same allele from parents to unaffected 
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offspring when that allele is implicated in susceptibility (Sun, Flanders, Yang, & Khoury, 1999).  
For the proposed study, offspring born to women who experience preeclampsia during their 
pregnancy are considered to be affected since preeclampsia only develops during pregnancy.   
Traditionally, TDT involves the analysis of a family trio, which includes both parents and 
the offspring.  In the proposed study, genetic information is only available for one parent and her 
offspring.  However, modifications have been introduced so that TDT can be conducted with 
only one parent and one offspring (1-TDT).  As a result, the genomic contribution of the 
endoglin pathway amongst the mother/child dyads in the proposed study can be explored using 
1-TDT. 
Additionally, there is strength in combining the unrelated case-control data from aim 1 
with the maternal fetal dyads from aim 2 and we plan to use the CCREL program to conduct 
these analyses.  CCREL is a program for case-control genetic analysis that takes relatedness 
between individuals into account, allowing one to analyze both related and unrelated individuals 
at the same time.  It will perform single-marker and haplotypic tests for biallelic markers, which 
is what this study will utilize, and it will allow for the compilation of effect sizes for use in future 
studies. 
1.5 POTENTIAL LIMITATIONS OF PROPOSED PROCEDURES AND 
ALTERNATIVE APPROACHES TO ACHIEVE THESE AIMS 
Several limitations are associated with the proposed study procedures.  Because the proposed 
research study is retrospective, inadequate matching of controls to cases on the variables of 
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interest along with inadequate minority representation due to an inadequate sample size 
represents a potential limitation.  Such a limitation could result in the findings of the 
investigation being underpowered, but a strength of the PEPP study is that minorities (Black 
subjects) are well represented.  However, given that population substructure can lead to issues 
when conducting genetic association studies it may be necessary to analyze populations from 
different ancestries separately for SNPs where allele frequency differs significantly.  If this 
occurs, it could impact power for that particular SNP, but the matching of cases to controls may 
help with this issue and would provide pilot data that may aid in understanding of health 
disparities related to preeclampsia. 
Another potential limitation that may be encountered would be inappropriate sample size 
if too many covariates need to be considered.  An alternative approach to address sample size 
and power issues would be to study additional subjects that may become available from the 
PEPP 3 cohort, which is currently recruiting and collecting data on subjects.  Thus, even though 
the proposed research may be exploratory, the results would have the potential to support follow-
up studies in which the investigator could attempt to rectify the potential sampling limitations 
that exist when utilizing existing samples.   
SNP incompatibility as a result of multiplexing presents another potential limitation. 
Although the investigator will attempt to develop primer sets in which the number of SNPs are 
maximized per multiplex assay, there may be some SNPs whose primers will not hybridize and 
allow for sample amplification in the presence of other SNP primers.  An alternative approach 
would be to genotype these SNPs separately using other methods such as TaqMan®. 
The utilization of a nested design may also present a potential limitation.  Because the 
investigator proposes to utilize samples and data from an existing parent study, she cannot 
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control the types of data that were collected, including information on potential covariates.  In 
the future, an alternative approach would be to design and implement one’s own parent study.  
This approach would allow her to define inclusion/exclusion criteria and choose the variables for 
which data will be collected. 
Finally, the investigator may find that none of the selected genes are significantly associated 
with PE.  Although not optimal, these results would provide the scientific community with 
valuable information.  Such information could potentially contribute to a better understanding of 
PE pathophysiology.   
1.6 HAZARDOUS MATERIALS AND PROCEDURES 
While working in the laboratory, I will come into contact with numerous substances, including 
blood, blood products, and certain chemicals.  In order to safely conduct protocols utilizing such 
substances, I will apply personal protective equipment, including gloves, goggles, a laboratory 
coat, and a mask as appropriate.  Additionally, I have completed the required Bloodborne 
Pathogen Training and the Chemical Hygiene Training. 
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1.7 RESEARCH PARTICIPANT RISK AND PROTECTION 
1.7.1 Human subjects 
IRB approval has been obtained for the proposed study (PR009110136) (Appendix 1).  
Specimens received for the study have been previously collected from subjects enrolled in PEPP.  
Because the proposed study is investigating variation in maternal and fetal genes involved in the 
ENG pathway for impact on development of PE, data from pregnant women and fetal subjects 
are included.  Furthermore, because the placenta is thought to be involved in the development of 
PE and the placenta is of fetal origin, the inclusion of fetal subjects, specifically fetal DNA 
obtained from cord blood samples, is inherent to the study of PE.  Lastly, young age has been 
indicated as a potential risk factor for the development of PE, which supports the inclusion of 
pregnant teenagers (children) in the study sample.  In reference to the PEPP study sample, 
pregnant children were included in the study if they were ≥ 14 years of age.  Thus, samples from 
pregnant women, fetuses, and children comprise the PEPP sample and the proposed study 
sample.  Furthermore, minorities have not been excluded from the PEPP or proposed study. 
1.7.2 Potential risks and data/safety monitoring 
While breach of confidentiality is a concern of genetic studies, the following precautions will 
attempt to mitigate this risk.  First, all biological samples and clinical, demographic, and 
laboratory data have been obtained from PEPP in a de-identified manner via an honest broker. 
Neither I nor the laboratory staff will have access to the data linking the subject’s ID number to 
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personal identifiers.  Second, all data generated from the proposed study will be stored in a 
database of a password protected computer or on removable storage that will be stored in locked 
file cabinets or be password protected.  Third, all data generated from the proposed study will be 
reported as aggregate data and results will not be revealed to subjects.  Fourth, genetic and 
clinical data will be used solely for research purposes and will be continuously safeguarded by 
myself and my mentor. 
1.7.3 Potential benefits 
Although results generated will provide no direct benefit to study subjects, findings may increase 
our knowledge of the underlying pathophysiologic mechanisms involved in PE development.  
Such knowledge has the potential to serve as a foundation in the design and implementation of 
interventions aimed at prevention, detection, and treatment of PE. 
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2.0  SUMMARY OF STUDY 
The purpose of this dissertation research was to examine the relationship between endoglin 
(ENG) pathway genetic variation and the development of preeclampsia.  Two articles that were 
written during the course of this dissertation project are provided in Appendices B and D.  
Published in the Journal of Obstetric, Gynecologic, & Neonatal Nursing, the article titled “A 
Historical Overview of Preeclampsia-eclampsia” (Appendix B) highlights theories on disease 
causation and reviews changes in the treatment and classification of preeclampsia from Ancient 
times through the 21st century.  The second article titled “A Systematic Review of Endoglin 
Gene Expression in Preeclampsia,” (Appendix D) which is published in Biological Research for 
Nursing, was written to summarize gene expression studies addressing the role of endoglin in 
preeclampsia and further highlighted the need for the investigation of endoglin at the molecular 
level.  Together, these two articles provided the rationale for this dissertation project.  The results 
for specific aim 1 are presented in the data based manuscript in the section that follows this 
summary of the study.  A discussion of study aim 2 is provided below.  
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2.1 PROPOSAL CHANGES 
Throughout the course of this project, several changes were made to the approved dissertation 
proposal.  The changes, along with the rationale for these changes, are provided below.  A 
separate section addressing the decision to forgo the analysis of study aim 2 is presented after 
discussion of the other proposal changes. 
2.1.1 Candidate genes evaluated 
This study originally proposed to evaluate 13 ENG pathway candidate genes (ENG, TGFβ1, 
ALK1, TGFβR1, TGFβR2, and SMADs 1-8).  Based on a HapMap (Data Phase III/Rel#2, Feb09, 
on NCBI B36 assembly, dbSNP b126) query conducted on March 24, 2011, 117 tSNPs across 
the 13 candidate genes were needed to fully evaluate their genetic variability.  Due to the large 
number of tSNPs and the financial costs implicated with genotyping such a large number of 
tSNPs, the decision was made to exclude candidate genes from this study.  Because the SMAD 
genes were more extrinsic to the pathway and a total of 70 tSNPs needed to be genotyped to fully 
evaluate these genes, the SMAD genes were excluded from this study.  With this exclusion of 
these genes, the number of tSNPs to be analyzed across ENG, TGFβ1, ALK1, TGFβR1, and 
TGFβR2 totaled 47 tSNPs, which required two separate iPLEX® assays to accommodate this 
reduced number of SNPs.    
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2.1.2 Tagging SNP selection criteria 
This study originally proposed to select tSNPs for both Caucasian (CEU) and African (YRI) 
ancestry.  Because the majority of this study’s sample was comprised of Caucasian subjects, the 
decision was made to only select tSNPs for Caucasian ancestry.  We do acknowledge that 
linkage disequilibrium in the candidate genes may be different for Caucasian and African 
ancestries, thereby decreasing the informativeness of the data generated in our our black 
subgroup; however, we knew that our analysis in the black subgroup would be exploratory in 
nature given the small sample size.  
2.1.3 iPLEX® assay design and potentially functional SNPs 
Since the writing of the proposal, the versions of the software utilized to design iPLEX® assays 
have been updated.  The updated software, which includes the online Human GenoTyping Tools 
and the MassARRAY® Designer v4.0 software, was used to design two multiplex assays.  
Because the tSNPs from ENG, TGFβ1, ALK1, TGFβR1, and TGFβR2 were of highest priority, 
the assays were designed to first include these tSNPs.  Two potentially functional SNPs that did 
not interfere with the assays’ abilities to genotype the candidate gene tSNPs were also included.   
2.1.4 Genotype data collection with TaqMan® allelic discrimination 
Originally all of the genotype data was to be generated using iPLEX®; however, five SNPs did 
not meet the data quality criteria with the iPLEX® platform either because call rates were < 86% 
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(3 SNPs) or the SNPs were multi-allelic (3 allele and 4 allele).  For these SNPs, pre-developed 
and commercially available TaqMan® SNP Genotyping assays (Applied Biosystems®) were 
used to conduct TaqMan® allelic discrimination with the ABI Prism® 7000 Sequence Detection 
System and SDS software v1.2.3 (Applied Biosystems Inc., Carlsbad, CA). 
2.1.5 Haplotyping and linkage disequilibrium estimation 
We originally proposed to estimate haplotypes and estimate linkage disequilibrium for all 
candidate genes using the HAPLO.STATS Package (version 1.2.2) of the R Genetics Package 
and Haploview (version 3.32) (Barrett, Fry, Maller, & Daly, 2005).  Instead, we used PLINK 
software (version 1.07) (Purcell et al., 2007), which was capable of completing both of these 
tasks.  Because of the small number of black cases and controls (30/30) and the use of only 
Caucasian ancestry to select tSNPs, we did not conduct haplotype analysis or estimate linkage 
disequilibrium in blacks.  In the white subgroup, we decided to only conduct haplotype analyses 
and estimates of linkage disequilibrium in ENG because of significant associations at the allele 
and genotype level.  Although TGFβR2 had a significant allele and genotype test for one tSNP, 
we did not estimate haplotypes or linkage disequilibrium given the large number of tSNP (32) 
data that would need to be utilized in conducting the haplotyping.  
2.1.6 Statistical changes to Aim 1 
Several statistical changes were made during the analysis of aim 1.  First, binary logistic 
regression was only utilized to compute odds ratios in tSNPs that had significant genotype tests.  
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We felt that the computation of odds ratios for those tSNPs with non-significant genotype tests 
was not needed given the lack of association.  Second, we decided not to conduct predictive 
modeling via hierarchical multivariate logistic regression since our study’s purpose was not 
aimed at prediction.  Third, we identified clinical characteristics (e.g., blood pressure, pre-
pregnancy BMI) that were significantly different among cases and controls.  We then tested the 
association between those clinical characteristics and genotype assignment for tSNPs found to 
have significant genotype tests in the white and black subgroups separately.  
2.2 PROPOSAL CHANGE: STUDY AIM 2 
The purpose of this study’s second aim was to explore how variation in endoglin (ENG) pathway 
genes (ENG, TGFβ1, TGFβR1, and TGFβR2) of maternal/fetal dyads may be associated with the 
development of preeclampsia.  Tagging single nucleotide polymorphisms (tSNPs) and 
potentially functional SNPs identified in the literature were selected to evaluate candidate gene 
variability in mother/fetal dyads with a preeclampsia diagnosis (cases) compared to healthy 
maternal/fetal dyads (controls).  Maternal and fetal biological samples along with demographic, 
clinical, and laboratory data were provided by the Prenatal Exposures and Preeclampsia 
Prevention study (PEPP) conducted at Magee-Womens Hospital of UPMC (Pittsburgh, Pa).  A 
total of 215 maternal controls were 1:1 frequency matched to 215 maternal cases on age (+/- 2 
years), ancestry (black/white), and parity.  For maternal subjects, PEPP provided genomic DNA 
aliquots (100 μl).  The genomic DNA samples had been extracted from peripherally collected 
blood samples via protein precipitation from white blood cell pellets and passed our quality 
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assessment checks.  For fetal subjects, PEPP provided serum aliquots (300 μl) obtained from 
umbilical cord blood after delivery.  In order to conduct aim 2, we first needed to extract 
genomic DNA from the fetal serum samples and assess DNA yield, quality, and utility of the 
extracted samples.   
 
2.2.1 DNA extraction and DNA yield/quality assessment of fetal samples 
QIAGEN QIAamp® DNA Mini Kits (QIAGEN, Valencia, CA) were used to extract genomic 
DNA from 300 μl umbilical cord serum aliquots per manufacturer’s instructions.  TaqMan® 
allelic discrimination (Applied Biosystems Inc., Carlsbad, CA) was utilized to assess DNA yield, 
quality, and utility of extracted samples.  We used the following thermal profile: (a) AmpliTaq 
Gold Enzyme activation at 95°C for 10 minutes, (b) denature at 95°C for 15 seconds, (c) 
anneal/extend at 58°C for 1:30 minutes, (d) go to step b 50 times, (e) hold at 10°C.  For those 
fetal samples with initial insufficient yield, whole genome amplification was carried out with the 
REPLI-g® Midi Kit per manufacturer’s instructions (QIAGEN, Valencia, CA) to increase 
available template for investigation.  These samples, once amplified, were subjected to the same 
TaqMan® assessment to ensure utility of the samples.    
2.2.2 Genotyping methods for fetal samples 
The iPLEX® Gold-SNP Genotyping assay (Sequenom® Inc, San Diego, CA) was utilized to 
genotype the 49 SNPs.  Two multiplex assays consisting of two amplification primers and one 
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single base extension primer for each SNP locus were designed with the online Human 
GenoTyping Tools and MassARRAY® Designer v4.0 software 
(https://www.mysequenom.com).  Genotyping was conducted at the University of Pittsburgh 
Genomics and Proteomics Core Labratories using the MassARRAY® Nanodispenser (Samsung, 
Irvine, CA), MassARRAY® Compact Analyzer (Bruker, Newark, DE), SpectroACQUIRE 
v3.3.1.3 software (Sequenom®), and MassARRAY® Typer v4.0 software (Sequenom®) 
(http://www.genetics.pitt.edu/). 
Five SNPs did not meet data quality criteria with the iPLEX® platform.  Three SNPs 
(rs1800468, rs10739778, rs6809777) had genotype call rates of < 86% across both assays 
(looking at maternal and fetal data together) and two SNPs (rs3087465, rs8179181) were multi-
allelic (>2 alleles), causing genotype data validity to be questioned.  For these five SNPs, we 
performed TaqMan® allelic discrimination with the ABI Prism® 7000 Sequence Detection 
System and SDS software v1.2.3 (Applied Biosystems Inc., Carlsbad, CA), using pre-developed 
and commercially available TaqMan® SNP Genotyping assays (Applied Biosystems®).  We 
used the following thermal profile: (a) AmpliTaq Gold Enzyme activation at 95°C for 10 
minutes, (b) denature at 95°C for 15 seconds, (c) anneal/extend at 58°C for 1:30 minute, (d) go 
to step b 50 times, (e) hold at 10°C.  Genotype data collection for these five SNPs was collected 
at the University of Pittsburgh School of Nursing Molecular Genetics Laboratory. 
2.2.3 Assessment of genotype reliability in fetal samples 
The following steps were taken to assess genotype reliability for the white subgroup fetal 
samples.  The starting sample was comprised of 362 fetal samples due to the removal of a 
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maternal/fetal dyad from the case group (poor maternal sample call rate) and a randomly selected 
maternal/fetal dyad from the control group.  
1. Global assessment of 49 SNP call rates across the two iPLEX® assays (maternal and 
fetal data collectively analyzed) and removal of 5 SNPs that were multi-allelic or had 
global call rates < 80% on both assays 
2. Assessment of fetal sample call rates across the two iPLEX® assays and removal of 32 
fetal samples with global call rates < 80% on both assays. 
3. HWE checks were performed for 41 of the 44 remaining SNPs in 330 fetal subjects.  Of 
the three SNPs not evaluated, one was monomorphic and two had call rates of < 12% 
when just looking at the fetal data. 
4. Fetal subjects born prematurely in the control group were removed from the sample and 
SNP call rates were re-evaluated in the fetal sample.  SNPs with call rates < 80% in just 
fetal samples were removed. 
5. Call rates of the remaining 324 fetal samples were re-evaluated and those samples with 
call rates < 86% were removed. 
6. HWE checks were started for the 38 remaining SNPs in the 284 remaining fetal samples, 
but were stopped to evaluate the fetal sample for potential segregation issues (e.g., 
maternal genotype = CC and fetal genotype = TT). 
7. Fetal samples with segregation issues on at least 1 of the 38 SNPs were noted. 
8. Three of the five SNPs not able to be genotyped with iPLEX® were successfully 
genotyped with TaqMan®.  Sample call rates were re-evaluated after inclusion of these 
three SNPs and those samples with call rates < 86% across the 41 SNPs were removed.  
These three SNPs were also analyzed for segregation issues. 
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9. Umbilical cord serum aliquots (500 μL) for fetal samples with segregation issues on ≥ 2 
SNPs were obtained and genomic DNA was extracted with QIAGEN QIAamp® DNA 
Midi Kits (QIAGEN, Valencia, CA). 
10. TaqMan® allelic discrimination was used to compare maternal genotype, fetal genotype 
from the initial sample, and fetal genotype from the new sample. 
11. Samples with segregation issues on ≥ 2 SNPs were removed and HWE was checked for 
40 of the 41 SNPs in the remaining 255 fetal subjects.  (Note: one SNP had expected 
frequency counts < 5 with the chi square test of independence and therefore needed to be 
checked with an exact test). 
12. Samples with segregation issues on just 1 SNP were removed and HWE was re-checked 
for 40 of the 41 SNPS in the remaining 219 fetal subjects. 
A similar assessment was made in the black fetal subgroup.  First, 49 SNP call rates were 
globally assessed across the two iPLEX® assays (maternal and fetal data collectively analyzed) 
and 5 SNPs that were either multi-allelic or had global call rates < 80% on both assays were 
removed.  Second, the assessment of fetal sample call rates across the two iPLEX® assays 
resulted in the removal of 1 fetal sample with a global call rate < 80% on both assays.  Third, 
HWE was evaluated in 19 of the 44 SNPs in 59 fetal subjects (18 SNPs could not be assessed 
with a chi square test of independence, 6 SNPs had call rates of < 86%, and 1 SNP was basically 
monomorphic in the black fetal samples).  Given these results and what we were observing in the 
white fetal subgroup, the decision was made to evaluate the fetal samples for segregation issues, 
as noted in steps 9 and 10.  Addition of 3 tSNPs genotyped with TaqMan®, resulted in the 
evaluation of segregation issues for 40 SNPs across 56 dyads (3 fetal samples removed for 
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sample call rates < 86%).  Based on those results, no further analysis of the black fetal sample 
was conducted. 
2.2.4 Results in white fetal subgroup 
The first round of HWE checks (step 3) found that 32 of the 41 SNPs (78.0%) were out of HWE 
in 330 white fetal subjects.  A closer evaluation of fetal genotype data compared to maternal 
genotype data revealed that there were segregation issues for 63 maternal/fetal dyads, with 26 
dyads having segregation issues on ≥ 2 SNPs.  After removal of fetal subjects with segregation 
issues on ≥ 2 SNPs and the removal of subjects with call rates < 86%, re-evaluation of HWE 
(step 11) showed that 17 out of 40 SNPs (42.5%) were still out of HWE in the reduced sample of 
255 fetal subjects.  After the removal of subjects with a noted segregation issue on just one SNP, 
a final round of HWE checks was performed.  Despite the removal of all fetal subjects with poor 
call rates and segregation issues on at least one SNP, 13 of 40 SNPs (32.5%) were out of HWE 
in the reduced sample of 219 fetal subjects.   
In addition to the multiple rounds of sample reduction and HWE checks, fetal samples 
with segregation issues on ≥ 2 SNPs were further analyzed by comparison of the maternal 
sample genotype, the original fetal sample genotype, and the new fetal sample genotype.  Of the 
25 original fetal sample genotypes that we compared to the 25 new fetal sample genotypes with 
TaqMan® allelic discrimination, 4 (16%) of the original fetal sample genotypes did not match 
the genotypes of their respective new fetal samples; noting that this was only conducted for one 
SNP as proof of concept. 
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2.2.5 Results in black fetal subgroup 
In the black fetal sample, 6 of 19 SNPs (31.6%) that could be checked for HWE using a chi 
square test were out of HWE in 59 subjects.  A closer evaluation of fetal genotype data compared 
to maternal genotype data showed that there were segregation issues for 15 maternal/fetal dyads, 
with 8 dyads having segregation issues on ≥ 2 SNPs.  Of the 7 original fetal sample genotypes 
that we compared to the 7 new fetal sample genotypes with TaqMan® allelic discrimination, 1 
(14.3%) of the original fetal sample genotypes did not match the genotypes of their respective 
new fetal samples; noting that this was only conducted for one SNP as proof of concept. 
2.2.6 Discussion 
At the beginning of this study, we were not certain if DNA obtained from serum aliquots would 
be of high enough yield/quality to move forward with aim 2.  We have found that the use of 
genomic DNA extracted from small-volume aliquots of umbilical cord serum does not appear to 
represent a high quality template that can be used for genotype data collection with the iPLEX® 
template.  Even after removal of white fetal subjects with poor call rates and segregation issues, 
32.5% of the SNPs to be analyzed were out of HWE in the white fetal subgroup.  Moreover, 
31.6% of the SNPs that were analyzed in the black fetal subgroup were also found to be out of 
HWE.  The mismatch of original fetal sample genotypes and new fetal samples genotypes in 
both subgroups also suggests that the DNA sample quality is an issue particularly when using the 
iPLEX® platform, or there may have been aliquotting issues or sample mix ups that occurred at 
some point ranging from sample collection to genotype data collection.  Given these findings, the 
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decision was made to not proceed with the analysis of aim 2 in both the white subgroup and 
black subgroup. 
2.3 STUDY STRENGTHS AND LIMITATIONS 
There were several strengths associated with this dissertation study.  The major strength of this 
project is that study of the ENG pathway at the molecular level is novel.  The pathway approach, 
rather than a singular gene approach, also allows one to draw global and biologically meaningful 
conclusions, resulting in increased understanding of preeclampsia pathophysiology.  The tSNP 
approach also gave us the ability to fully evaluate the genetic variability of each candidate gene 
with the fewest number of SNPs. 
There were also several limitations associated with this dissertation study.  This project 
was limited to and guided by the data/samples collected by the parent study.  This limitation was 
most evident in Aim 2.  Because fetal DNA extracted from white blood cell pellets was not 
available, we used the available umbilical cord serum samples for DNA extraction.  
Unfortunately, we found that this template was not suitable for genotype data collection with 
iPLEX® and we were not able to analyze Aim 2.  The small black subgroup sample size, which 
could lead to type 2 error, and the use of tSNPs only selected for Caucasian ancestry, which may 
not guarantee sufficient coverage of the candidate genes in the Black subgroup, represent two 
additional limitations.      
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2.4 FUTURE STUDIES AND IMPLICATIONS FOR GLOBAL HEALTH AND 
NURSING 
Preeclampsia is a global problem that affects women of all ancestries.  Future studies are needed 
to confirm the results of this study in different samples of women from non-Caucasian 
ancestries.  Moreover, studies examining ENG pathway genetic variation in women of other 
ancestries are needed to determine if ENG pathway variation is universally involved in 
preeclampsia development regardless of ancestry.  Because our results suggest that the ENG 
pathway genes involved in preeclampsia differ in white and black women, studies examining 
how these documented variations impact the function of ENG pathway candidate genes will 
further improve our understanding of how preeclampsia etiology may differ in women of 
different ancestries.  Confirmation of these results and exploration of the functional significance 
associated with these variations could lead to the development of clinically relevant, stable 
biomarkers of preeclampsia susceptibility that can be used in the early identification of at risk 
women around the globe.  Ultimately, as frontline providers, nurses are likely to be the 
healthcare providers that would be involved in the education of patients on biomarker testing, the 
administration of biomarker testing, and the creation of individualized nursing care plans based 
on biomarker test results.   
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3.0  DATA-BASED MANUSCRIPT: VARIATION IN ENDOGLIN PATHWAY 
GENES IS ASSOCIATED WITH PREECLAMPSIA 
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3.1 ABSTRACT 
This case-control candidate gene association study investigated endoglin (ENG) pathway genetic 
variation and its association with preeclampsia.  Data on 355 white women (181 cases/174 
controls) and 60 black women (30 cases/30 controls) matched on ancestry, age, and parity were 
analyzed.  Tagging single nucleotide polymorphisms (tSNPs) in ENG, TGFβ1, TGFβR1, ALK1, 
and TGFβR2 were evaluated with iPLEX® and TaqMan® technologies.  
Allele/genotype/haplotype tests were conducted separately in white/black subgroups with a χ2 
test or Fisher’s exact test.  Odds ratios were computed with binary logistic regression for tSNPs 
with significant genotype tests.    In white women, variation in ENG (rs11792480, rs10121110) 
and TGFβR2 (rs6550005) was associated with preeclampsia.  Allelic frequency distributions in 
rs11792480, rs10121110, and rs6550005 were significantly different among cases and controls 
while genotype distributions of rs10121110 and rs6550005 were further associated with 
preeclampsia (p-values < .05).  For rs10121110, women with the AA genotype were 2.290 times 
more likely to develop preeclampsia compared to the GG genotype (99% CI [1.022, 5.133], p = 
.008).  The ENG haplotype TACGA, which contains the risk alleles for rs11792480 and 
rs10121110, was also over-represented in cases (p = .022).  In black women, variation in TGFβ1 
(rs4803455, rs4803457), TGFβR1 (rs10739778), and TGFβR2 (rs6550005, rs1346907, 
rs877572) was associated with preeclampsia.  Allelic frequency distributions in rs10739778, 
rs6550005, rs1346907, and rs877572 were significantly different among cases and controls while 
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genotype distributions of rs10739778, rs4803455, and rs4803457 were further associated with 
preeclampsia (p-values < .05).  For rs4803457, women with the CT genotype were 7.437 more 
times likely to develop preeclampsia compared to the CC genotype (99% CI [1.192, 46.408], p = 
.005).  These results demonstrate that variation in ENG pathway genes is associated with 
preeclampsia in white and black women, with different genes from the same pathway being 
involved in white women compared to black women.    
Keywords: preeclampsia, endoglin pathway, tagging SNPs, iPLEX® 
3.2 INTRODUCTION 
Preeclampsia is a multi-system disorder of pregnancy that is clinically diagnosed when a 
previously normotensive women presents with new onset hypertension and proteinuria after 20 
weeks’ gestation (American College of Obstetricians and Gynecologists [ACOG], 2002; 
National Heart, Lung, and Blood Institute [NHLBI] National High Blood Pressure Education 
Program, 2000).  Although we have made great strides in trying to identify preeclampsia’s 
pathophysiology, its heterogeneous nature suggests that a variety of mechanisms rather than a 
singular, universal mechanism may lead to preeclampsia.  Research focusing on the role of the 
anti-angiogenic factor endoglin (ENG) in preeclampsia has identified one such mechanism that 
may contribute to the development of preeclampsia in a subgroup of women.  
ENG is a trans-membrane glycoprotein that serves as a co-receptor of the transforming 
growth factor beta (TGFβ) signaling system (Cheifetz et al., 1992).  It is expressed on vascular 
endothelial cells (Gougos & Letarte, 1990), synctyiotrophoblasts, and transitioning 
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cytotrophoblasts (St-Jacques, Forte, Lye, & Letarte, 1994).  ENG is also involved in the 
maintenance of vascular tone by regulating nitric oxide dependent vasodilatation (Jerkic et al., 
2004; Toporsian et al., 2005).  Moreover, ENG is likely to be involved in the regulation of 
placental implantation and spiral artery remodeling during pregnancy (Caniggia, Taylor, Ritchie, 
Lye, & Letarte, 1997; Mano et al., 2011).  Both Caniggia, Taylor, Know Ritchie, Lye and Letarte 
(1997) and Mano et al. (2011) have demonstrated that inhibition of ENG translation, either in 
first trimester human villous explants or a human extravillous tropholast (EVT) cell line, has 
improved the invasive capacity of EVTs.   
Given that systemic endothelial dysfunction and shallow placental implantation/spiral 
artery remodeling are hallmark abnormalities observed in preeclampsia (Roberts & Hubel, 
2009), investigation of ENG’s potential role has been warranted and the results thus far are 
promising.  To date, multiple studies have found that ENG gene expression (mRNA)  is 
increased in the placenta and/or blood throughout pregnancy in women who develop 
preeclampsia (Farina et al., 2008; Farina et al., 2010; Nishizawa et al., 2007; Purwosunu et al., 
2008; Purwosunu, Sekizawa, Okazaki, et al., 2009; Purwosunu, Sekizawa, Yoshimira, et al., 
2009; Sekizawa et al., 2012; Sitras et al., 2009; Toft et al., 2008; Tsai et al., 2011; Venkatesha et 
al., 2006).  Soluble endoglin (sENG) protein, which is released into circulation after cleavage of 
trans-membrane ENG by MMP-14 (Kaitu’u-Lino et al., 2012), has also been found to be 
elevated in preeclampsia compared to healthy controls (Rana et al., 2007).  Despite these 
findings, little research has examined what contributes to the differences in ENG mRNA 
expression and sENG protein levels in women with preeclampsia.  The purpose of this study was 
to investigate how variation in endoglin pathway genes (ENG, TGFβ1, TGFβR1, ALK1, and 
TGFβR2) may be associated with the development of preeclampsia.  Tagging single nucleotide 
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polymorphisms (tSNPs) and potentially functional SNPs identified in the literature were used to 
evaluate candidate gene variability in women with preeclampsia compared to healthy controls 
that were matched on age (+/- 2 years), ancestry (white/black), and parity.   
3.3 METHODS 
3.3.1 Study population 
This case-control, candidate gene association study obtained subjects with and without 
preeclampsia from the first two cohorts of the Prenatal Exposures and Preeclampsia Prevention  
(PEPP) study.  Conducted at Magee-Womens Hospital of UPMC (Pittsburgh, Pa), the PEPP 
study examines factors predisposing women to preeclampsia via two recruitment approaches.  In 
PEPP’s first two cohorts, women 14-44 years of age were recruited/enrolled during early 
pregnancy (≤ 20 weeks’ gestation) and followed through delivery/postpartum period at Magee-
Womens Hospital or they were recruited/enrolled at the labor/delivery unit of Magee-Womens 
Hospital due to a suspected diagnosis of preeclampsia. Women with a history of chronic renal 
disease, hypertension, diabetes, or other disorders that increased the risk of preeclampsia were 
excluded from longitudinal enrollment. Cross-sectionally enrolled women found to have the 
aforementioned conditions were excluded from any analyses involving women with 
preeclampsia and healthy controls. Demographic, clinical, and laboratory data were collected by 
appropriately trained individuals.  Genomic DNA was extracted from peripherally collected 
venous blood samples via protein precipitation from white blood cell pellets. All aspects of 
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PEPP, including the use of samples/data for genetically-based research, were approved by the 
University of Pittsburgh and Magee Womens Hospital Institutional Review Board (IRB). 
Separate University of Pittsburgh IRB approval was also granted for this study.  PEPP subjects 
not consenting to future genetic evaluation and subjects without a stored genetic sample were 
excluded from this study. 
 
3.3.2 Phenotype classification 
Determination of pregnancy outcome was made after the review of clinical data by an expert 
panel of clinicians/researchers.  Preeclampsia diagnosis was based on blood pressure (BP), 
urinary protein, and serum uric acid criteria.  The average of the last five BPs taken in the 
hospital prior to therapeutic intervention (e.g., medication, anesthesia) were compared to the 
average BP prior to 20 weeks’ gestation to establish the presence/absence of hypertension. 
Hypertension was defined as a BP ≥ 140 mmHg systolic and/or 90 mmHg diastolic AND an 
increase of BP > 30 mmHg systolic and/or 15 mmHg diastolic after 20 weeks’ gestation.  Blood 
pressure abnormalities were to resolve by 12 weeks postpartum.  Proteinuria was defined as ≥ 
300 mg/ 24hours, ≥ 0.3 protein/creatinine ratio, ≥ 2+ on a random urine specimen, or ≥ 1+ on a 
catheterized urine specimen.  Hyperuricemia was defined as a serum uric acid concentration > 1 
standard deviation from normal for gestational age (Lind, Godfrey, Otun, & Philips, 1984).  A 
severe preeclampsia diagnosis was made when subjects with preeclampsia also had ≥ 1 of the 
following conditions: (a) systolic BP ≥ 160 mmHg, (b) diastolic BP ≥ 110 mmHg, (c) proteinuria 
≥ 5 grams/ 24 hours, (d) elevated liver enzymes, or (e) platelet count ≤ 100,000.  Hemolysis, 
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elevated liver enzymes, and low platelets in subjects with preeclampsia indicated the presence of 
HELLP syndrome.  Clinically evaluated subjects that had negative past medical histories (e.g., 
chronic renal disease, hypertension, diabetes) and did not meet the criteria for preeclampsia, 
severe preeclampsia, or HELLP syndrome were designated as healthy controls. 
For this case-control study, the case group included PEPP subjects diagnosed with 
preeclampsia, severe preeclampsia, or HELLP syndrome while the control group was comprised 
of healthy PEPP subjects.  A total of 215 controls were 1:1 frequency matched to 215 cases on 
self-reported ancestry (black/white), age, and parity.   
3.3.3 Polymorphism selection 
To fully evaluate the genetic variability of the candidate genes (ENG, TGFβ1, TGFβR1, ALK1, 
and TGFβR2), including upstream and downstream regulatory regions, tSNPs were selected from 
the International HapMap Project database (HapMap Data Phase III/Rel#2, Feb09, on NCBI B36 
assembly, dbSNP b126).  tSNP selection was based on the following criteria: (a) minor allele 
frequency ≥ 20% for each SNP, (b) R2 cutoff= 0.8, and (c) Caucasian (CEU) ancestry given that 
the majority of the sample self classified as white.  Potentially functional SNPs identified in the 
scientific literature were also included in the assessment of the candidate genes.  A total of 47 
tSNPs and 2 potentially functional SNPs were selected for evaluation (Table 6).  The UCSC 
Genome Browser (Fujita et al., 2011) was utilized to identify the nucleotide position of the 
selected SNPs.  The UCSC Genome Browser (Fujita et al.,) or the Database of Single Nucleotide 
Polymorphisms (dbSNP; http://www.ncbi.nlm.nih.gov/projects/SNP/) was used to identify the 
location of the significantly associated tSNPs within the genes of interest (e.g., exon, intron). 
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Table 6. iPLEX Assays 
Note.  aAdditional space in Assay 1 allowed for inclusion of 12 non-candidate gene tSNPs not 
analyzed within the context of this project.  rs# for these tSNPs are not shown.  
 
3.3.4 Genotyping methods 
The iPLEX® Gold-SNP Genotyping assay (Sequenom® Inc, San Diego, CA) was utilized to 
genotype the 49 SNPs in each of the 430 subjects.  Two multiplex assays consisting of two 
amplification primers and one single base extension primer for each SNP locus were designed 
with the online Human GenoTyping Tools and MassARRAY® Designer v4.0 software 
(https://www.mysequenom.com).  Genotyping was conducted at the University of Pittsburgh 
Genomics and Proteomics Core Labratories using the MassARRAY® Nanodispenser (Samsung, 
Irvine, CA), MassARRAY® Compact Analyzer (Bruker, Newark, DE), SpectroACQUIRE 
v3.3.1.3 software (Sequenom®), and MassARRAY® Typer v4.0 software (Sequenom®) 
(http://www.genetics.pitt.edu/). 
Five SNPs did not meet data quality criteria with the iPLEX® platform.  Three SNPs 
(rs1800468, rs10739778, rs6809777) had genotype call rates of < 86% and two SNPs 
Assay 1a 
 
Assay 2 
Gene rs numbers Gene rs numbers 
ENG rs10987746, rs10819309, 
rs10760505, rs11792480, 
rs10121110 
 
TGFβR2 rs2043136, rs13075948, rs1346907, 
rs3773652, rs4955212, rs1155708, 
rs3773640, rs1036097, rs2082224, 
rs876688, rs744751, rs1078985, 
rs17025785, rs877572, rs5020833, 
rs6809777, rs6802220, rs9843942, 
rs6550005, rs3773644, rs3773645, 
rs13083813, rs12487185, 
rs13086588, rs6792117, rs3773663, 
rs4522809, rs11129420, rs995435, 
rs11924422 
TGFβ1 rs4803455, rs1800469, rs4803457, 
rs8179181, rs1800468, rs11466314 
 
TGFβR1 rs6478974, rs420549, rs10739778 
 
ALK1 rs3759178, rs11169953, rs706819 
 
TGFβR2 rs749794, rs3087465 
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(rs3087465, rs8179181) were multi-allelic (> 2 alleles), causing genotype data validity to be 
questioned.  For these five SNPs, we performed TaqMan® allelic discrimination with the ABI 
Prism® 7000 Sequence Detection System and SDS software v1.2.3 (Applied Biosystems Inc., 
Carlsbad, CA), using pre-developed and commercially available TaqMan® SNP Genotyping 
assays (Applied Biosystems®).  We used the following thermal profile: (a) AmpliTaq Gold 
Enzyme activation at 95°C for 10 minutes, (b) denature at 95°C for 15 seconds, (c) anneal/extend 
at 58°C for 1:30 minute, (d) go to step b 50 times, (e) hold at 10°C.  Genotype data collection for 
these five SNPs was collected at the University of Pittsburgh School of Nursing Molecular 
Genetics Laboratory. 
3.3.5 Genotype data reliability, haplotype assignment, and linkage disequilibrium 
estimation 
Reliability of genotype data was evaluated in several steps, with attention focused on validation 
of data for consistency and integrity. Steps included comparison of expected homozygosity to 
observed homozygosity at each SNP, comparison of study allele frequencies to allele frequencies 
from the Database of Short Genetic Variations (dbSNP) (http://www.ncbi.nlm.nih.gov/snp), 
consideration of genotype call rates, inclusion of blind duplicates, double call of genotypes, and 
checks for Hardy-Weinberg Equilibrium (HWE) consistency.  HWE calculations were conducted 
using PLINK software version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 
2007) or the online HWE calculator available at http://www.oege.org/software/hwe-mr-
calc.shtml.  In both the non-related white and black subgroups, PLINK software was used to 
estimate ENG haplotypes. Pair-wise linkage disequilibrium (R2 and D’) across the ENG gene 
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was also estimated in the white subgroup. Due to small sample size and haplotype frequencies, 
we did not conduct further haplotype analysis in the black subgroup.     
3.3.6 Statistical analysis 
Within each ancestral subgroup (white, black), demographic characteristics were compared 
between cases and controls.  Continuous variables with parametric distributions were assessed 
with either an independent samples t-test or an independent samples t-test with unequal 
variances.  The Mann-Whitney U test was used to assess continuous variables with non-
parametric distributions.  Categorical variables were assessed with either the Mann-Whitney U 
test or the χ2 test of independence.  Multiple imputation was utilized to estimate missing pre-
pregnancy body mass index (BMI) values for n = 22 white cases. 
For both ancestral subgroups, a χ2 goodness-of-fit test or an exact test was used to detect 
deviations from HWE.  tSNPs and/or functional SNPs that violated HWE (p < .005) were further 
assessed by checking for HWE consistency in cases and controls separately. 
Chi-square tests of independence were used to test the association between the candidate 
gene tSNP/functional SNP alleles and preeclampsia status (allele test) in each ancestral 
subgroup.  The association between tSNP/functional SNP genotypes and preeclampsia status 
(genotype test) in each ancestral subgroup was tested with either a χ2 test of independence or a 
Fisher’s exact test.  SNPs with homozygote variant frequencies of < 10% in either cases, 
controls, or both were dichotomized (homozygote wildtype; homozygote variant + heterozygote) 
prior to conducting the genotype test.  Binary logistic regression was utilized to compute odds 
ratios and 99% confidence intervals (CI) for SNPs found to have a significant genotype test.  A 
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99% CI was selected to account for inflation of type 1 error resulting from multiple testing.  As 
an effect size statistic, the odds ratio provided information on the direction and magnitude of the 
relationship (Lipsey & Wilson, 2001) between genotype assignment and preeclampsia status.  
Odds ratio values of 2.0, 3.0, and 4.0 were considered small, moderate, and strong effects, 
respectively (Ferguson, 2009).      
The association between genotype assignment and clinical characteristics (blood 
pressure, pre-pregnancy BMI) was also assessed in SNPs with significant genotype tests. An 
ANOVA, independent samples t-test, Kruskal Wallis test, or Mann-Whitney U test was used to 
test these associations according to number of genotype groups and sample distributions.   
Statistical analyses were conducted with SPSS version 19 (SPSS Inc., Chicago, IL.). 
The most probable ENG haplotypes estimated for each white subject were selected for 
analysis.  Haplotype allele frequencies were analyzed separately in cases and controls.  
Haplotypes with < 10 % in either cases, controls, or both were collapsed into one category.  A χ2 
test of independence was used to determine if the frequency distributions of the 4 haplotype 
categories differed in cases and controls.  Separate pair-wise comparisons of haplotype 
frequency distributions were also analyzed.  Diplotypes were also generated from the ENG 
haplotypes.  Diplotypes were generated based on the categories formed during the haplotype test.  
Diplotypes with frequencies < 10% in either cases, controls, or both were combined into one 
category.  SPSS version 19 (SPSS Inc., Chicago, IL.) was used to compare the association 
between diplotype and preeclampsia status via a χ2 test of independence.   
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3.4 RESULTS 
3.4.1 White subgroup 
3.4.1.1 Demographic and clinical characteristics 
Demographic and clinical characteristics for the white subgroup comprised of 181 cases and 174 
controls (see Figure 2 for final sample size explanation) are presented in Table 7.  A post hoc 
power analysis using Quanto version 1.2.4 revealed that a sample of 181 controls matched to 181 
cases resulted in a power ranging from .8979 to .9990 for an α = .05 and .07437 to .9934 for an α 
= .01. Cases and controls did not significantly differ for variables on which they were matched 
(age, parity).  Women with preeclampsia had a higher pre-pregnancy BMI (M = 25.8 kg/m2 vs. 
M = 22.9 kg/m2, p < .001), a higher average blood pressure at < 20 weeks gestation (SBP: M = 
116.6 mmHg vs. M = 112.1 mmHg, p < .001; DBP: M = 71.7 mmHg vs. M = 68.1 mmHg, p < 
.001) and a higher average blood pressure in labor (SBP: M = 154.8 mmHg vs. M = 120.4 
mmHg, p < .001; DBP: M = 92.6 mmHg vs. M = 72.3 mmHg, p < .001) compared to healthy 
controls.  Gestational age at delivery was earlier in women with preeclampsia (M = 36.1 weeks 
vs. M = 39.6 weeks, p < .001) and the percentage of cesarean section deliveries was higher in 
women with preeclampsia (42% vs. 18.1%, p < .001).  Babies born to women with preeclampsia 
were of lower birthweight (M = 2497.5 grams vs. M = 3481.6 grams, p <.001) and were more 
likely to be small for gestational age (26.0% vs. 4.0%, p < .001).   
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Figure 2. Sample Flow Chart of White Subgroup 
 
 
 
182 white cases and 182 white controls 
(1:1 frequency matched on age, parity)  
Removal of n = 1 case with poor 
sample call rate across both iPLEX® 
assays along with the removal of n = 
1 randomly selected matched control 
Removal of n = 7 controls that 
delivered prior to 37.0 weeks of 
gestation.  To prevent further loss of 
power, the decision was made to not 
remove randomly selected matched 
cases.  
FINAL SAMPLE SIZE: 
181 cases and 174 controls 
181 white cases and 181 white controls 
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Table 7. Demographic and Clinical Characteristics of White Subgroup 
Variable Cases (n = 181) Controls (n = 174) p-value 
Maternal age (M (SD), years) 28.3 (5.8) 28.4 (5.7) .866a 
Gravida (Mdn (min-max)) 1 (1-6) 1 (1-8) .082b 
Nulliparous (n, %) 146 (80.7%) 139 (79.9%) .854c 
Gestational age at delivery (M (SD), weeks) 36.1 (3.2) 39.6 (1.1) < .001d 
Birthweight (M (SD), grams)e 2497.5 (841.2) 3481.6 (446.3) < .001d 
Caesarean section (n, %)f 74 (42%) 30 (18.1%) < .001c 
Small for gestational age (n, %) 47 (26.0%) 7 (4.0%) < .001c 
Avg. SBP < 20 weeks gestation (M (SD), mmHg)g 116.6 (9.6) 112.1 (7.5) < .001d 
Avg. DBP < 20 weeks gestation (M (SD), mmHg)g 71.7 (7.2) 68.1 (4.9) < .001d 
Avg. SBP in labor (M (SD), mmHg)h 154.8 (13.9) 120.4 (10.2) < .001d 
Avg. DBP in labor (M (SD), mmHg)i 92.6 (8.0) 72.3 (7.2) <. 001a 
Pre-pregnancy BMI (Mdn (min-max))j 25.8 (17-46) 22.9 (16-37) < .001b 
Note.  aIndependent samples t-test; bMann-Whitney U test; cχ2 test of independence; 
dIndependent samples t-test with unequal variances; eOutlier removed in control group; fn = 176 
cases and n = 166 controls due to missing data; Avg. = average; SBP = systolic blood pressure; 
mmHg = millimeters of mercury; gn = 168 cases and n = 170 controls due to missing data; DBP 
= diastolic blood pressure; hn = 181 cases and n = 173 controls due to missing data; in = 180 
cases and  n = 173 controls due to missing data and removal of outlier in case group; BMI = 
body mass index; jBMI values imputed for n = 22 cases, sample size was n = 178 cases and n = 
172 controls due to removal of outliers 
 
3.4.1.2 Genotype call rates, MAF, HWE 
Descriptive information for each tSNP and functional SNP is provided in Table 8.  tSNPs 
rs8179181 and rs3087465 could not be genotyped, despite multiple attempts with iPLEX® and 
TaqMan®, and functional SNP rs11466314 was monomorphic in the white subgroup, resulting 
in their omission from analysis.  The remaining 46 SNPs had genotype call rates that ranged 
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from 98% – 100%.  Of the 46 SNPs included in the analysis, five tSNPs violated HWE (p < .05) 
in the white subgroup.  One tSNP was located in TGFβR1 (rs10739778), one tSNP was located 
in ENG (rs11792480), and three tSNPs were located in TGFβR2 (rs3773652, rs1346907, 
rs877572). Separate evaluation of HWE in cases and controls revealed that rs10739778 was in 
HWE in controls (p = .846), rs11792480 was in HWE in cases (p = .193), rs3773652 was in 
HWE in controls and cases separately (p = .069 & p = .238), rs1346907 was in HWE in controls 
(p = .098), and rs877572 was in HWE in controls (p = .315).   
Table 8. tSNP and Functional SNP Information in White Subgroup (N = 355) 
Gene-Chromosome 
tSNP 
Wildtype Allele/ Nucleotide 
#/ Variant Allelea 
n for 
each SNP 
Study 
MAF 
HapMap 
MAF 
HWEb 
ALK5(TGFBR1)-
Chr9 
     
rs6478974 T/101874403/A 349 A = .483 A = .469 p = .434 
rs10739778 A/101875789/C 352 C = .314 C = .292 p = .040 
rs420549 G/101914873/C 350 C = .169 C = .204 p = .433 
ALK1-Chr12      
rs3759178 T/52299259/G 350 G = .369 G = .398 p = .917 
rs11169953 C/52304399/T 350 T = .351 T = .250 p = .958 
rs706819 G/52315923/A 350 A = .226 A = .286 p = .799 
TGFB1-Chr19      
rs8179181 --/41838206/-- ---- ---- ---- ---- 
rs4803455 C/41851509/A 350 A = .487 A = .496 p = .840 
rs11466314 G/41860236/A 350 A = .000 A = .000 ---- 
rs1800469 C/41860296/T 350 T = .301 T = .288 p = .286 
rs1800468 C/41860587/T 353 T = .086 T = .050 p = .312 
rs4803457 C/41861359/T 350 T = .384 T = .381 p = .601 
ENG-Chr9      
rs10987746 T/130580093/C 349 C = .493 C = .415 p = .869 
rs10819309 G/130581723/A 349 A =.367 A = .473 p = .99 
rs10760505 C/130589853/T 348 T = .386 T = .341 p = .495 
rs11792480 G/130598125/A 350 A = .326 A = .353 p = .008 
rs10121110 A/130602408/G 348 G = .392 G = .412 p = .057 
TGFBR2-Chr3      
rs3087465 --/30647160/-- ---- ---- ---- ---- 
rs6550005 G/30650064/A 355 A = .192 A = .243 p = .088 
rs11129420 A/30658541/T 355 T = .475 A = .487 p = .671 
rs6802220 G/30659652/A 355 A = .414 A = .363 p = .199 
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Gene-Chromosome 
tSNP 
Wildtype Allele/ Nucleotide 
#/ Variant Allelea 
n for 
each SNP 
Study 
MAF 
HapMap 
MAF 
HWEb 
rs17025785 T/30667425/C 355 C = .334 C = .330 p = .708 
rs4522809 C/30668684/T 355 T = .499 C = .478 p = .708 
rs4955212 C/30669358/T 351 T = .268 T = .252 p = .752 
rs5020833 C/30670425/G 355 G = .304 G = .296 p = .823 
rs6809777 C/30672362/T 355 T = .261 T = .270 p = .104 
rs12487185 A/30677269/G 355 G = .283 G = .323 p = .146 
rs11924422 A/30677484/C 355 C = .431 C = .456 p = .655 
rs13083813 T/30679558/A 354 A = .377 A = .398 p = .888 
rs13075948 C/30683506/T 355 T = .275 T = .265 p > .999 
rs1155708 G/30686740/A 354 A = .322 A = .336 p = .424 
rs13086588 T/30688757/G 355 G = .314 G = .332 p = .141 
rs2082224 G/30689755/A 355 A = .235 A = .235 p = .920 
rs1078985 T/30690911/C 349 C = .256 C = .332 p = .764 
rs1036097 G/30693643/A 355 A = .472 A = .412 p = .671 
rs995435 C/30700922/T 348 T = .263 T = .257 p = .791 
rs6792117 A/30704007/G 353 G = .482 A = .451 p = .689 
rs749794 T/30708432/C 350 C = .319 C = .332 p = .532 
rs3773640 A/30709511/T 355 T = .242 T = .270 p > .999 
rs3773644 C/30712344/T 355 T = .380 T = .438 p = .450 
rs3773645 C/30712460/G 354 G = .301 G = .367 p = .308 
rs3773652 A/30718942/G 355 G = .480 G = .469 p = .032 
rs2043136 T/30720304/C 355 C = .268 C = .239 p = .484 
rs1346907 C/30723470/T 355 T = .473 T = .451 p = .001 
rs876688 G/30725776/A 354 A = .340 A = .376 p = .238 
rs877572 G/30726432/C 355 C = .466 C = .460 p = .021 
rs9843942 G/30729636/A 354 A = .380 A = .375 p = .842 
rs3773663 G/30730872/A 355 A = .396 A = .429 p = .752 
rs744751 C/30735937/T 355 T = .265 T = .363 p = .396 
Note.  MAF = mean allele frequency; HWE= hardy weinberg equilibrium; awildtype and variant 
alleles based on study sample, nucleotide # obtained from UCSC Genome Browser assembly 
Feb. 2009 (GRCh37/hg19) (Fujita et al., 2011); b χ2 goodness-of-fit test or exact test (significant 
results bolded); ---- = not analyzed 
3.4.1.3 Allele test 
Allele test results are presented in Table 9.  In ENG, allelic frequency distributions for 
rs11792480 and rs10121110 were significantly different in cases and controls (Figure 3a-b).  
Compared to controls, the G allele of rs11792480 was over-represented in cases (71.7% vs. 
63.0%, p = .014) and the A allele of rs10121110 was over-represented in cases (66.0% vs. 
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55.3%, p = .004).  In TGFβR2, the allelic frequency distribution for rs6550005 was significantly 
different in cases and controls (Figure 3c).  Compared to controls, the G allele of rs6550005 was 
over-represented in cases (84.0% vs. 77.6%, p = .031).  Allele tests for the remaining tSNPs and 
functional SNP demonstrated no significant differences.   
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Table 9. Results of Association Analysis in White Subgroup (N = 355) 
Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
ALK5 (TGFBR1)         
rs6478974 T: 185 (51.7%) 
A: 173(48.3%) 
T: 176 (51.8%) 
A: 164 (48.2%) 
698 p > .999 TT: 50 (27.9%) 
AA: 44 (24.6%) 
TA: 85 (47.5%) 
TT: 47 (27.6%) 
AA: 41 (24.1%) 
TA: 82 (48.2%) 
349 p = .990 
rs10739778* A: 244 (68.2%) 
C: 114 (31.8%) 
A: 239 (69.1%) 
C: 107 (30.9%) 
704 p = .791 AA: 92 (51.4%) 
CC: 27 (15.1%) 
AC: 60 (33.5%) 
AA: 82 (47.4%) 
CC: 16 (9.2%) 
AC: 75 (43.4%) 
352 p = .453 
rs420549* G: 296 (82.2%) 
C: 64 (17.8%) 
G: 286 (84.1%) 
C: 54 (15.9%) 
700 p = .502 GG: 125 (69.4%) 
CC: 9 (5.0%) 
GC: 46 (25.6%) 
GG: 119 (70.0%) 
CC: 3 (1.8%) 
GC: 48 (28.2%) 
350 p = .910 
ALK1         
rs3759178 T: 235 (65.3%) 
G: 125 (34.7%) 
T: 207 (60.9%) 
G: 133 (39.1%) 
700 p = .229 TT: 75 (41.7%) 
GG: 20 (11.1%) 
GT: 85 (47.2%) 
TT: 65 (38.2%) 
GG: 28 (16.5%) 
GT: 77 (45.3%) 
350 p = .340 
rs11169953 C: 228 (63.3%) 
T: 132 (36.7%) 
C: 226 (66.5%) 
T: 114 (33.5%) 
700 p = .383 CC: 72 (40.0%) 
TT: 24 (13.3%) 
CT: 84 (46.7%) 
CC: 75 (44.1%) 
TT: 19 (11.2%) 
CT: 76 (44.7%) 
350 p = .685 
rs706819* G: 282 (78.3%) 
A: 78 (21.7%) 
G: 260 (76.5%) 
A: 80 (23.5%) 
700 p = .554 GG: 111 (61.7%) 
AA: 9 (5.0%) 
GA: 60 (33.3%) 
GG: 98 (57.6%) 
AA: 8 (4.7%) 
GA: 64 (37.6%) 
350 p = .444 
TGFB1         
rs4803455 C: 176 (48.9%) 
A: 184 (51.1%) 
C: 183 (53.8%) 
A: 157 (46.2%) 
700 p = .192 CC: 41 (22.8%) 
AA: 45 (25.0%) 
CA: 94 (52.2%) 
CC: 52 (30.6%) 
AA: 39 (22.9%) 
CA: 79 (46.5%) 
350 p = .253 
rs1800469* C: 259 (71.9%) 
T: 101 (28.1%) 
C: 230 (67.6%) 
T: 110 (32.4%) 
700 p = .216 CC: 94 (52.2%) 
TT: 15 (8.3%) 
CT: 71 (48.3%) 
CC: 81 (47.6%) 
TT: 21 (12.4%) 
CT: 68 (40.0%) 
350 p = .392 
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Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
rs1800468* C: 325 (90.8%) 
T: 33 (9.2%) 
C: 320 (92.0%) 
T: 28 (8.0%) 
706 p = .578 CC: 147 (82.1%) 
TT: 1 (.6%) 
CT: 31 (17.3%) 
CC: 149 (85.6%) 
TT: 3 (1.7%) 
CT: 22 (12.6%) 
353 p = .370 
rs4803457 C: 229 (63.6%) 
T: 131 (36.4%) 
C: 202 (59.4%) 
T: 138 (40.6%) 
700 p = .254 CC: 71 (39.4%) 
TT: 22 (12.2%) 
CT: 87 (48.3%) 
CC: 64 (37.6%) 
TT: 32 (18.8%) 
CT: 74 (43.5%) 
350 p = .225 
ENG         
rs10987746 T: 192 (53.6%) 
C: 166 (46.4%) 
T: 162 (47.6%) 
C: 178 (52.4%) 
698 p = .114 TT: 51 (28.5%) 
CC: 38 (21.2%) 
TC: 90 (50.3%) 
TT: 38 (22.4%) 
CC: 46 (27.1%) 
TC: 86 (50.6%) 
349 p = .283 
rs10819309 G: 219 (61.2%) 
A: 139 (38.8%) 
G: 223 (65.6%) 
A: 117 (34.4%) 
698 p = .227 GG: 65 (36.3%) 
AA: 25 (14.0%) 
GA: 89 (49.7%) 
GG: 75 (44.1%) 
AA: 22 (12.9%) 
GA: 73 (42.9%) 
349 p = .324 
rs10760505 C: 222 (62.0%) 
T: 136 (38.0%) 
C: 205 (60.7%) 
T: 133 (39.3%) 
696 p = .708 CC: 70 (39.1%) 
TT: 27 (15.1%) 
CT: 82 (45.8%) 
CC: 64 (37.9%) 
TT: 28 (16.6%) 
CT: 77 (45.6%) 
348 p = .925 
rs11792480 G: 258 (71.7%) 
A: 102 (28.3%) 
G: 214 (63.0%) 
A: 126 (37.0%) 
700 p = .014 GG: 96 (53.3%) 
AA: 18 (10.0%) 
AG: 66 (36.7%) 
GG: 74 (43.5%) 
AA: 30 (17.6%) 
AG: 66 (38.8%) 
350 p = .062 
rs10121110 A: 235 (66.0%) 
G: 121 (34.0%) 
A: 188 (55.3%) 
G: 152 (44.7%) 
696 p = .004 AA: 81 (45.5%) 
GG: 24 (13.5%) 
AG: 73 (41.0%) 
AA: 56 (32.9%) 
GG: 38 (22.4%) 
AG: 76 (44.7%) 
348 p = .022 
TGFBR2         
rs6550005* G: 304 (84.0%) 
A: 58 (16.0%) 
G: 270 (77.6%) 
A: 78 (22.4%) 
710 p = .031 GG: 130 (71.8%) 
AA: 7 (3.9%) 
GA: 44 (24.3%) 
GG: 107 (61.5%) 
AA: 11 (6.3%) 
GA: 56 (32.2%) 
355 p = .039 
rs11129420 A: 193 (53.3%) 
T: 169 (46.7%) 
A: 180 (51.7%) 
T: 168 (48.3%) 
710 p = .671 AA: 50 (27.6%) 
TT: 38 (21.0%) 
TA: 93 (51.4%) 
AA: 46 (26.4%) 
TT: 40 (23.0%) 
TA: 88 (50.6%) 
355 p = .897 
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Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
rs6802220 G: 216 (59.7%) 
A: 146 (40.3%) 
G: 200 (57.5%) 
A: 148 (42.5%) 
710 p = .554 GG: 64 (35.4%) 
AA: 29 (16.0%) 
AG: 88 (48.6%) 
GG: 52 (29.9%) 
AA: 26 (14.9%) 
AG: 96 (55.2%) 
355 p = .446 
rs17025785 T: 240 (66.3%) 
C: 122 (33.7%) 
T: 233 (67.0%) 
C: 115 (33.0%) 
710 p = .862 TT: 79 (43.6%) 
CC: 20 (11.0%) 
TC: 82 (45.3%) 
TT: 77 (44.3%) 
CC: 18 (10.3%) 
TC: 79 (45.4%) 
355 p = .976 
rs4522809 C: 185 (51.1%) 
T: 177 (48.9%) 
C: 171 (49.1%) 
T: 177 (50.9%) 
 
710 p = .603 CC: 48 (26.5%) 
TT: 44 (24.3%) 
CT: 89 (49.2%) 
CC: 43 (24.7%) 
TT: 46 (26.4%) 
CT: 85 (48.8%) 
355 p = .872 
rs4955212* C: 257 (71.8%) 
T: 101 (28.2%) 
C: 257 (74.7%) 
T: 87 (25.3%) 
702 p = .383 CC: 91 (50.8%) 
TT: 13 (7.3%) 
CT: 75 (41.9%) 
CC: 96 (55.8%) 
TT: 11 (6.4%) 
CT: 65 (37.8%) 
351 p = .350 
rs5020833* C: 252 (69.6%) 
G: 110 (30.4%) 
C: 242 (69.5%) 
G: 106 (30.5%) 
710 p > .999 CC: 88 (48.6%) 
GG: 17 (9.4%) 
CG: 76 (42.0%) 
CC: 83 (47.7%) 
GG: 15 (8.6%) 
CG: 76 (43.7%) 
355 p = .863 
rs6809777* C: 270 (74.6%) 
T: 92 (25.4%) 
C: 255 (73.3%) 
T: 93 (26.7%) 
710 p = .689 CC: 103 (56.9%) 
TT: 14 (7.7%) 
CT: 64 (35.4%) 
CC: 97 (55.7%) 
TT: 16 (9.2%) 
CT: 61 (35.1%) 
355 p = .826 
rs12487185* A: 261 (72.1%) 
G: 101 (27.9%) 
A: 248 (71.3%) 
G: 101 (28.7%) 
710 p = .806 AA: 101 (55.8%) 
GG: 21 (11.6%) 
GA: 59 (32.6%) 
AA: 87 (50.0%) 
GG: 13 (7.5%) 
GA: 74 (42.5%) 
355 p = .274 
rs11924422 A: 209 (57.7%) 
C: 153 (42.3%) 
A: 195 (56.0%) 
C: 153 (44.0%) 
710 p = .647 AA: 60 (33.1%) 
CC: 32 (17.7%) 
CA: 89 (49.2%) 
AA: 57 (32.8%) 
CC: 36 (20.7%) 
CA: 81 (46.6%) 
355 p = .759 
rs13083813 T: 221 (61.4%) 
A: 139 (38.6%) 
T: 220 (63.2%) 
A: 128 (36.8%) 
708 p = .617 TT: 68 (37.8%) 
AA: 27 (15.0%) 
AT: 85 (47.2%) 
TT: 70 (40.2%) 
AA: 24 (13.8%) 
AT: 80 (46.0%) 
354 p = .880 
rs13075948* C: 261 (72.1%) 
T: 101 (27.9%) 
C: 254 (73.0%) 
T: 94 (27.0%) 
710 p = .791 CC: 97 (53.6%) 
TT: 17 (9.4%) 
CT: 67 (37.0%) 
CC: 90 (51.7%) 
TT: 10 (5.7%) 
CT: 74 (42.5%) 
355 p = .725 
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Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
rs1155708 G: 247 (68.2%) 
A: 115 (31.8%) 
G: 233 (67.3%) 
A: 113 (32.7%) 
708 p = .806 GG: 87 (48.1%) 
AA: 21 (11.6%) 
GA: 73 (40.3%) 
GG: 79 (45.7%) 
AA: 19 (11.0%) 
GA: 75 (43.4%) 
354 p = .847 
rs13086588 T: 246 (68.0%) 
G: 116 (32.0%) 
T: 241 (69.3%) 
G: 107 (30.7%) 
710 p = .708 TT: 87 (48.1%) 
GG: 22 (12.2%) 
GT: 72 (39.8%) 
TT: 86 (49.4%) 
GG: 19 (10.9%) 
GT: 69 (39.7%) 
355 p = .927 
rs2082224* G: 278 (76.8%) 
A: 84 (23.2%) 
G: 265 (76.1%) 
A: 83 (23.9%) 
710 p = .841 GG: 108 (59.7%) 
AA: 11 (6.1%) 
GA: 62 (34.3%) 
GG: 100 (57.5%) 
AA: 9 (5.2%) 
GA: 65 (37.4%) 
355 p = .674 
rs1078985* T: 271 (75.7%) 
C: 87 (24.3%) 
T: 248 (72.9%) 
C: 92 (27.1%) 
698 p = .403 TT: 106 (59.2%) 
CC: 14 (7.8%) 
TC: 59 (33.0%) 
TT: 88 (51.8%) 
CC: 10 (5.9%) 
TC: 72 (42.4%) 
349 p = .161 
rs1036097 G: 188 (51.9%) 
A: 174 (48.1%) 
G: 187 (53.7%) 
A: 161 (46.3%) 
710 p = .632 GG: 49 (27.1%) 
AA: 42 (23.3%) 
GA: 90 (49.7%) 
GG: 52 (29.9%) 
AA: 39 (22.4%) 
GA: 83 (47.7%) 
355 p = .841 
rs995435* C: 263 (73.5%) 
T: 95 (26.5%) 
C: 250 (74.0%) 
T: 88 (26.0%) 
696 p = .888 CC: 99 (55.3%) 
TT: 15 (8.4%) 
CT: 65 (36.3%) 
CC: 91 (53.8%) 
TT: 10 (5.9%) 
CT: 68 (40.2%) 
348 p = .784 
rs6792117 A: 185 (51.7%) 
G: 173 (48.3%) 
A: 181 (52.0%) 
G: 167 (48.0%) 
706 p = .920 AA: 48 (26.8%) 
GG: 42 (23.5%) 
GA: 89 (49.7%) 
AA: 45 (25.9%) 
GG: 38 (21.8%) 
GA: 91 (52.3%) 
353 p = .883 
rs749794* T: 252 (70.0%) 
C: 108 (30.0%) 
T: 225 (66.2%) 
C: 115 (33.8%) 
700 p = .277 TT: 90 (50.0%) 
CC: 18 (10.0%) 
TC: 72 (40.0%) 
TT: 70 (41.2%) 
CC: 15 (8.8%) 
TC: 85 (50.0%) 
350 p = .098 
rs3773640* A: 276 (76.2%) 
T: 86 (23.8%) 
A: 262 (75.3%) 
T: 86 (24.7%) 
710 p = .764 AA: 109 (60.2%) 
TT: 14 (7.7%) 
AT: 58 (32.0%) 
AA: 95 (54.6%) 
TT: 7 (4.0%) 
AT: 72 (41.4%) 
355 p = .284 
rs3773644 C: 220 (60.8%) 
T: 142 (39.2%) 
C: 220 (63.2%) 
T: 128 (36.8%) 
710 p = .502 CC: 64 (35.4%) 
TT: 25 (13.8%) 
CT: 92 (50.8%) 
CC: 69 (39.7%) 
TT: 23 (13.2%) 
CT: 82 (47.1%) 
355 p = .702 
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Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
rs3773645* C: 253 (69.9%) 
G: 109 (30.1%) 
C: 242 (69.9%) 
G: 104 (30.1%) 
708 p > .999 CC: 87 (48.1%) 
GG: 15 (8.3%) 
CG: 79 (43.6%) 
CC: 82 (47.4%) 
GG: 13 (7.5%) 
CG: 78 (45.1%) 
354 p = .900 
rs3773652 A: 196 (54.1%) 
G: 166 (45.9%) 
A: 173 (49.7%) 
G: 175 (50.3%) 
710 p = .237 AA: 57 (31.5%) 
GG: 42 (23.2%) 
AG: 82 (45.3%) 
AA: 49 (28.2%) 
GG: 50 (28.7%) 
AG: 75 (43.1%) 
355 p = .479 
rs2043136* T: 274 (75.7%) 
C: 88 (24.3%) 
T: 246 (70.7%) 
C: 102 (29.3%) 
710 p = .133 TT: 106 (58.6%) 
CC: 13 (7.2%) 
TC: 62 (34.3%) 
TT: 87 (50.0%) 
CC: 15 (8.6%) 
TC: 72 (41.4%) 
355 p = .105 
rs1346907 C: 194 (53.6%) 
T: 168 (46.4%) 
C: 180 (51.7%) 
T: 168 (48.3%) 
710 p = .617 CC: 62 (34.3%) 
TT: 49 (27.1%) 
CT: 70 (38.7%) 
CC: 52 (29.9%) 
TT: 46 (26.4%) 
CT: 76 (43.7%) 
355 p = .582 
rs876688 G: 239 (66.4%) 
A: 121 (33.6%) 
G: 228 (65.5%) 
A: 120 (34.5%) 
708 p = .806 GG: 85 (47.2%) 
AA: 26 (14.4%) 
GA: 69 (38.3%) 
GG: 74 (42.5%) 
AA: 20 (11.5%) 
GA: 80 (46.0%) 
354 p = .324 
rs877572 G: 193 (53.3%) 
C: 169 (46.7%) 
G: 186 (53.4%) 
C: 162 (46.6%) 
710 p > .009 GG: 59 (32.6%) 
CC: 47 (26.0%) 
CG: 75 (41.4%) 
GG: 53 (30.5%) 
CC: 41 (23.6%) 
CG: 80 (46.0%) 
355 p = .686 
rs9843942 G: 218 (60.6%) 
A: 142 (39.4%) 
G: 221 (63.5%) 
A: 127 (36.5%) 
708 p = .420 GG: 68 (37.8%) 
AA: 30 (16.7%) 
GA: 82 (45.6%) 
GG: 69 (39.7%) 
AA: 22 (12.6%) 
GA: 83 (47.7%) 
354 p = .565 
rs3773663 G: 219 (60.5%) 
A: 143 (39.5%) 
G: 210 (60.3%) 
A: 138 (39.7%) 
710 p > .999 GG: 69 (38.1%) 
AA: 31 (17.1%) 
AG: 81 (44.8%) 
GG: 62 (35.6%) 
AA: 26 (14.9%) 
AG: 86 (49.4%) 
355 p = .662 
rs744751* C: 269 (74.3%) 
T: 93 (25.7%) 
C: 253 (72.7%) 
T: 95 (27.3%) 
710 p = .624 CC: 105 (58.0%) 
TT: 17 (9.4%) 
TC: 59 (32.6%) 
CC: 90 (51.7%) 
TT: 11 (6.3%) 
TC: 73 (42.0%) 
355 p = .234 
Note.  aχ2 test of independence testing association between allele and preeclampsia status; bχ2 test of independence testing association 
between SNP genotype (homozygote wildtype, homozygote variant, heterozygote) and preeclampsia status; *SNP genotypes 
dichotomized (homozygote wildtype, homozygote variant + heterozygote) due to small homozygote variant frequencies in either 
cases, controls, or both 
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a.          b.  
c.  
Figure 3. Frequency Distributions of tSNPs with Significant Allele Tests in the White Subgroup 
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3.4.1.4 Genotype test and logistic regression 
Genotype test results are also presented in Table 9.  In ENG, rs10121110 genotype was 
significantly associated with the development of preeclampsia (p = .022).  This association was 
further explored with binary logistic regression and was evaluated with a more stringent criterion 
(α = 0.01; 99% CI) to account for multiple testing.  Further analysis (Table 10) revealed that 
women homozygous for the A allele were 2.290 times more likely to develop preeclampsia 
compared to women homozygous for the G allele (β = .829, χ2(1) = 6.993, p = .008, exp(B) = 
2.290, 99% CI [1.022, 5.133]).  There was no significant difference in likelihood of developing 
preeclampsia between heterozygous women (AG) and women homozygous for the G allele (β = 
.419, χ2(1) = 1.853, p = .173, exp(B) = 1.521 , 99% CI [.688, 3.362]).   In TGFβR2, rs6550005 
genotype (dichotomized) was significantly associated with the development of preeclampsia (p = 
.039).  Further exploration of this association with the stringent p-value criterion (α = 0.01; 99% 
CI) found no significant difference in the likelihood of developing preeclampsia between women 
homozygous for the G allele and the combined group of women that were homozygous for the A 
allele or heterozygous (β = .468, χ2(1) = 4.239, p = .039, exp(B) = 1.596, 99% CI [.889, 2.865]).  
The remaining genotype tests demonstrated no significant differences, but it is important to note 
that the genotype test for rs11792480 trended toward significance (p = .062). 
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Table 10. Logistic Regression Results for tSNPs with Significant Genotype Tests in White Subgroup 
 
Note.  tSNP = tagging SNP; OR = odds ratio; CI = confidence interval; * = SNP genotypes 
dichotomized (homozygote wildtype, homozygote variant + heterozygote) due to small 
homozygote variant frequencies in either cases, controls, or both 
 
 
3.4.1.5 Linkage disequilibrium estimates & haplotype analysis 
Pairwise comparison of linkage disequilibrium across the five tSNPs in ENG revealed no 
significant correlations with each other.  R2 values ranged from .007 (rs10121110 & rs10987746) 
to .637 (rs10760505 & rs10987746).  The R2 value for rs10121110 and rs11792480, which were 
both significantly associated with preeclampsia (rs10121110- allele and genotype test; 
rs11792480- allele test) and are separated by about 4000 bases, was .292.  This indicates that 
these two SNPs are not in linkage disequilibrium with each other.  Table 11 shows a correlation 
matrix of the R2 values obtained from the pairwise comparisons.   
 
Table 11: Correlation Matrix of ENG Pairwise Comparisons (R2) 
 rs10987746 rs10819309 rs10760505 rs11792480 rs10121110 
rs10987746      
rs10819309 .562     
rs10760505 .637 .356    
rs11792480 .01 .011 .019   
rs10121110 .007 .008 .091 .292  
 
Gene/tSNP Genotype Groups OR 99% CI p-value 
ENG     
rs10121110 AA vs. GG 2.290 1.022 - 5.133 .008 
 AG vs. GG 1.521 .688 - 3.362 .173 
TGFBR2     
rs6550005* GG vs. AA + GA 1.596 .889 - 2.865 .039 
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PLINK software estimated 19 possible haplotypes across the five ENG tSNPs.  Only 17 
of the 19 estimated haplotypes were present in the white sample.  Table 12 displays the 
haplotype alleles and the frequencies of each allele in cases and controls.  The order of the 5 
tSNPs used in haplotype construction was as follows: rs10987746, rs10819309, rs10760505, 
rs11792480, rs10121110.  We found that the haplotype distributions (CGTGA, TACAG, 
TACGA, and combined) were significantly different in cases and controls (χ2(3) = 8.26, p = 
.041).  Further analysis revealed that TACGA, the haplotype containing the risks alleles from our 
significantly associated tSNPS, was over-represented in cases (χ2(1) = 5.23, p = .022) when 
comparing TACGA to all of the other alleles combined.  The combined haplotype category 
(CGCAA, CGCAG, CGCGG, CGTAA, CGTAG, CGTGG, TACGG, TGCAG, TGCGA, 
CGCGA, TACAA, TGCGG, CATAA, TGTGG) was over-represented in controls (χ2(1) = 5.75, 
p = .016) when compared to the other alleles (CGTGA, TACAG, TACGA) combined.  Pairwise 
comparisons of either CGTGA or TACAG compared to all of the other alleles combined were 
non-significant (data not shown).  We did not find any significant differences in ENG diplotypes 
among cases and controls (χ2(4) = 7.275, p = .122).  Table 13 demonstrates that there are 
differences in observed ENG haplotype frequencies among the white subgroup and black 
subgroup, with a 6.1% difference in TACGA frequency between the two groups (19.7% in white 
subgroup vs. 13.6% in black subgroup.  
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Table 12. ENG Haplotype Allele Frequencies in White Cases & Controls 
Haplotype Cases (n = 180 subjects) 
Allele Counts N (%) 
Controls (n = 170 subjects) 
Allele Counts N (%) 
CGTGA 94 (26.1%) 79 (23.2%) 
TACAG 51 (14.2%) 51 (15.0%) 
TACGA 83 (23.1%) 55 (16.2%) 
Combined: CGCAA, CGCAG, 
CGCGG, CGTAA, CGTAG, 
CGTGG, TACGG, TGCAG, 
TGCGA, CGCGA, TACAA, 
TGCGG, CATAA, TGTGG 
132 (36.7%) 155 (45.6%) 
Note.  tSNP order for haplotype assignment was rs10987746, rs10819309, rs10760505, 
rs11792480, rs10121110.  Allele frequencies based on analysis of the most probable haplotypes 
for each subject.  Haplotypes CATAG and TATAG (not listed above) did not represent the most 
probable haplotype for any of the subjects and were not included in any analyses.  
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Table 13. Comparison of Observed ENG Haplotype Frequencies Between Black & White Subgroups 
 Haplotype Black Total Subroup (n = 59 
subjects) Allele Frequencies (%) 
White Total Subgroup (n = 350 
subjects) Allele Frequencies (%) 
B
ot
h 
 S
ub
gr
ou
ps
 
CGTGA 9.3% 24.7% 
TACAG 10.2% 14.6% 
TACGA 13.6% 19.7% 
CGCGG 23.7% 5.4% 
TACGG 8.5% 2.1% 
TGCAG 0.8% 4.4% 
TGCGA 4.2% 9.3% 
CGCGA 10.2% 0.4% 
TGCGG 16.1% 0.14% 
W
hi
te
s 
 
 
CGCAA 0.0% 0.6% 
CGCAG 0.0% 4.4% 
CGTAA 0.0% 5.6% 
CGTAG 0.0% 2.6% 
CGTGG 0.0% 5.4% 
TACAA 0.0% 0.3% 
CATAA 0.0% 0.14% 
TGTGG 0.0% 0.14% 
B
la
ck
s 
CGTGG 2.5% 0.0% 
TGCAA 0.8% 0.0% 
Note.  The haplotype frequencies were based on what was observed in the subjects using the 
most probable haplotypes for each subject.  One subject from the black subgroup and five 
subjects from the white subgroup did not have available haplotypes.  
 
3.4.1.6 Clinical characteristics by SNP genotype assignment 
Blood pressure measurements and pre-pregnancy BMI were significantly different in cases and 
controls (Table 7).  Given these results, we further examined whether genotype assignment of the 
tSNPs with significant genotype tests (rs10121110 and rs6550005) were associated with these 
clinical characteristics.  Neither average SBP less than 20 weeks’ gestation (F(2, 328) = .500, p = 
.607), average DBP less than 20 weeks’ (F(2, 177.984) = .265, p = .767), average SBP in labor 
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(F(2, 172.976) = 2.137, p = .121), average DBP in labor (F(2, 344) = 1.767, p = .172), or pre-
pregnancy BMI (H(2) = 1.321, p = .517) were significantly different between rs10121110 
genotype groups.  Moreover, rs6550005 genotype assignment (dichotomized) was not 
significantly associated with average SBP less than 20 weeks’ gestation (t(336) = -1.196, p = 
.233), average DBP less than 20 weeks’ (t(336) = -.563, p = .574), average SBP in labor (U = 
12198.0, p = .066), average DBP in labor (t(352) = 1.552, p = .122), or pre-pregnancy BMI (U  = 
13565.5, p = .840).  
3.4.2 Black subgroup 
3.4.2.1 Demographic and clinical characteristics 
Demographic and clinical characteristics for the black subgroup comprised of 30 cases and 30 
controls (Figure 4) are presented in Table 14.  Cases and controls did not significantly differ for 
variables on which they were matched (age, parity).  Unlike what we observed in the white 
subgroup, women with preeclampsia were not significantly different from healthy controls with 
respect to pre-pregnancy BMI, average systolic and diastolic blood pressure at < 20 weeks’ 
gestation, or percent of cesarean section deliveries in the black subgroup.  Women with 
preeclampsia had a higher average blood pressure in labor (SBP: M = 159.9 mmHg vs. M = 
120.7 mmHg, p < .001; DBP: M = 97.1 mmHg vs. M = 72.6 mmHg, p < .001) and delivered at 
an earlier gestational age (M = 36.9 weeks vs. M = 40.6 weeks, p < .001) compared to healthy 
controls.  Babies born to women with preeclampsia were of lower birthweight (M = 2313.9 
grams vs. M = 3388.8 grams, p <.001) and were more likely to be small for gestational age 
(33.3% vs. 3.3%, p = .003).    
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Figure 4. Sample Flow Chart of Black Subgroup 
 
 
 
 
 
 
 
 
 
 
33 black cases and 33 black controls 
(1:1 frequency matched on age, parity) 
Removal of n = 2 cases and n = 1 
control with poor sample call rates 
across both iPLEX® assays along 
with the removal of n =2  randomly 
selected matched controls and n = 1 
randomly selected matched case  
FINAL SAMPLE SIZE: 
30 black cases and 30 black controls 
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Table 14. Demographic and Clinical Characteristics of Black Subgroup 
Variable Cases (n = 30) Controls (n = 30) p-value 
Maternal age (Mdn (min-max), years) 20.0 (14-37) 20.0 (14-37) .988a 
Gravida (Mdn (min-max)) 1 (1-6) 1 (1-6) .384a 
Nulliparous (n, %) 25 (83.3%) 25 (83.3%) ------- 
Gestational age at delivery (Mdn (min-max), weeks) 36.9 (27.4-40.0) 40.6 (37.1-42.1) <  .001a 
Birthweight (M (SD), grams) 2313.9 (715.8) 3388.8 (405.3) < .001b 
Caesarean section (n, %)c 17 (65.4%) 19 (70.4%) .697d 
Small for gestational age (n, %) 10 (33.3%) 1 (3.3%) .003d 
Avg. SBP < 20 weeks gestation (M (SD), mmHg)e 113.3 (9.2) 114.4 (6.8) .599f 
Avg. DBP < 20 weeks gestation (M (SD), mmHg)e 70.4 (6.5) 69.2 (4.2) .405f 
Avg. SBP in labor (M (SD), mmHg)g 159.9 (17.8) 120.7 (9.1) < .001b 
Avg. DBP in labor (M (SD), mmHg)g 97.1 (10.4) 72.6 (7.4) < .001f 
Pre-pregnancy BMI (Mdn (min-max))h 23.0 (17.7-38.4) 25.8 (19.4-49.9) .250a 
Note.  aMann-Whitney U test; bIndependent samples t-test with unequal variances; cn = 26 cases 
and n = 27 controls due to missing data;  dχ2 test of independence; SBP = systolic blood 
pressure; mmHg = millimeters of mercury; en = 24 cases and n = 29 controls due to missing data; 
fIndependent samples t-test; DBP = diastolic blood pressure; gn = 30 cases and n = 29 controls 
due to missing data; hn = 27 cases and n = 30 controls due to missing data  
 
3.4.2.2 Genotype call rates, MAF, HWE 
Descriptive information for each tSNP and functional SNP is provided in Table 15.  tSNPS 
rs8179181 and rs3087465 could not be genotyped and functional SNP rs11477314 was 
essentially monomorphic in the black subgroup, resulting in their omission from analysis.  The 
remaining 46 SNPs had genotype call rates that ranged from 98.3% - 100%.  Of the 46 SNPs 
analyzed, 3 tSNPs violated HWE (p < .05) in the black subgroup.  One tSNP was located in 
81 
 
ALK1 (rs11169953) and two tSNPs were located in TGFβR2 (rs12487185 and rs1078985).  
Separate evaluation of HWE in cases and controls revealed that rs11169953 was in HWE in 
cases and controls separately (p = .119 & p = .145), rs12487185 was in HWE in cases (p = .099), 
and rs1078985 was in HWE in cases and controls separately (p = .155 & p = .165). 
Table 15. tSNP and Functional SNP Information in Black Subgroup (N = 60) 
Gene-Chromosome 
tSNP 
Wildtype Allele/ 
Nucleotide #/ Variant Allelea 
n for 
each SNP 
Study 
MAF 
HapMap 
MAF 
HWEb 
ALK5(TGFBR1)-
Chr9 
     
rs6478974 T/101874403/A 59 A = .237 A = .075 p = .276 
rs10739778 A/101875789/C 59 C = .322 C = .339 p = .597 
rs420549 G/101914873/C 59 C = .119 C = .106 p = .582 
ALK1-Chr12      
rs3759178 T/52299259/G 59 G = .398 T = .491 p = .146 
rs11169953 C/52304399/T 59 T = .466 T = .482 p = .028 
rs706819 G/52315923/A 59 A = .297 A = .236 p = .899 
TGFB1-Chr19      
rs8179181 --/41838206/-- ---- ---- ---- ---- 
rs4803455 C/41851509/A 59 A = .492 C = .397 p = .157 
rs11466314 G/41860236/A 59 A = .051 A = .025 ---- 
rs1800469 C/41860296/T 59 T = .271 T = .208 p = .741 
rs1800468 C/41860587/T 60 T = .050 T = .033 p > .999 
rs4803457 C/41861359/T 59 T = .483 T = .420 p = .237 
ENG-Chr9      
rs10987746 T/130580093/C 59 C = .458 C = .438 p = .371 
rs10819309 G/130581723/A 59 A = .322 A = .195 p = .249 
rs10760505 C/130589853/T 59 T = .119 T = .058 p = .169 
rs11792480 G/130598125/A 59 A = .119 A = .004 p = .169 
rs10121110 G/130602408/A 59 A = .381 A = .310 p = .823 
TGFBR2-Chr3      
rs3087465 --/30647160/-- ---- ---- ---- ---- 
rs6550005 G/30650064/A 60 A = .367 G = .491 p = .294 
rs11129420 A/30658541/T 60 T = .292 T = .097 p = .572 
rs6802220 A/30659652/G 60 G = .358 G = .243 p = .484 
rs17025785 T/30667425/C 60 C = .300 C = .283 p = .380 
rs4522809 T/30668684/C 60 C = .475 C = .411 p = .069 
rs4955212 C/30669358/T 60 T = .208 T = .208 p = .429 
rs5020833 C/30670425/G 60 G = .292 G = .142 p = .233 
rs6809777 C/30672362/T 60 T = .225 T = .204 p = .147 
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Gene-Chromosome 
tSNP 
Wildtype Allele/ 
Nucleotide #/ Variant Allelea 
n for 
each SNP 
Study 
MAF 
HapMap 
MAF 
HWEb 
rs12487185 A/30677269/G 60 G = .200 G = .088 p = .007 
rs11924422 A/30677484/C 60 C = .367 C = .381 p = .554 
rs13083813 T/30679558/A 60 A = .225 A = .075 p = .261 
rs13075948 C/30683506/T 60 T = .192 T = .155 p > .999 
rs1155708 G/30686740/A 60 A = .392 A = .358 p = .913 
rs13086588 T/30688757/G 60 G = .375 G = .319 p = .403 
rs2082224 G/30689755/A 60 A = .267 A = .243 p > .999 
rs1078985 T/30690911/C 59 C = .169 C = .221 p = .047 
rs1036097 G/30693643/A 60 A = .333 A = .292 p = .856 
rs995435 C/30700922/T 59 T = .356 T = .429 p = .390 
rs6792117 A/30704007/G 60 G = .383 G = .363 p = .655 
rs749794 T/30708432/C 59 C = .381 C = .451 p = .442 
rs3773640 A/30709511/T 60 T = .250 T = .248 p = .487 
rs3773644 C/30712344/T 60 T = .325 T = .332 p = .856 
rs3773645 C/30712460/G 60 G = .225 G = .111 p = .055 
rs3773652 G/30718942/A 60 A = .467 A = .292 p = .277 
rs2043136 T/30720304/C 60 C = .225 C = .279 p = .712 
rs1346907 C/30723470/T 60 T = .283 T = .221 p > .001 
rs876688 G/30725776/A 60 A = .433 A = .429 p = .517 
rs877572 G/30726432/C 60 C = .292 C = .246 p = .549 
rs9843942 G/30729636/A 60 A = .467 G = .385 p = .310 
rs3773663 G/30730872/A 60 A = .450 A = .385 p = .938 
rs744751 C/30735937/T 60 T = .125 T = .058 p > .001 
Note.  MAF = mean allele frequency; HWE= hardy weinberg equilibrium; awildtype and variant 
alleles based on study sample, nucleotide # obtained from UCSC Genome Browser assembly 
Feb. 2009 (GRCh37/hg19) (Fujita et al., 2011); bχ2 goodness-of-fit test or exact test (significant 
results bolded); ---- = not analyzed 
 
3.4.2.3 Allele test 
Allele test results are presented in Table 16.  In TGFβR1, the allelic distribution for rs10739778 
was significantly different in cases and controls (Figure 5a).  Compared to controls, the A allele 
was over-represented in cases (79.3% vs. 56.7%, p = .008).  In TGFβR2, allelic frequency 
distributions for rs6550005, rs1346907, and rs877572 were significantly different in cases and 
controls (Figure 5b-d).  Compared to controls, the A allele of rs6550005 was over-represented in 
cases (46.7% vs. 26.7%, p = .023), the C allele of rs1346907 was over-represented in cases 
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(70.0% vs. 63.3%, p = .043), and the G allele of rs877572 was over-represented in cases (70.0% 
vs. 61.7%, p = .027).  Allele tests for the remaining tSNPs and functional SNP were non-
significant.   
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Table 16. Results of Association Analysis in Black Subgroup (Total N = 60) 
Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
ALK5 (TGFBR1)         
rs6478974* T: 40 (69.0%) 
A: 18 (31.0%) 
 
T: 50 (83.3%) 
A: 10 (16.7%) 
118 p = .067 TT: 15 (51.7%) 
AA: 4 (13.8%) 
TA: 10 (34.5%) 
TT: 21 (70.0%) 
AA: 1 (3.3%) 
TA: 8 (26.7%) 
59 p = .150 
rs10739778 A: 46 (79.3%) 
C: 12 (20.7%) 
A: 34 (56.7%) 
C: 26 (43.3%) 
118 p = .008 AA: 19 (65.5%) 
CC: 2 (6.9%) 
AC: 8 (27.6%) 
AA: 9 (30.0%) 
CC: 5 (16.7%) 
AC: 16 (53.3%) 
59 p = .028 
rs420549* G: 53 (91.4%) 
C: 5 (8.6%) 
G: 51 (85.0%) 
C: 9 (15.0%) 
118 p = .284 GG: 24 (82.8%) 
CC: 0 (0.0%) 
GC: 5 (17.2%) 
GG: 22 (73.3%) 
CC: 1 (3.3%) 
GC: 7 (23.3%) 
59 p = .383 
ALK1         
rs3759178 T: 33 (56.9%) 
G: 25 (43.1%) 
T: 38 (63.3%) 
G: 22 (36.7%) 
118 p = .475 TT: 10 (34.5%) 
GG: 6 (20.7%) 
GT: 13 (44.8%) 
TT: 14 (46.7%) 
GG: 6 (20.0%) 
GT: 10 (33.3%) 
59 p = .594 
rs11169953 C: 34 (58.6%) 
T: 24 (41.4%) 
C: 29 (48.3%) 
T: 31 (51.7%) 
118 p = .264 CC: 12 (41.4%) 
TT: 7 (24.1%) 
CT: 10 (34.5%) 
CC: 9 (30.0%) 
TT: 10 (33.3%) 
CT: 11 (36.7%) 
59 p = .610 
rs706819* G: 43 (74.1%) 
A: 15 (25.9%) 
G: 40 (66.7%) 
A: 20 (33.3%) 
118 p = .374 GG: 16 (55.2%) 
AA: 2 (6.9%) 
GA: 11 (37.9%) 
GG: 13 (43.3%) 
AA: 3 (10.0%) 
GA: 14 (46.7%) 
59 p = .363 
TGFB1         
rs4803455 C: 33 (56.9%) 
A: 25 (43.1%) 
C: 27 (45.0%) 
A: 33 (55.0%) 
118 p = .196 CC: 8 (27.6%) 
AA: 4 (13.8%) 
CA: 17 (58.6%) 
CC: 10 (33.3%) 
AA: 13 (43.3%) 
CA: 7 (23.3%) 
59 p = .010 
rs1800469* C: 40 (69.0%) 
T: 18 (31.0%) 
C: 46 (76.7%) 
T: 14 (23.3%) 
118 p = .348 CC: 13 (44.8%) 
TT: 2 (6.9%) 
CT: 14 (48.3%) 
CC: 19 (63.3%) 
TT: 3 (10.0%) 
CT: 8 (26.7%) 
59 p = .154 
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Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
rs1800468* C: 57 (95.0%) 
T: 3 (5.0%) 
C: 57 (95.0%) 
T: 3 (5.0%) 
120 p > .999 CC: 27 (90.0%) 
TT: 0 (0.0%) 
CT: 3 (10.0%) 
CC: 27 (90.0%) 
TT: 0 (0.0%) 
CT: 3 (10.0%) 
60 p > .999 
rs4803457 C: 25 (43.1%) 
T: 33 (56.9%) 
C: 36 (60.0%) 
T: 24 (40.0%) 
118 p = .066 CC: 4 (13.8%) 
TT: 8 (27.6%) 
CT: 17 (58.6%) 
CC: 14 (46.7%) 
TT: 8 (26.7%) 
CT: 8 (26.7%) 
59 p = .012 
ENG         
rs10987746 T: 31 (53.4%) 
C: 27 (46.6%) 
T: 33 (55.0%) 
C: 27 (45.0%) 
118 p = .862 TT: 9 (31.0%) 
CC: 7 (24.1%) 
TC: 13 (44.8%) 
TT: 10 (33.3%) 
CC: 7 (23.3%) 
TC: 13 (43.3) 
59 p = .982 
rs10819309 G: 41 (70.7%) 
A: 17 (29.3%) 
G: 39 (65.0%) 
A: 21 (35%) 
118 p = .507 GG: 16 (55.2%) 
AA: 4 (13.8%) 
GA: 9 (31.0%) 
GG: 13 (43.3%) 
AA: 4 (13.3%) 
GA: 13 (43.3%) 
59 p = .590 
rs10760505* C: 50 (86.2%) 
T: 8 (13.8%) 
C: 54 (90.0%) 
T: 6 (10.0%) 
118 p = .522 CC: 22 (75.9%) 
TT: 1 (3.4%) 
CT: 6 (20.7%) 
CC: 25 (83.3%) 
TT: 1 (3.3%) 
CT: 4 (13.3%) 
59 p = .476 
rs11792480* G: 49 (84.5%) 
A: 9 (15.5%) 
G: 55 (91.7%) 
A: 5 (8.3%) 
118 p = .227 GG: 22 (75.9%) 
AA: 2 (6.9%) 
AG: 5 (17.2%) 
GG: 25 (83.3%) 
AA: 0 (0.0%) 
AG: 5 (16.7%) 
59 p = .476 
rs10121110 G: 37 (63.8%) 
A: 21 (36.2%) 
G: 36 (60.0%) 
A: 24 (40.0%) 
118 p = .671 GG: 13 (44.8%) 
AA: 5 (17.2%) 
AG: 11 (37.9%) 
GG: 10 (33.3%) 
AA: 4 (13.3%) 
AG: 16 (53.3%) 
59 p = .472 
TGFBR2         
rs6550005 G: 32 (53.3%) 
A: 28 (46.7%) 
G: 44 (73.3%) 
A: 16 (26.7%) 
120 p = .023 GG: 9 (30.0%) 
AA: 7 (23.3%) 
GA: 14 (46.7%) 
GG: 17 (56.7%) 
AA: 3 (10.0%) 
GA: 10 (33.3%) 
60 p = .094 
rs11129420 A: 40 (66.7%) 
T: 20 (33.3%) 
A: 45 (75.0%) 
T: 15 (25.0%) 
120 p = .315 AA: 13 (43.3%) 
TT: 3 (10.0%) 
TA: 14 (46.7%) 
AA: 18 (60.0%) 
TT: 3 (10.0%) 
TA: 9 (30.0%) 
60 p = .419 
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Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
rs6802220 A: 37 (61.7%) 
G: 23 (38.3%) 
 
A: 40 (66.7%) 
G: 20 (33.3%) 
120 p = .566 AA: 11 (36.7%) 
GG: 4 (13.3%) 
AG: 15 (50.0%) 
AA: 15 (50.0%) 
GG: 5 (16.7%) 
AG: 10 (33.3%) 
60 p = .418 
rs17025785* T: 42 (70.0%) 
C: 18 (30.0%) 
T: 42 (70.0%) 
C: 18 (30.0%) 
120 p > .999 TT: 14 (46.7%) 
CC: 2 (6.7%) 
TC: 14 (46.7%) 
TT: 14 (46.7%) 
CC: 2 (6.7%) 
TC: 14 (46.7%) 
60 p > .999 
rs4522809 T: 33 (55.0%) 
C: 27 (45.0%) 
T: 30 (50.0%) 
C: 30 (50.0%) 
120 p = .584 TT: 8 (26.7%) 
CC: 5 (16.7%) 
CT: 17 (56.7%) 
TT: 5 (16.7%) 
CC: 5 (16.7%) 
CT: 20 (66.7%) 
60 p = .626 
rs4955212* C: 48 (80.0%) 
T: 12 (20.0%) 
C: 47 (78.3%) 
T: 13 (21.7%) 
120 p = .823 CC: 18 (60.0%) 
TT: 0 (0%) 
CT: 12 (40.0%) 
CC: 18 (60.0%) 
TT: 1 (3.3%) 
CT: 11 (36.7%) 
60 p > .999 
rs5020833* C: 45 (75.0%) 
G: 15 (25.0%) 
C: 40 (66.7%) 
G: 20 (33.3%) 
120 p = .315 GG: 17 (56.7%) 
AA: 2 (6.7%) 
GA: 11 (36.7%) 
GG: 15 (50.0%) 
AA: 5 (16.7%) 
GA: 10 (33.3%) 
60 p = .605 
rs6809777* C: 48 (80.0%) 
T: 12 (20.0%) 
C: 45 (75.0%) 
T: 15 (25.0%) 
120 p = .512 CC: 21 (70.0%) 
TT: 3 (10.0%) 
CT: 6 (20.0%) 
CC: 17 (56.7%) 
TT: 2 (6.7%) 
CT: 11 (36.7%) 
60 p = .422 
rs12487185* A: 51 (85.0%) 
G: 9 (15.0%) 
A: 45 (75.0%) 
G: 15 (25.0%) 
120 p = .170 AA: 23 (76.7%) 
GG: 2 (6.7%) 
GA: 5 (16.7%) 
AA: 19 (63.3%) 
GG: 4 (13.3%) 
GA: 7 (23.3%) 
60 p = .260 
rs11924422* A: 33 (55.0%) 
C: 27 (45.0%) 
A: 43 (71.7%) 
C: 17 (28.3%) 
120 p = .058 AA: 8 (26.7%) 
CC: 5 (16.7%) 
CA: 17 (56.7%) 
AA: 15 (50.0%) 
CC: 2 (6.7%) 
CA: 13 (43.3%) 
60 p = .063 
rs13083813* T: 44 (73.3%) 
A: 16 (26.7%) 
T: 49 (81.7%) 
A: 11 (18.3%) 
120 p = .275 TT: 15 (50.0%) 
AA: 1 (3.3%) 
AT: 14 (46.7%) 
TT: 19 (63.3%) 
AA: 0 (0.0%) 
AT: 11 (36.7%) 
60 p = .297 
rs13075948* C: 48 (70.0%) 
T: 12 (30.0%) 
C: 49 (81.7%) 
T: 11 (18.3%) 
120 p = .823 CC: 19 (63.3%) 
TT: 1 (3.3%) 
CT: 10 (33.3%) 
CC: 20 (66.7%) 
TT: 1 (3.3%) 
CT: 9 (30.0%) 
60 p = .787 
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Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
rs1155708 G: 39 (65.0%) 
A: 21 (35.0%) 
G: 34 (56.7%) 
A: 26 (43.3%) 
120 p = .351 GG: 12 (40.0%) 
AA: 3 (10.0%) 
GA: 15 (50.0%) 
GG: 10 (33.3%) 
AA: 6 (20.0%) 
GA: 14 (46.7%) 
60 p = .611 
rs13086588 T: 41 (68.3%) 
G: 19 (31.7%) 
T: 34 (56.7%) 
G: 26 (43.3%) 
120 p = .187 TT: 14 (46.7%) 
GG: 3 (10.0%) 
GT: 13 (43.3%) 
TT: 11 (36.7%) 
GG: 7 (23.3%) 
GT: 12 (40.0%) 
60 p = .368 
rs2082224* G: 46 (76.7%) 
A: 14 (23.3%) 
G: 42 (70.0%) 
A: 18 (30.0%) 
120 p = .410 GG: 17 (56.7%) 
AA: 1 (3.3%) 
GA: 12 (40.0%) 
GG: 15 (50.0%) 
AA: 3 (10.0%) 
GA: 12 (40.0%) 
60 p = .605 
rs1078985* T: 50 (83.3%) 
C: 10 (16.7%) 
T: 48 (82.8%) 
C: 10 (17.2%) 
118 p = .920 TT: 22 (73.3%) 
CC: 2 (6.7%) 
TC: 6 (20.0%) 
TT: 21 (72.4%) 
CC: 2 (6.9%) 
TC: 6 (20.7%) 
59 p = .937 
rs1036097* G: 39 (65.0%) 
A: 21 (35.0%) 
G: 41 (68.3%) 
A: 19 (31.7%) 
120 p = .699 GG: 11 (36.7%) 
AA: 2 (6.7%) 
GA: 17 (56.7%) 
GG: 16 (53.3%) 
AA: 5 (16.7%) 
GA: 9 (30.0%) 
60 p = .194 
rs995435 C: 40 (66.7%) 
T: 20 (33.3%) 
C: 36 (62.1%) 
T: 22 (37.9%) 
118 p = .603 CC: 14 (46.7%) 
TT: 4 (13.3%) 
CT: 12 (40.0%) 
CC: 12 (41.4%) 
TT: 5 (17.2%) 
CT: 12 (41.4%) 
59 p = .940 
rs6792117 A: 35 (58.3%) 
G: 25 (41.7%) 
A: 39 (65.0%) 
G: 21 (35.0%) 
120 p = .454 AA: 8 (26.7%) 
GG: 3 (10.0%) 
GA: 19 (63.3%) 
AA: 14 (46.7%) 
GG: 5 (16.7%) 
GA: 11 (36.7%) 
60 p = .140 
rs749794* T: 41 (70.7%) 
C: 17 (29.3%) 
T: 32 (53.3%) 
C: 28 (46.7%) 
118 p = .052 TT: 14 (48.3%) 
CC: 2 (6.9%) 
TC: 13 (44.8%) 
TT: 10 (33.3%) 
CC: 8 (26.7%) 
TC: 12 (40.0%) 
59 p = .243 
rs3773640* A: 47 (78.3%) 
T: 13 (21.7%) 
A: 43 (71.7%) 
T: 17 (28.3%) 
120 p = .399 AA: 20 (66.7%) 
TT: 3 (10.0%) 
AT: 7 (23.3%) 
AA: 15 (50.0%) 
TT: 2 (6.7%) 
AT: 13 (43.3%) 
60 p = .190 
rs3773644* C: 37 (61.7%) 
T: 23 (38.3%) 
C: 44 (73.3%) 
T: 16 (26.7%) 
120 p=.173 CC: 11 (36.7%) 
TT: 4 (13.3%) 
CT: 15 (50.0%) 
CC: 16 (53.3%) 
TT: 2 (6.7%) 
CT: 12 (40.0%) 
60 p = .194 
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Gene 
SNP 
Allele Counts 
(%) Cases 
Allele Counts 
(%) Controls 
Total 
Alleles 
(n) 
Allele 
Testa 
Genotype Counts 
(%) Cases 
Genotype Counts 
(%) Controls 
Total 
Genotypes 
(n) 
Genotype 
Testb 
rs3773645* C: 45 (75.0%) 
G: 15 (25.0%) 
C: 48 (70.0%) 
G: 12 (30.0%) 
120 p = .512 CC: 20 (66.7%) 
GG: 5 (16.7%) 
CG: 5 (16.7%) 
CC: 19 (63.3%) 
GG: 1 (3.3%) 
CG: 10 (33.3%) 
60 p = .787 
rs3773652 G: 30 (50.0%) 
A: 30 (50.0%) 
G: 34 (56.7%) 
A: 26 (43.3%) 
120 p = .462 GG: 7 (23.3%) 
AA: 7 (23.3%) 
AG: 16 (53.3%) 
GG: 8 (26.7%) 
AA: 4 (13.3%) 
AG: 18 (60.0%) 
60 p = .606 
rs2043136* T: 48 (70.0%) 
C: 12 (30.0%) 
T: 45 (75.0%) 
C: 15 (15.0%) 
120 p = .512 TT: 19 (63.3%) 
CC: 1 (3.3%) 
TC: 10 (33.3%) 
TT: 16 (53.3%) 
CC: 1 (3.3%) 
TC: 13 (43.3%) 
60 p = .432 
rs1346907* C: 48 (70.0%) 
T: 12 (30.0%) 
C: 38 (63.3%) 
T: 22 (36.7%) 
120 p = .043 CC: 18 (60.0%) 
TT: 0 (0%) 
CT: 12 (40.0%) 
CC: 13 (43.3%) 
TT: 5 (16.7%) 
CT: 12 (40.0%) 
60 p = .196 
rs876688 G: 32 (53.3%) 
A: 28 (46.7%) 
G: 36 (60.0%) 
A: 24 (40.0%) 
120 p = .462 GG: 7 (23.3%) 
AA: 5 (16.7%) 
GA: 18 (60.0%) 
GG: 11 (36.7%) 
AA: 5 (16.7%) 
GA: 14 (46.7%) 
60 p = .499 
rs877572* G: 48 (70.0%) 
C: 12 (30.0%) 
G: 37 (61.7%) 
C: 23 (38.3%) 
120 p = .027 GG: 18 (60.0%) 
CC: 0 (0.0%) 
CG: 12 (40.0%) 
GG: 13 (43.3%) 
CC: 6 (20.0%) 
CG: 11 (36.7%) 
60 p = .196 
rs9843942 G: 35 (58.3%) 
A: 25 (41.7%) 
G: 29 (48.3%) 
A: 31 (51.7%) 
120 p = .271 GG: 11 (36.7%) 
AA: 6 (20.0%) 
GA: 13 (43.3%) 
GG: 8 (26.7%) 
AA: 9 (30.0%) 
GA: 13 (43.3%) 
60 p = .585 
rs3773663 G: 28 (46.7%) 
A: 32 (53.3%) 
G: 38 (63.3%) 
A: 22 (36.7%) 
120 p = .066 GG: 6 (20.0%) 
AA: 8 (26.7%) 
AG: 16 (53.3%) 
GG: 12 (40.0%) 
AA: 4 (13.3%) 
AG: 14 (46.7%) 
60 p = .177 
rs744751* C: 50 (83.3%) 
T: 10 (16.7%) 
C: 55 (91.7%) 
T: 5 (8.3%) 
120 p = .168 CC: 21 (70.0%) 
TT: 1 (3.3%) 
TC: 8 (26.7%) 
CC: 25 (83.3%) 
TT: 0 (0.0%) 
TC: 5 (16.7%) 
60 p = .222 
Note. aχ2 test of independence or Fisher’s exact test testing association between allele and preeclampsia status; bχ2 test of 
independence or Fisher’s Exact exact test testing association between SNP genotype (homozygote wildtype, homozygote variant, 
heterozygote) and preeclampsia status; *SNP genotypes dichotomized (homozygote wildtype, homozygote variant + heterozygote) 
due to small homozygote variant frequencies in either cases, controls, or both 
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a.             b.   
c.            d.    
Figure 5. Frequency Distributions of tSNPs with Significant Allele Tests in the Black Subgroup 
3.4.2.4 Genotype test and logistic regression 
Genotype test results are also presented in Table 16.  In TGFβ1, rs4803455 genotype was 
significantly associated with the development of preeclampsia (p = .010).  This association was 
further explored with binary logistic regression and was evaluated with a more stringent criterion 
(α = .01; 99% CI) to account for multiple testing.  Further analysis of rs4803455 (Table 17) 
revealed no significant difference in likelihood of developing preeclampsia between women 
homozygous for the A allele and women homozygous for the C allele (β = -.956, χ2(1) = 1.654, 
p = .198, exp(B) = .385 , 99% CI [.057, 2.607]).  Moreover, there was no significant difference 
in likelihood of developing preeclampsia between heterozygous women (CA) and women 
homozygous for the C allele (β = 1.110, χ2(1) = 2.890, p = .089, exp(B) = 3.036 , 99% CI [.564, 
16.330]).  In addition to rs4803455, TGFβ1 tSNP rs4803457 genotype was also significantly 
associated with the development of preeclampsia (p = .012).  Further analysis of rs4803457 
revealed that heterozygous women (CT) were 7.437 times more likely to develop preeclampsia 
compared to women homozygous for the C allele (β = 2.007, χ2(1) = 7.969, p = .005, exp(B) = 
7.437, 99% CI [1.192, 46.408]).  There was no significant difference in likelihood of developing 
preeclampsia between women homozygous for the T allele and women homozygous for the C 
allele (β = 1.253, χ2(1) = 2.746, p = .097, exp(B) = 3.500, 99% CI [.499, 24.530]).  Lastly, in 
TGFβR1, rs10739778 genotype was significantly associated with the development of 
preeclampsia (p = .028).  Further exploration of this association with the stringent p-value 
criterion (α = .01; 99% CI) found no significant difference in the likelihood of developing 
preeclampsia between heterozygous women (AC) and women homozygous for the A allele (β = -
1.440, χ2(1) = 5.907, p = .015, exp(B) = .237, 99% CI [.051, 1.090]).  Moreover, there was no 
significant difference in likelihood of developing preeclampsia between women homozygous for 
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the C allele and women homozygous for the A allele (β = -1.664, χ2(1) = 3.204, p = .073, exp(B) 
= .189, 99% CI [.017, 2.076]).  Genotype tests for the remaining tSNPs demonstrated no 
significant differences; however, the genotype test for rs11924422 trended toward significance (p 
= .063). 
 
Table 17. Logistic Regression Results for tSNPS with Significant Genotype Tests in Black Subgroup 
Note.  tSNP = tagging SNP; OR = odds ratio; CI = confidence interval 
3.4.2.5 Clinical characteristics by SNP genotype assignment 
In the black subgroup, average blood pressure measurement during labor was significantly 
different between cases and controls, but pre-pregnancy BMI and average blood pressure 
measurements < 20 weeks’ gestation were not statistically different (Table 14).  Because a small 
sample size may lack the needed power to detect significant differences, we decided to include 
pre-pregnancy BMI and all blood pressure measurement variables in our examination of the 
association between tSNP genotype assignment and the selected clinical characteristics.  tSNPs 
with significant genotype tests (rs4803455, rs4803457, and rs10739778) were evaluated.   
Neither average SBP less than 20 weeks’ gestation (H(2) = 0.155, p = .093), average 
DBP less than 20 weeks (H(2) = 0.092, p = .955), or pre-pregnancy BMI (H(2) = 1.360, p = 
.507) were significantly different between rs4803455 genotype groups.   Average SBP less than 
Gene/tSNP Genotype 
Groups 
OR 99% CI p-value 
TGFβ1     
rs4803455 AA vs. CC .385 .057 - 2.607 p = .198 
 CA vs. CC 3.036 .564 - 16.330 p = .089 
rs4803457 TT vs. CC 3.500 .499 - 24.530 p = .097 
 CT vs. CC 7.437 1.192 - 46.408 p = .005 
TGFβR1     
rs10739778 CC vs. AA .189 .017 - 2.076 p = .073 
 AC vs. AA .237 .051 - 1.090 p = .015 
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20 weeks’ gestation (H(2) = 0.272, p = .873), average DBP less than 20 weeks (H(2) = 0.311, p = 
.856), and pre-pregnancy BMI (H(2) = .907, p = .635) were not significantly different between 
rs4803457 genotype groups.  For rs10739778, average SBP less than 20 weeks gestation (H(2) = 
1.82, p = .404), average DBP less than 20 weeks (H(2) = 1.29, p = .526), and pre-pregnancy BMI 
(H(2) = .1.57, p = .458) were not significantly different between the genotype groups.  Average 
SBP in labor and average DBP in labor were significantly associated with rs4803455, rs4803457, 
and rs1039778 (rs4803455: SBP- H(2) = 5.873, p = .053, DBP- H(2) = 6.582, p = .037; 
rs4803457: SBP- H(2) = 6.537, p = .038, DBP- H(2) = 6.362, p = .042; rs10739778: SBP- H(2) 
= 7.174, p = .028, DBP- H(2) = 7.090, p = .029). 
3.5 DISCUSSION 
The ENG gene codes for a trans-membrane receptor that influences systemic endothelial function 
(Jerkic et al., 2004; Toporsian et al., 2005) and the degree of placental implantation/remodeling 
of uterine spiral arteries during pregnancy (Caniggia et al., 1997; Mano et al., 2011).  Women 
with preeclampsia have increased levels of ENG mRNA in the placenta and/or blood (Farina et 
al., 2008; Farina et al., 2010; Nishizawa et al., 2007; Purwosunu et al., 2008; Purwosunu, 
Sekizawa, Okazaki, et al., 2009; Purwosunu, Sekizawa, Yoshimira, et al., 2009; Sekizawa et al., 
2012; Sitras et al., 2009; Toft et al., 2008; Tsai et al., 2011; Venkatesha et al., 2006) along with 
increased protein levels of soluble ENG (sENG) in the maternal circulation throughout 
pregnancy (Rana et al., 2007).  Because genetic variation could impact the level of ENG 
transcription/translation and/or protein structure/function, the purpose of this case-control 
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candidate gene association study was to examine the association between ENG pathway genetic 
variation and the development of preeclampsia.  Using iPLEX® and TaqMan® technologies, we 
evaluated 47 tSNPs and 2 potentially functional SNPs across five ENG pathway candidate genes.  
We found that genetic variation in ENG (rs10121110 and rs11792480) and TGFβR2 (rs6550005) 
was associated with susceptibility to/protection from preeclampsia in white women. In ENG, 
rs10121110 and rs11792480 are located next to each other, with approximately 4000 bases 
between them (Figure 6).  Our data further suggest that genetic variation in TGFβ1 (excluding 
rs8179181- not genotyped), TGFβR1, and ALK1 is not associated with the development of 
preeclampsia in white women. 
There are several potential explanations that could account for why ENG (rs10121110 
and rs11792480) and TGFβR2 (rs6550005) genetic variation may be associated with the 
development of preeclampsia.  As depicted in Figure 6, rs10121110 is located in the intronic 
region between the second and third exons and it tags a genomic region that includes the ENG 
promoter region.  The promoter region lacks a TATA and CAAT box, but contains an SP1 site 
and SMAD binding elements (SBE) needed for the respective binding of SP1 and Smad 
transcription factors (Botella, Sánchez-Elsner, Rius, Corbí, & Bernabéu, 2001).  Given the 
location of rs1012110, it is possible rs1012110 is capturing an association that represents a 
promoter variant that impacts transcription factor access/binding (e.g., SP1 and/or SMAD) and 
subsequently influences transcription and translation of ENG.     
 
 
 
  
 
 
Figure 6. ENG Gene Structure 
Extracellular domain exons are shaded purple.  The transmembrane domain exon is shaded green.  The intracellular domain exon is 
shaded orange.  tSNPs with significant allele &/or genotype tests are bolded.  Illustration modified from Bosler, Richards, George, 
Godmilow, & Ganguly, 2006.  Information from Guerrero-Esteo et al., 2002 and UCSC Genome Browser (Fujita et al., 2011) was 
utilized to create this illustration.  Sequence and tSNP location determined by UCSC Genome Browser (Fujita et al.), information 
about promoter region obtained from Botella et al., 2001, and information on soluble endoglin obtained from Hawinkles et al., 2010 
 
Research has shown that knockdown of ENG in human extravillous trophoblast (EVT) 
cell line via short hairpin RNA specific for ENG (Mano et al., 2011) or knockdown of first 
trimester human trophoblast villous explants via antisense endoglin nucleotides (Caniggia et al., 
1997) improves the invasive capacity of EVTs, which are essential to uterine spiral artery 
remodeling in pregnancy (Caniggia et al.; Mano et al.).  As such, a promoter variant in ENG 
could contribute to the elevated expression of placental ENG, reducing the invasive capacity of 
EVTs, and explaining the observed increase in ENG noted in preeclampsia.  This elevation in 
placental ENG expression could therefore inhibit EVT invasion of uterine spiral arteries, 
resulting in the shallow implantation and reduced placental perfusion that is observed in 
preeclampsia.  Hypothetically, to compensate for excess membrane-bound placental ENG 
receptors, matrix metalloproteinase-14 (MMP-14) could cleave the excess receptors in order to 
improve uterine spiral artery invasion and remodeling.  Consequently, MMP-14 cleavage of 
membrane-bound ENG results in the release of sENG (Kaitu’u-Lino et al., 2012), which is 
elevated in the maternal circulation of women with preeclampsia and has been suggested to 
cause endothelial dysfunction (e.g., vascular tone abnormalities) (Venkatesha et al., 2006).  
Future studies examining the ENG promoter, its transcription factors, and MMP-14 will help us 
to better understand the mechanisms driving the observed differences in ENG and sENG.    
Intronic tSNPs rs10121110 and rs11792480 are also located between exons that code for 
the extracellular domain of the ENG receptor (Figure 6).  As part of the TGFβ1 signaling 
cascade, TGFβR1 interacts with amino acid residues 26-437of ENG’s extracellular domain 
(Guerrero-Esteo, Sánchez-Elsner, Letamendia, & Bernabéu, 2002).  It is only through the 
interaction of ENG and the type 1 and 2 receptors that ENG can gain access to TGFβ1 
(Guerrero-Esteo et al.).  For that reason, genetic variation within ENG’s extracellular domain 
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could influence ENG’s ability to interact with TGFβR1, thereby affecting ENG’s access to 
TGFβ1 and the transmission of TGFβ1 signals.  Since TGFβ1 induces ENG expression (Mano et 
al., 2011) and stimulates ENG promoter activity (Rius et al., 1998), a genetic variation that 
impacts the degree of TGFβ1 transmission may also explain the differences in ENG expression 
(mRNA) observed in women with/without preeclampsia.  Future studies directed at the 
examination of the genetic regions tagged by rs10121110 and rs11792480 may provide greater 
insight into how ENG is involved in the development of preeclampsia.   
Based on the Human Feb. 2009 (GRCh37/hg19) Assembly of UCSC genome browser, 
TGFβR2 tSNP rs6550005 is intronically located between the first two exons.  Given rs6550005’s 
proximity to TFGβR2’s promoter region, rs6550005 may tag a promoter variant that influences 
level of TGFβR2 transcription/translation.  Because ENG can only bind TGFβ1 ligand in the 
presence of the type 1 and 2 signaling receptors (Guerrero-Esteo et al., 2002), alteration in 
TGFβR2 transcription and translation could impact the number of TGFβR2 receptors available 
for ENG interaction and transmission of TGFβ1 ligand signaling.  
Our haplotype analysis further supports the association between ENG gene variation and 
the development of preeclampsia.  We found that the TACGA haplotype, which houses the risk 
alleles of each of the independently associated tSNPs (rs10121110, rs11792480) was over-
represented in cases.  This consistency in findings from the allele, genotype, and haplotype tests 
increases our confidence in our findings. 
Analysis of the association between ENG pathway candidate genes and preeclampsia was 
a more exploratory endeavor in the black sample given the much smaller sample size.  Despite 
this potential lack of power, variation in several candidate genes (TGFβ1, TGFβR1, and 
TGFβR2) was associated with development of preeclampsia in black women.  TGFβR2 tSNP 
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rs6550005 was the only tSNP significantly associated with preeclampsia in both blacks and 
whites.  The remaining associations in TGFβR2 (intronic tSNPs rs1346907 and rs877572), 
TGFβ1 (intronic tSNPs rs4803455 and rs4803457), and TGFβR1 (intronic tSNP rs107399778) 
were only found in the black sample.  Our data further suggest that variation in ENG and ALK1 
may not be associated with preeclampsia development in black women.   
Mechanistically, these results suggest that the pathway’s involvement in preeclampsia 
development may differ in blacks and whites.  The study of TGFβ1 overexpression in black 
hypertensive subjects compared to white hypertensive subjects by Suthanthiran et al. (2001) 
provides support for this suggested etiologic difference.  Operating under the premise that 
TGFβ1 over-expression in blacks may be associated with the increased incidence/prevalence of 
hypertension; Suthanthiran et al. compared TGFβ1 mRNA and protein levels in hypertensive 
black and hypertensive white subjects.  TGFβ1 protein levels were significantly higher in 
hypertensive blacks compared to hypertensive whites (p < .001), suggesting that different 
physiologic and genetic differences drive the hypertensive phenotype in blacks.   
Like Sunthanthiran et al. (2001), TGFβ1 variation was associated with the hypertensive 
disorder of preeclampsia in our black sample.  Moreover, average blood pressure in labor (SBP 
and DBP) was significantly associated with TGFβ1 tSNP rs4803455 and tSNP rs4803457 
genotypes along with TGFβR1 tSNP rs10739778 genotypes in our cohort.  Given these 
associations, it is feasible to hypothesize that these tSNPS could tag genetic variants in TGFβ1 
and/or TGFβR1 that alter protein function and/or structure, affect transcription/translation, or 
affect the interaction between TGFβ1 and TGFβR1.  Such genetic perturbations also lead to the 
following question:  Is TGFβ1 a common risk factor for preeclampsia and later life 
cardiovascular disease (e.g., hypertension) in black women?  Further investigation with a larger 
107 
 
sample size is needed to answer this question, verify these findings, and provide greater insight 
into the mechanisms of these candidate genes in black women with preeclampsia.  
To date, only one additional study has looked at the association between ENG and 
preeclampsia separately in white and black women.  Srinivas, Morrison, Andrela, and Elovitz 
(2010) used a pre-designed IBCv2 array (Illumina Inc, San Diego, CA) to examine angiogenic 
pathway genes.  Of the five candidate genes examined in our study, only ENG was included their 
array.  Srinivas et al. (2010) did not find any significant associations between ENG tSNPs and 
preeclampsia in white women (32 cases/85 controls) and black women (184 cases/305 controls).  
This is in contrast to the current study in which we found two ENG tSNPs (rs10121110 and rs 
rs11792480) to be significantly associated with preeclampsia in white women.  Ultimately, the 
lack of association in the study by Srinivas et al. is likely driven by lack of power in the white 
subgroup.  Like Srinivas et al., we did not find any tSNPs in ENG to be significantly associated 
with preeclampsia in the black subgroup; and their evaluation did not include the genes we found 
to be associated with preeclampsia in our black subjects.   
There were several limitations associated with this case-control candidate gene 
association study.  First, TGFβ1 tSNP rs8179181 and TGFβR2 tSNP rs3087465 could not be 
genotyped despite multiple attempts with iPLEX® and TaqMan® platforms likely due to the fact 
that these tSNPs were multiallelic (4 alleles & 3 alleles).  Without this information, our ability to 
fully evaluate the genetic variability of TGFβ1 and TGFβR2 was impaired.  Second, the black 
subgroup may have been underpowered and associations between the candidate genes and 
preeclampsia may have been missed.  Third, tSNPs were selected for Caucasian ancestry.  
Because linkage disequilibrium in the candidate genes may be different for those of African 
ancestry, the haploblocks tagged by tSNPs selected for Caucasian ancestry may be different than 
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haploblocks tagged by tSNPs selected based on African Ancestry, resulting in decreased 
informativeness in blacks.  Fourth, our study was limited to white and black women.  Results 
generated for these subgroups may not be generalizable to other ancestries.  Fifth, we evaluated 
our logistic regression results with a more stringent p-value criterion (α = .01) in order to account 
for multiple testing.  Although some results were significant at the p < .05 level, they became 
non-significant at the p < .01 level.  This change in significance may have decrease our interest 
in the association, but our sample may not have had enough power to detect these associations at 
the α = .01 level.  
3.6 CONCLUSION 
Our study demonstrated that ENG pathway genetic variation is associated with preeclampsia in 
white and black women.  Our results further suggest that the pathway’s involvement in 
preeclampsia differs in whites and blacks, with ENG and TGFBR2 being associated in whites 
and TGFβ1, TGFβR1, and TGFβR2 being associated in blacks.  However, replication of these 
results is needed to confirm these findings, especially in the black subgroup because of its small 
sample size.  Moreover, because these significant associations between ENG pathway tSNPs and 
preeclampsia are likely not causative, further examination of the genomic regions (e.g., promoter 
region of ENG) tagged by these polymorphisms would further improve our understanding of this 
pathway’s role in preeclampsia.     
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ABSTRACT
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Preeclampsia is a hypertensive, multisystemdisorder of pregnancy that signi¢cantly con-
tributes to maternal and fetal/neonatal morbidity
and mortality (American College of Obstetricians
and Gynecologists [ACOG], 2002; National Heart,
Lung, and Blood Institute [NHLBI] National High
Blood Pressure Education Program, 2000). At pres-
ent, the etiology of preeclampsia remains unknown.
As a result, preventative measures and screening
tools are lacking, treatments are directed at the
management of overt clinical manifestations, and
delivery remains the only de¢nitive cure (ACOG;
NHLBI National High Blood Pressure Education
Program; Norwitz & Repke, 2009).
Despite our inability to identify preeclampsia’s etiol-
ogy, hypotheses and scienti¢c contributions
throughout history have in£uenced our current un-
derstanding of preeclampsia pathophysiology.
Such contributions are further re£ected in current
management strategies and classi¢cation criteria.
To provide insight into how current practice trends
have been shaped by past hypotheses and scien-
ti¢c contributions, this article provides a historical
overview of preeclampsia-eclampsia from ancient
times through present day. Although it is not the
intent of this article to provide an all-inclusive histor-
ical analysis of primary sources, attention is
directed toward an overview of theories on disease
causation, treatments, and disease classi¢cations
extracted from available primary and reliable sec-
ondary sources.
Ancient Times
Theories on Disease Causation
In ancient Greece, between the late 5th and early
4th centuries BC, the Hippocratics subscribed to
the theory of the four humors to describe the cause
of illness and disease. They believed that the body
was made up of four humors (£uids) that included
blood, phlegm, yellow bile, and black bile. Health
depended on a balance of the humors, and any im-
balance in the humors resulted in illness (Demand,
1994; Green,1985).
The wet and dry theory was used to explain the vul-
nerability of female physiology to disease (Green,
1985).Women were considered wet while men were
considered dry (Green; Trotula of Solerno, 1544/
1940). Because a woman’s £esh was porous and
soft, she was at risk of drawing in too much mois-
ture, resulting in an overabundance of £uids
(humors) and subsequent illness (Green).
More speci¢cally, many female ailments were attrib-
uted to the wandering womb. Central to this
theory was that the uterus was able to physically
uproot itself from its seat in the pelvis and travel
anywhere within a woman’s body in search of satis-
faction. Although Hippocrates believed that a
dried-up uterus wandered the body in search of
moisture, Plato viewed the uterus as an animal that
wandered because it was sexually unsatis¢ed
and desired to make children (Thompson, 1999).
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Regardless of reason, as the uterus wandered
the body, it was capable of wreaking havoc
upon the liver, stomach, spleen, lungs (Thompson),
and head (Veith, 1965), ultimately leading to
disease.
Treatment
Because disease was believed to result from either
an imbalance in the four humors, a woman’s overly
porous skin (Demand,1994; Green,1985), or a wan-
dering womb (Thompson,1999), treatments focused
on the restoration and maintenance of internal bal-
ance and health. As a result, remedies to restore
balance included altered diets, purging, and blood-
letting. As for methods to maintain balance and
health, the Hippocratics believed that a woman
needed to be pregnant, lactating, or regularly
menstruating. These methods were based on the
belief that pregnancy, lactation, and menstruation
provided mechanisms for the elimination of
excess £uids. During pregnancy, extra blood
was used to nourish the growing fetus. During
lactation, extra blood was diverted to the breasts
where it was converted to milk and eliminated
through breast feeding. During menstruation,
excess blood was eliminated through menstrual
£ow (Green).
Disease Classification
Preeclampsia-eclampsia was not formally classi-
¢ed as a disorder of pregnancy during Ancient
times. Despite limited knowledge and technology,
the writings of this period did demonstrate that the
concept of eclampsia was recognized. For example,
aphorism XXXI 507 in the Coan Prognosis states
that a headache accompanied by heaviness and
convulsions during pregnancy is considered bad
(Hippocrates, 400 BC/1950).
Middle Ages & the Renaissance
Theories on Disease Causation
During the Middle Ages, medical and scienti¢c prog-
ress came to a standstill. Between 400 and 700 AD,
Christianity greatly in£uenced such progress, for
Christians were opposed to science and forbade hu-
man dissection (Cianfrani, 1960; Graham, 1951).
Closing of medical schools at Athens and Alexandria
by Byzantium Emperor Justinian in the 6th century
further slowed medicine’s progression (Cianfrani).
Consequently, little original work was accomplished.
Instead, individuals such as Oribasius, Aetius of Am-
ida, and Paulus of Aegina focused on the
compilation and rewriting of the medical works of
their predecessors (Cianfrani; Graham).
Between 700 and 1200 AD, Byzantium deteriorated,
Christian in£uence began to decline, and Salerni-
tan (Salerno, Italy) and Arabian in£uences
increased. The ¢rst European medical school was
opened in Salerno, Italy, and a slightly altered four
humors theory emerged. Under this newer theory,
it was believed that one humor dominated the
other humors to form a new balance. Furthermore,
the dominant humor determined an individual’s
physical and emotional characteristics (Cianfrani,
1960).
During the Renaissance, an acceleration in the pro-
gression of medicine resulted from the further
waning in£uence of the church, freedom of the
intellect, rearrangement of government and geog-
raphy, and discovery of printing (Cianfrani,1960). In
1537, Pope Clement VIII granted permission to teach
anatomy by human dissection (Burton, 2005). With
this new-found freedom, anatomists and artists
such as Jacopo Berengario da Capri (1460^1530),
Nicolaus Massa (1499^1569), Leonardo da Vinci
(1452^1519), Andreas Vesalius (1514^1564), and
Fallopius (1523^1562) were instrumental in more
clearly and accurately describing the female repro-
ductive tract. For example, the ¢rst accurate
description of the tubes and ovaries was provided
by Fallopius. He is also credited with naming the
placenta and indicating that it was only found in
the uterus during pregnancy (Cianfrani).
In the 17th century, medicine continued to gain mo-
mentum and men began to enter the ¢eld of
obstetrics (McMillen, 2003). Born in 1637, French-
man Francois Mauriceau was one such man
whose writings helped to establish obstetrics as a
specialty (Speert, 1958). According to McMillen, he
was the ¢rst to systematically describe eclampsia
and to note that primigravidas were at greater risk
for convulsions compared to multigravidas. As for
the causes of convulsions, Mauriceau attributed
convulsions to either abnormalities in lochial £ow
or intrauterine fetal death. In the case of supressed
lochial £ow, in£ammation, pains in the head, con-
vulsions, su¡ocation, and death could arise. In the
case of intrauterine fetal death, a retained dead fe-
tus gave o¡ foul-smelling and cadaverous humors
in the womb, predisposing a woman to convulsions
(Mauriceau,1668/1710).
By viewing preeclampsia-eclampsia from a historical
perspective, nurses gain insight into how past hypotheses
and scientific contributions have influenced and shaped
current practices.
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Treatment
Treatment of disease during the Middle Ages was
greatly in£uenced by Christian beliefs. Remedies
prescribed by physicians in Ancient times were of-
ten replaced with charms, amulets, faith healing,
miracles, and prayers (Cianfrani, 1960; Graham,
1951). However, as time passed and Christian in£u-
ence waned, remedies similar to those used to treat
disease in Ancient times became prominent again.
For example, in an attempt to decrease cerebral
congestion and prevent eclampsia, Mauriceau rec-
ommended two to three phlebotomies during
pregnancy (Chesley,1978,1984; McMillen, 2003).
Disease Classification
Near the end of the Reniassance, the classi¢cation
of disease progressed. Gabelchoverus distin-
guished between four types of epilepsy in 1596,
which included epilepsy resulting from the head,
stomach, the pregnant uterus, and chilled extremi-
ties (Chesley, 1978). However, it wasn’t until 1619
that the word eclampsia ¢rst appeared in Va-
randaeus’ treatise on gynecology (Ong, 2004).
18th Century Through 19th Century
Theories on Disease Causation
In the 18th century, Boissier de Sauvages distin-
guished eclampsia from epilepsy. Along with the
distinction he made in disease classi¢cation, de
Sauvages o¡ered his views on the cause of convul-
sions. He believed that convulsions resulted from
nature trying to free the organism of any morbid
element (Temkin,1971).
Theories on disease causation continued to be pro-
posed and thoroughly discussed in the writings of
19th century physicians. In his work titled Introduc-
tion to the Practice of Midwifery, Dr. Thomas
Denman (1821) focusedmuch attention on the labors
a¡ected by convulsions. Although Denman attrib-
uted convulsions to certain customs and manners
associated with living in large cities and towns, he
noted that the greatest risk of convulsions came from
the uterus. According to Denman, as the uterus ex-
panded with pregnancy, greater pressure was
placed upon the descending blood vessels. Such an
increase in pressure lead to the regurgitation of blood
in the head and resulted in an overload of the cere-
bral vessels and subsequent convulsions (Denman).
In his 1849 work, Parturition and the Principles and
Practice of Obstetrics, Dr. William Tyler Smith chal-
lenged the theory of cerebral congestion, for he
believed that pregnancy was a state of increased full-
ness in circulation.Given that contractions during the
second stage of labor normally interfered with the
circulation of blood, he believed that more cases of
convulsions would be observed if such congestion
caused convulsions. In contrast, Smith attributed pu-
erperal convulsions to several other causes: (a) any
mechanical or emotional stimulus applied in excess
to the spinal center; (b) bloodletting; (c) variations in
the wind, temperature, and other atmospheric
changes; (d) irritation of the uterus, uterine pas-
sages, intestinal canal, and the stomach; and (e)
‘‘toxic’’ elements. As for Smith’s theory on ‘‘toxic’’ ele-
ments, he believed that preservation of health
during pregnancy depended on the exponential in-
crease in the elimination of wastes (e.g., secretions
of the bowels) and debris from the maternal and fetal
systems. Failure to do so resulted in a ‘‘toxemia’’ in
which morbid elements accumulated in the blood
causing irritation to the nervous center (Smith,1849).
Treatment
Bloodletting remained a staple in the prevention
and treatment of preeclampsia-eclampsia during
the early 1800s. The amount and frequency of
bloodletting depended on the strength of the pa-
tient and symptom severity. Bleeding from the arm
was attempted initially, but if convulsions contin-
ued, bleeding was repeated. In some cases the
jugular vein or temporal artery were opened in an
attempt to stop convulsions (Denman,1821).
The use of opiates, warm baths, splashing of the face
with cold water, and hastening of delivery were also
recommended by Denman. Opiates were used to
decrease irritability of the female constitution. If
bloodletting and opiates failed, splashing of cold wa-
ter to the patient’s face or placement of the patient in
a warm bath were attempted. In cases where all treat-
ments were unsuccessful, the physician had to
choose between either hastening delivery orallowing
natural labor to ensue. Per Denman, hastening of de-
livery was only to be attempted when a woman was
physiologically ready (completely dilated, ruptured
membranes, and fetus descended) because inter-
vention in the early stage of labor increased
maternal mortality (Denman,1821).
When the theory of disease causation shifted to the
toxin theory in the late 1800s, treatments were tar-
geted at the elimination of overabundant toxins.
Those who believed that preeclampsia-eclampsia
was caused by meat toxins restricted the consump-
tion of meat and prescribed diets of fruits,
vegetables, and milk products (Chesley, 1978). With
the recognition of the preeclamptic state, women
with headaches and edema of the superior extrem-
ities were admitted to lying-in hospitals where they
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underwent treatments such as bleeding and purg-
ing to prevent convulsions (Johns,1843).
Disease Classification
After the introduction of the word eclampsia, Boss-
ier de Sauvages (1739) di¡erented eclampsia from
epilepsy (Chesley,1978; Friedlander, 2001). Eclamp-
sia was acute in nature because convulsions
resolved once the precipitating event was removed.
Epilepsy was chronic in nature because
convulsions recurred over time (Friedlander). Fur-
thermore, eclampsia was not restricted to
pregnancy. Severe hemorrhage, various sources of
pain, vermicular infestations, and eclampsia asso-
ciated with pregnancy were several species of
eclampsia noted by de Sauvages (Chesley,1978).
At the end of the 18th century and through the
19th century, the classi¢cation of preeclampsia-
eclampsia continued to become more re¢ned as
the classic signs and symptoms of preeclampsia-
eclampsia became more readily recognized. In
1797, Demanet noted a connection between ede-
matous women and eclampsia (Chesley, 1978)
whereas John Lever discovered albumin in the
urine of eclamptic women in 1843 (Thomas, 1935).
The connection between premonitory symptoms
during the later months of pregnancy and the de-
velopment of puerperal convulsions was also
recognized in 1843 by Dr. Robert Johns. These pre-
monitory symptoms included headache, temporary
loss of vision, severe pain in the stomach, and
edema of the hands, arms, neck, and face (Johns,
1843). In1897, Vaquez and Nobecourt were credited
with the discovery of eclamptic hypertension
(Chesley, 1978). As a result of these contributions,
the concept of the preeclamptic state was recog-
nized. Physicians were now aware that the
presence of edema, proteinuria, and headaches
should raise concern about the possibility of con-
vulsions (Sinclair & Johnston,1858).
20th Century
Theories on Disease Causation
Although researchers in the 20th century failed
to uncover the etiology of preeclampsia, much
progress was made in the understanding of patho-
physiological changes associated with its
development. In the 1960s, several groups de-
scribed dramatic di¡erences in placental
physiology between placentas from pregnancies
a¡ected by preeclampsia versus placentas from
pregnancies una¡ected by preeclampsia. Through
the examination of placental bed biopsies, it was
discovered that placental trophoblast cells failed to
adequately invade maternal spiral arteries and
convert the arteries from small muscular vessels
into large, low-resistant vessels in preeclampsia.
With the lack of spiral artery conversion, arterial lu-
men diameter and distensibility was limited,
resulting in restricted blood £ow to the placenta
and growing fetus (Brosens, Robertson, & Dixon,
1967,1972; Gerretsen, Huisjes, & Elema,1981; Kong,
DeWolf, Robertson, & Brosens,1986).
Although these ¢ndings were instrumental in laying
the groundwork for the current understanding of
preeclampsia-elcampsia, not all theories or scien-
ti¢c discoveries have readily been accepted by the
scienti¢c community. Published in the American
Journal of Obstetrics and Gynecology in 1983, the
Hydatoxi lualba (parasitic worm) theory of pre-
eclampsia was one such theory quickly refuted by
the scienti¢c community. Under this theory, it was
posited that the development of preeclampsia-
eclampsia may be associated with the presence of
a worm-like organism. Specimens collected from
women with preeclampsia-eclampsia, including
peripheral circulating blood, bloody £uid on the
maternal surface of the placenta, and umbilical
cord blood, were found to be positive for Hydatoxi
lualba (Lueck, Brewer, Aladjem, & Novotny, 1983).
However, several other research groups demon-
strated that starch powder from gloves, cellulose
debris from common laboratory paper products,
and alterations in staining technique produced the
same characteristic worm-like organisms (Papout-
sis, Irwin, Curry, & Zuspan, 1983; Sibai & Spinnato,
1983), which lead to refutation of the theory.
Unlike the parasitic worm theory, the theory posited
by Roberts and colleagues in 1989 continues to
guide research related to preeclampsia-eclampsia
etiology. Dr. Roberts and colleagues posited that
preeclampsia represented an endothelial dis-
order. Drawing on past work that associated pre-
eclampsia with shallow trophoblast invasion and
subsequent reduction in placental perfusion, they
hypothesized that the ischemic placenta released
a damaging factor(s) into the maternal circulation.
Although factor identity was unknown, the circulat-
ing factor was hypothesized to have caused
endothelial dysfunction and would lead to activa-
tion of the coagulation cascade, blood pressure
abnormalities, and loss of £uid from the intravascu-
lar space (e.g., proteinuria) (Roberts et al.,1989).
Treatment
At the end of the19th century and into the beginning
of the 20th century, two very diverse approaches
were used in the treatment of eclampsia. According
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to Chesley, physicians in Germany and the Nether-
lands advocated for aggressive management (e.g.,
prompt abdominal or vaginal Cesarean section),
but the associated maternal mortality rates were
extremely high. As a result, a more conservative
management gained popularity and was widely
used up until the 1930s (Chesley, 1978, 1984). Physi-
cian pioneers of this conservative method included
Tweedy of Dublin and Strogano¡ of Russia (Speert,
1958).
Tweedy’s rationale for conservative management
(as cited in Speert, 1958) was rooted in the belief
that hastening of labor and delivery increased the
occurrence of convulsions through the induction of
re£ex stimulation. Physicians were to abstain from
vaginal examinations, abdominal palpation, mas-
sage of the kidneys, cold blasts of air, and the
dilatation of the cervix in an e¡ort to mitigate the
risk of re£ex stimulation. In contrast, his manage-
ment plan revolved around patient sedation and
included large doses of morphine. However, if a pa-
tient went into labor, he believed that the appli-
cation of forceps was permissible given that the os
would safely permit their application (Speert).
Because convulsions disrupted the functions of the
heart, lungs, kidneys, and liver, Strogano¡’s main ob-
jective was to eliminate convulsions (Speert,1958). He
treated the eclampsia, ignored the pregnancy, and
waited for natural onset of labor. All examinations
and treatments were performed under light anesthe-
sia, and sensory stimuli were reduced by keeping the
patient’s room dark and quiet (Chesley, 1984). Mor-
phine and chloral hydrate were administered to keep
patients sedated and to decrease frequency of con-
vulsions. To restore respiratory function, oxygen was
administered. To restore cardiac function, digitalis
was administered if the pulse was found to be rapid
and weak after a seizure (Chesley, 1984; Speert). La-
bor was to progress naturally and once a woman’s
cervix had dilated to 6 cm, the membranes were arti-
¢cially ruptured (Chesley,1984).
In addition to the diverse approaches to manage
preeclampsia-eclampsia in the 20th century, the
use of magnesium sulfate was introduced. Al-
though a mainstay of current treatment, it was not
until 1906 that Horn ¢rst used magnesium sulfate
to manage preeclampsia-eclampsia (Chesley,
1984). During the 1920s, the parenteral use of mag-
nesium sulfate in the treatment of preeclampsia-
eclampsia was popularized by Lazard and Dorsett
(Chesley, 1984), for Dr. Lazard’s work (as cited in
Gabbe, 1996) demonstrated that treatment with
intravenous magnesium sulfate was e⁄cacious
and safe.
Since the 1960s, few alterations have been made in
the management of preeclampsia. Such consis-
tency can be observed by studying the obstetrical
textbooks used to educate students within the
health care ¢elds. Routine prenatal care (e.g., rou-
tine blood pressure measurement, urinalysis,
maternal weight) remained a hallmark surveillance
method because early signs and symptoms of
preeclampsia may not be readily recognized
by pregnant women. Once diagnosed with pre-
eclampsia, management consistently included
hospitalization, frequent blood pressure measure-
ment and weighing, urinalysis, bed rest, fetal
surveillance, and assessment of maternal head-
ache, blurry vision, and epigastric pain. With
fulminating preeclampsia or the development of
eclampsia, magnesium sulfate and antihyperten-
sives were administered over the later part of the
20th century to prophylactically prevent or manage
convulsions and acute hypertension, respectively.
Ultimately, the decision to proceed with a vaginal
delivery or Cesarean section depended on a myr-
iad of factors, including gestational age, condition
of the cervix, and maternal and fetal condition
(Eastman & Hellman,1966; Hibbard,1988; Pritchard
& MacDonald,1976).
Disease Classification
As with the treatment of preeclampsia, review
of obstetrical textbooks provides insight into the
changes made in preeclampsia-eclampsia disease
classi¢cation throughout the 20th century (Table 1).
According to Chesley (1978), the ‘‘preeclamptic’’
state was not included in textbooks until 1903. Fur-
thermore, restriction of preeclampsia-eclampsia to
the obstetric de¢nition was not observed until 1961
(Chesley,1978).
In the 13th edition of Williams Obstetrics (1966),
preeclampsia-eclampsia fell under the category of
the toxemias of pregnancy. According to the classi-
¢cation set forth by the American Committee on
Maternal Welfare, toxemias of pregnancy included
acute toxemia of pregnancy (preeclampsia and
eclampsia), chronic hypertensive disease with
pregnancy, and unclassi¢ed toxemia. Criteria for
the diagnosis of preeclampsia included the pres-
ence of hypertension, edema, or proteinuria after
the 24th week of gestation. Moreover, this classi¢-
cation required that a woman must meet only
one of the three criteria to be diagnosed with pre-
eclampsia (Eastman & Hellman,1966).
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In the 15th edition of Williams Obstetrics (1976),
the term toxemia of pregnancy was replaced
with hypertensive disorders of pregnancy. The
Committee onTerminology of the American College
of Obstetricians and Gynecologists recommended
new classi¢cations. The new classi¢cation of pre-
eclampsia included the development of hyper-
tension with proteinuria, edema, or both com-
mencing after 20 weeks gestation (Pritchard &
MacDonald,1976).
In Hibbard’s 1988 text titled Principles of Obstetrics,
the classi¢cation of preeclampsia underwent yet an-
other revision. Although preeclampsia fell under the
hypertensive disorders of pregnancy classi¢cation, it
was further grouped under the term pregnancy-in-
duced hypertension. In addition to preeclampsia,
hypertension that developed during pregnancy ex-
cluding the features of preeclampsia was also
grouped under the term pregnancy-induced hyper-
tension. Mild to moderate preeclampsia was
classi¢ed as the presence of hypertension and ede-
ma whereas severe preeclampsia was classi¢ed as
the presence of hypertension and proteinuria with or
without edema or cerebral or visual disturbances
(Hibbard,1988).
21st Century
Theories on Disease Causation
At present, the scienti¢c community has failed to
uncover the etiologic mechanisms responsible for
the development of preeclampsia-eclampsia. As
evidenced by the many review articles published in
Table 1: Progression of Preeclampsia-Eclampsia Classification During the 20th Century
Year & Citation Milestone
1903 Chesley (1978) ‘‘Pre-eclamptic state’’ included in textbooks
1961Chesley (1978) Preeclampsia-eclampsia restricted to
the obstetric de¢nition
Obstetrical Textbook
PublicationYear & Citation Terminology Classification Description
1966 Eastman and
Hellman (1966)
Toxemias of pregnancy A. Acute toxemia of pregnancy
(preeclampsia and eclampsia);
chronic hypertensive disease with pregnancy;
unclassi¢ed toxemia
B. Preeclampsia diagnostic criteria:
presence of hypertension, edema, or
proteinuria after 24 weeks gestation
1976 Pritchard and
MacDonald (1976)
Hypertensive disorders
of pregnancy
A. ‘‘Toxemias of pregnancy’’ replaced with
‘‘hypertensive disorders of pregnancy’’
B. Preeclampsia diagnostic criteria:
development of hypertension with proteinuria, edema,
or both commencing after 20 weeks gestation
1988 Hibbard (1988) Pregnancy induced
hypertension
A. Under the classi¢cation of hypertensive
disorders of pregnancy,
preeclampsia was further grouped under
‘‘pregnancy-induced hypertension,’’
which also included hypertension that
developed during pregnancy excluding the
features of preeclampsia
B. Preeclampsia diagnostic criteria:
mild to moderate preeclampsiaçpresence of
hypertension and edema; severe
preeclampsiaçpresence
of hypertension and proteinuria with or
without edema or cerebral or visual
disturbances after 20^24 weeks gestation
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the scienti¢c literature, the theories on disease cau-
sation are numerous and diverse. Such theories are
related to mechanisms involving oxidative stress,
immunologic intolerance between the fetoplacental
unit and maternal tissue, and angiogenic imbal-
ance (Leeman & Fontaine, 2008). For example, the
endoglin protein, which is involved in regulation
of placental trophoblast di¡erentiation/invasion
of the uterus (Caniggia, Taylor, Ritchie, Lye, & Le-
tarte, 1997) and maintenance of vascular tone
(Jerkic et al., 2004; Toporsian et al., 2005), repre-
sents an antiangiogenic factor potentially involved
in preeclampsia development given that placental
and blood pressure abnormalities are observed in
preeclampsia.
Regardless of the mechanism, a two-stage model of
preeclampsia has been developed to provide a
guiding framework for scientists in their search of
disease causation (Hladunewich, Karumanchi, &
Lafayette, 2007; Roberts & Gammill, 2005; Roberts
& Hubel, 2009). For an in-depth review, consultation
of the latest model iteration presented by Roberts
and Hubel is recommended. Brie£y, the model pro-
poses that reduced placental perfusion (Stage 1),
secondary to abnormal implantation and subse-
quent vascular remodeling, interacts with maternal
constitutional factors (genetic, behavioral, and en-
vironmental) to produce the maternal syndrome
(Stage 2) of preeclampsia. The systemic maternal
syndrome is characterized by reduced perfusion
brought about by vasospasm and activation of the
coagulation cascade with the formation of occlu-
sive microthrombae. This leads to reduced
perfusion to multiple organs, hypertension, protein-
uria, and loss of £uid from the intravascular space
(Roberts & Gammill).
Although it was initially thought that maternal
factors only interacted with reduced placental
perfusion to produce the maternal syndrome
(Stage 2), it is now believed that maternal factors
may be involved in the genesis of reduced placental
perfusion (Stage 1). It has been further hypothe-
sized that the linkage between Stage 1 and 2 may
involve multiple factors, whose constitution may
vary from individual to individual. For example, re-
cent suggestions indicate that the placentally
derived ‘‘toxins’’ (e.g., cytokines, antiangiogenic
factors, and syncytiotrophoblast microparticles)
thought to link Stage 1 and 2 may not be patho-
genic. In contrast, it has been proposed that
placental factors are appropriately released by the
fetal/placental unit to increase nutrient availability
but are not tolerated by some women who develop
preeclampsia (Roberts & Hubel).
Treatment
In an era of evidenced-based practice, the stan-
dardized care of women a¡ected by preeclampsia-
eclampsia is guided by the best available evidence.
Based on the National High Blood Pressure Educa-
tion Program (2000) Working Group on High Blood
Pressure report, the American College of Obstetri-
cians and Gynecologists’ (ACOG, 2002) most
recent practice bulletin indicates that current man-
agement of preeclampsia-eclampsia is re£ective of
past treatments. Although ACOG’s bulletin was
published 8 years ago, a more current review of ev-
idence-based information on the management of
preeclampsia further demonstrates that the main-
stay of treatment has remained consistent (Norwitz
& Repke, 2009). Despite consistent, evidenced-
based management strategies, the etiology of pre-
eclampsia remains unknown. As a result, e¡ective
preventative measures and screening tools are
lacking, treatments remain directed at the manage-
ment of overt clinical signs and symptoms, and the
only de¢nitive cure remains delivery (ACOG; NHLBI
National High Blood Pressure Education Program,
2000; Norwitz & Repke). However, it is likely that
our current evidence-based practices will continue
to evolve as we gain a more comprehensive under-
standing of preeclampsia-eclampsia.
Diagnosis of preeclampsia continues to be based
on prenatal blood pressure and urinary protein
measurements and initial disease severity is evalu-
ated with laboratory testing. Fetal well-being is
monitored via fetal movement counts, nonstress
tests, and biophysical pro¢les. Blood pressure and
urine protein measurements, follow-up laboratory
testing, and assessment of additional signs/symp-
toms suggestive of preeclampsia (headache,
blurred vision, right upper quadrant or epigastric
pain) are used to monitor maternal well-being. The
timing and type of delivery ultimately depends on
gestational age, maternal and fetal conditions, and
the severity of preeclampsia. As for pharmacologic
management, magnesium sulfate is administered
during labor, delivery, and postpartum to prevent
convulsions in womenwith preeclampsia or to deter
recurrent convulsions in women with eclampsia. In
addition, antihypertensive therapy (e.g., hydra-
lazine or labetalol) is administered to treat acute
Although preeclampsia-eclampsia management is guided
by the best available evidence, preventative measures/
screening tools are lacking, treatments are symptom
based, and delivery remains the only cure.
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hypertensive episodes (NHLBI National High Blood
Pressure Education Program, 2000; Norwitz & Rep-
ke, 2009).
Disease Classification
In 2000, the National High Blood Pressure Educa-
tion Program Working Group on High Blood
Pressure in Pregnancy published a report with revi-
sions to preeclampsia-eclampsia classi¢cation
criteria. Preeclampsia is currently classi¢ed as a
pregnancy-speci¢c syndrome characterized by the
presence of new-onset hypertension in a previously
normotensive woman after 20 weeks gestation with
proteinuria. Blood pressure (BP) criteria include
a systolic BP 4 140 mm Hg or a diastolic BP 4
90 mm Hg. Proteinuria is de¢ned as urinary excre-
tion of  0.3 g of protein in a 24-hour specimen,
which correlates with a random  11urine dip-
stick in the absence of a urinary tract infection. The
presence of edema was dropped from the diagnos-
tic criteria because many pregnant women with
normal pregnancies develop edema.
Furthermore, eclampsia is classi¢ed as the pres-
ence of seizures, nonattributable to other causes,
in a woman diagnosed with preeclampsia. For
additional information on classi¢cation of other
hypertensive disorders of pregnancy (e.g., gesta-
tional hypertension or chronic hypertension, and
preeclampsia superimposed on chronic hyperten-
sion), a review of the Report of the National High
Blood Pressure Education ProgramWorking Group
on High Blood Pressure in Pregnancy is recom-
mended (NHLBI National High Blood Pressure
Education Program, 2000).
Conclusion: Nursing Implications
This historical overview provides present-day nurses
with a broadened perspective of preeclampsia-
eclampsia related to theories on disease causation,
evolution of treatments, and re¢nement of disease
classi¢cation.With such a perspective, nurses gain
insight into how past hypotheses and scienti¢c
contributions have in£uenced and shaped current
practices. Although the etiology of preeclampsia
remains unknown, ongoing research has vastly im-
proved our understanding of preeclampsia over the
years and continues to guide evidence-based
management of women with preeclampsia and re-
¢ne its classi¢cation. However, as we continue to
gain a more comprehensive understanding of pree-
clampsia, it is likely that the current practices used
to care for womenwith preeclampsia-eclampsia will
also evolve to re£ect the most up-to-date scienti¢c
evidence related to preeclampsia etiology and
treatment.
As in the past, the current role of nurses in the man-
agement of preeclampsia-eclampsia continues to
revolve around the protection of maternal^fetal
well-being and optimization of positive health out-
comes. Given that e¡ective preventative measures
and screening tools are presently lacking, routine
nursing assessments of the signs/symptoms indica-
tive of preeclampsia-eclampsia remains critical
to the detection, monitoring, and e¡ective manage-
ment of preeclampsia-eclampsia. Nurse-led patient
education and the provision of a supportive
environment are also essential to the optimal
management of preeclampsia-eclampsia. Active
participation in one’s care can be promoted
through nurse-led education related to self-moni-
toring of fetal activity and maternal symptoms (e.g.,
headaches, blurred vision, epigastric pain). Fur-
thermore, review of the rationale behind all tests
(e.g., laboratory analysis, nonstress test) and treat-
ments (e.g., magnesium sulfate, antihypertensive)
keeps patients informed and may help to alleviate
stress and anxiety during an emotionally and phys-
ically trying time. Ultimately, individually tailored
and compassionate nursing care of women with
preeclampsia-eclampsia will serve to enhance the
well-being of mother and baby.
Acknowledgment
Funded by National Institute of Nursing Research
grantsT32NR009759 and 1F31NR011379.
REFERENCES
American College of Obstetricians and Gynecologists. (2002). ACOG
practice bulletin: Diagnosis and management of preeclampsia
and eclampsia. Number 33, January 2002. Obstetrics and Gyne-
cology, 99(1),159-167.
Brosens, I., Robertson, W. B., & Dixon, H. G. (1967). The physiological re-
sponse of the vessels of the placental bed to normal pregnancy.
Journal of Pathology and Bacteriology, 93(2), 569-579.
Brosens, I. A., Robertson,W. B., & Dixon, H. G. (1972). The role of the spiral
arteries in the pathogenesis of preeclampsia. Obstetrics and Gy-
necology Annual, 1,177-191.
Burton, J. L. (Ed.). (2005) ‘Six hundred miseries’: The seventeenth century
womb. In Riviere, L. (1678). Book 15 of ‘The Practice of Physick’ (N.
Culpeper,Trans.). London, U.K. (Original work published 1655).
Caniggia, I., Taylor, C. V., Ritchie, J.W., Lye, S. J., & Letarte, M. (1997). Endo-
glin regulates trophoblast di¡erentiation along the invasive path-
way in human placental villous explants. Endocrinology, 138(11),
4977-4988.
Preeclampsia is currently classified as a
pregnancy-specific syndrome characterized by new-onset
hypertension in a previously normotensive woman after
20 weeks gestation with proteinuria.
JOGNN 2010; Vol. 39, Issue 5 517
Bell, M. J. P R I N C I P L E S & P R A C T I C E
Chesley, L. C. (1978). Hypertensive disorders in pregnancy. New York, NY:
Appleton-Century-Crofts.
Chesley, L. C. (1984). History and epidemiology of preeclampsia-eclamp-
sia.Clinical Obstetrics and Gynecology, 27(4), 801-820.
Cianfrani,T. (1960). A short history of obstetrics and gynecology. Spring-
¢eld, IL: Thomas Books.
Demand, N. (1994). Birth, death, and motherhood in classical Greece.
Baltimore, MD: The John Hopkins University Press.
Denman,T. (1821). Introduction to the practice of midwifery. NewYork, NY:
E. Bliss & E.White.
Eastman, N. J., & Hellman, L. M. (1966).Williams obstetrics (13th ed.). New
York, NY: Meredith Publishing Company.
Friedlander, W. J. (2001). The history of modern epilepsy: The beginning,
1865-1914.Westport, CT: Greenwood Press.
Gabbe, S. G. (1996). A preliminary report on the intravenous use of mag-
nesium sulphate in puerperal eclampsia. 1925. American Journal
of Obstetrics and Gynecology, 174(4),1390-1391.
Gerretsen, G., Huisjes, H. J., & Elema, J. D. (1981). Morphological changes
of the spiral arteries in the placental bed in relation to pre-eclamp-
sia and fetal growth retardation. British Journal of Obstetrics and
Gynaecology, 88(9), 876-881.
Graham, H. (1951). Eternal eve: The history of gynecology & obstetrics.
Garden City, NY: Doubleday & Company Inc.
Green, M. H. (1985). The transmission of ancient theories of
female physiology and disease through the early Middle Ages
(Unpublished doctoral dissertation). Princeton University, Prince-
ton, NJ.
Hibbard, B. M. (1988). Principles of obstetrics. Boston: Butterworths.
Hippocrates. (1950). The medical works of Hippocrates ((J. Chadwick &
W. N. Mann, Trans.). Oxford, U.K.: Blackwell Scienti¢c Publications.
(Original work published 5th century B.C.).
Hladunewich, M., Karumanchi, S. A., & Lafayette, R. (2007). Pathophysiol-
ogy of the clinical manifestations of preeclampsia.Clinical Journal
of the American Society of Nephrology, 2, 543-549. doi:10.2215/
CJN.03761106.
Jerkic, M., Rivas-Elena, J. V., Prieto, M., Carron, R., Sanz-Rodriguez, F., Per-
ez-Barriocanal, F., et al. (2004). Endoglin regulates nitric oxide-
dependent vasodilatation. FASEB Journal, 18(3), 609-611. doi:10.
1096/fj.03-0197fje.
Johns, R. (1843). Observations of puerperal convulsions. Dublin Journal
of Medical Science, 24(1),101-115.
Kong, T. Y., De Wolf, F., Robertson, W. B., & Brosens, I. (1986). Inadequate
maternal vascular response to placentation in pregnancies com-
plicated by pre-eclampsia and by small-for-gestational age
infants. British Journal of Obstetrics and Gynaecology, 93(10),
1049-1059.
Leeman, L., & Fontaine, P. (2008). Hypertensive disorders of pregnancy.
American Family Physician, 78(1), 93-100.
Lueck, J., Brewer, J. I., Aladjem, S., & Novotny, M. (1983). Observation of an
organism found in patients with trophoblastic disease and in pa-
tients with toxemia of pregnancy. American Journal of Obstetrics
and Gynecology, 145(1),15-26.
Mauriceau, F. (1710). The diseases of women with child, and in childbed:
As also, the best means of helping them in natural and
unnatural labours . . . To which is pre¢x’d an exact description of
the parts of generation in women . . . The fourth edition
corrected, and augmented with several new ¢gures
(H. Chamberlen, Trans.). London, U.K. (Original work published
1668). Retrieved from http://¢nd.galegroup.com/ecco/infomark.
do?&contentSet=ECCOArticles&type=multipage&tabID=T001&pro
dId=ECCO&docId=CW3309817161&source=gale&userGroup
Name=upitt_main&version=1.0&docLevel=FASCIMILE
McMillen, S. (2003). Eclampsia. In K. F. Kiple (Ed.),The Cambridge histori-
cal dictionary of disease (pp. 110-112). New York, NY: Cambridge
University Press.
National Heart, Lung, and Blood Institute National High Blood Pressure
Education Program. (2000). Report of the national high blood
pressure education program working group on high blood pres-
sure in pregnancy. American Journal of Obstetrics and
Gynecology, 183(1), S1-S22. doi:10.1067/mob.2000.107928.
Norwitz, E. R., & Repke, J. T. (2009). Management of preeclampsia. In V. A.
Barass (Ed.),UpToDate.Waltham, MA: UpToDate.
Ong, S. (2004). Pre-eclampsia: A historical perspective. In P. N. Baker & J.
C. P. Kingdom (Eds.), Pre-eclampsia: Current perspectives on
management (pp. 15-24). New York, NY: Parthenon Publishing
Group.
Papoutsis, D. V., Irwin, R. L., Curry, J. J., & Zuspan, F. P. (1983). Parasitic eti-
ology for preeclampsia: Fact or artifact? American Journal of
Obstetrics and Gynecology, 147(8), 977-979.
Pritchard, J. A., & MacDonald, P. C. (1976).Williams obstetrics (15th ed.).
New York, NY: Appleton-Century-Crofts.
Roberts, J. M., & Gammill, H. S. (2005). Preeclampsia: Recent insights.
Hypertension, 46, 1243-1249. doi:10.1161/01.HYP.0000188408.
49896.e5.
Roberts, J. M., & Hubel, C. A. (2009). The two stage model of preeclamp-
sia: Variations on the theme. Placenta, 23, S32-S37. doi:10.1016/j.
placenta.2008.11.009.
Roberts, J. M., Taylor, R. N., Musci, T. J., Rodgers, G. M., Hubel, C. A., &
McLaughlin, M. K. (1989). Preeclampsia: An endothelial cell disor-
der. American Journal of Obstetrics and Gynecology, 161(5),1200-
1204.
Sibai, B. M., & Spinnato, J. A. (1983). Hydatoxi lualba: Artifact produced by
sulfation. American Journal of Obstetrics and Gynecology, 147(7),
854.
Sinclair, E. B., & Johnston, G. (1858). Practical midwifery: Comprising an
account of 13,748 deliveries which occurred in the Dublin lying-in
hospital, during a period of seven years, commencing November,
1847. Dublin, Ireland: The University Press.
Smith, W. T. (1849). Parturition and the principles and practice of obstet-
rics. Philadelphia, PA: Lea & Blanchard.
Speert, H. (1958). Obstetric and gynecologic milestones: Essays in epo-
nymy. New York, NY: Macmillan Company.
Temkin, O. (1971). The falling sickness: A history of epilepsy from the
Greeks to the beginnings of modern neurology (Rev. ed.). Balti-
more, MD: The Johns Hopkins Press.
Thomas, H. (1935).Classical contributions to obstetrics and gynecology.
Baltimore, MD: Charles C. Thomas.
Thompson, L. (1999). The wondering womb: A cultural history of outra-
geous beliefs about women. Amherst, NY: Prometheus Books..
Toporsian, M., Gros, R., Kabir, M. G., Vera, S., Govindaraju, K., Eidelman, D.
H., et al. (2005). A role for endoglin in coupling eNOS activity and
regulating vascular tone revealed in hereditary hemorrhagic tel-
angiectasia. Circulation Research, 96(6), 684-692. doi:10.1161/01.
RES.0000159936.38601.22.
Trotula of Salerno. (1940).The diseases of women (E. Mason-Hohl,Trans.).
Los Angeles, California: Ward Ritchie Press. (Original work pub-
lished 1544).
Veith, I. (1965).Hysteria: The history of a disease. Chicago, IL: University of
Chicago Press.
518 JOGNN, 39, 510-518; 2010. DOI: 10.1111/j.1552-6909.2010.01172.x http://jognn.awhonn.org
P R I N C I P L E S & P R A C T I C E Overview of Preeclampsia-Eclampsia
123 
 
APPENDIX C 
LICENSE AGREEMENT FOR MANUSCRIPT #1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




128 
 
APPENDIX D 
MANUSCRIPT #2: A SYSTEMATIC REVIEW OF ENDOGLIN GENE EXPRESSION 
IN PREECLAMPSIA 
Citation per SAGE publications:  
Bell, M. J. & Conley, Y. P. (2011). A systematic review of endoglin gene expression in 
preeclampsia.  Biological Research for Nursing. Advance online publication. doi: 
10.1177/1099800411420133. 
 
 
 
 
 
 
 
 
 
 
 
 
 http://brn.sagepub.com/
Biological Research For Nursing
 http://brn.sagepub.com/content/early/2011/09/10/1099800411420133
The online version of this article can be found at:
 
DOI: 10.1177/1099800411420133
 published online 15 September 2011Biol Res Nurs
Mandy J. Bell and Yvette P. Conley
A Systematic Review of Endoglin Gene Expression in Preeclampsia
 
 
Published by:
 http://www.sagepublications.com
 can be found at:Biological Research For NursingAdditional services and information for 
 
 
 
 
 
 http://brn.sagepub.com/cgi/alertsEmail Alerts: 
 
 http://brn.sagepub.com/subscriptionsSubscriptions:  
 http://www.sagepub.com/journalsReprints.navReprints: 
 
 http://www.sagepub.com/journalsPermissions.navPermissions: 
 
 What is This?
 
- Sep 15, 2011 OnlineFirst Version of Record>> 
 at UNIV OF PITTSBURGH on April 17, 2012brn.sagepub.comDownloaded from 
A Systematic Review of Endoglin Gene
Expression in Preeclampsia
Mandy J. Bell, BSN, RN1 and Yvette P. Conley, PhD1
Abstract
Objective: To synthesize scientific literature that addresses the role of endoglin (ENG) gene expression in preeclampsia (PE). Data
sources: A literature search of PubMed and Ovid MEDLINE was conducted using the keywords endoglin, gene, and preeclampsia.
Restrictions included English language and humans. Additional articles were identified/selected for evaluation via PubMed e-mail
updates (keywords: endoglin and preeclampsia) and review of article reference lists obtained from the search. Study selection: The
initial 14 abstracts retrieved from the literature search were reviewed and 9 studies were selected for evaluation. Review articles
and studies not addressing ENG expression (messenger RNA [mRNA] level) in the context of PE were excluded. An additional six
articles were selected from PubMed e-mail updates and reference lists. Data extraction: Data related to study objective, design,
setting, subject information, phenotype, tissue type, data collection method, statistics, and results were extracted. Data synthesis:
Regardless of PE definition, ancestral background, gene expression analysis method, tissue type, and time of specimen collection,
endoglin appears to play a role in PE development. Moreover, results suggest that a variety of biological mechanisms have
the ability to modulate ENG expression in PE, demonstrating the potential complexity associated with endoglin’s role in PE.
Conclusions: This review article is the first to systematically synthesize evidence related to ENG expression in PE. Findings can
be utilized to design future studies that (a) address methodological limitations observed in the reviewed studies and (b) specifically
examine why ENG expression levels are altered and address mechanisms explaining how these alterations are involved in PE
development.
Keywords
preeclampsia, endoglin, gene
Preeclampsia (PE) is a hypertensive, multisystem disorder of
pregnancy that significantly impacts maternal and fetal/neona-
tal health (National Heart, Lung, and Blood Institute [NHLBI]
National High Blood Pressure Education Program, 2000).
Classified as new-onset hypertension and proteinuria after
20 weeks’ gestation in a previously normotensive woman, PE
complicates 3–5% of pregnancies (Roberts & Cooper, 2001)
and is estimated to cost the United States $7 billion annually
(Preeclampsia Foundation, 2000–2010). Although it is believed
that PE development involves (a) reduced placental perfusion
secondary to abnormal placentation and (b) the maternal
syndrome characterized by systemic endothelial dysfunction
(Roberts & Hubel, 2009), the factors/mechanisms responsible
for these aberrations remain unknown. Several investigations,
however, have identified endoglin as a potential factor in the
genesis of PE.
Endoglin (ENG) gene, which is expressed on syncytiotro-
phoblasts and transitioning cytotrophoblast cells of the placenta
(St-Jacques, Forte, Lye, & Letarte, 1994), has been shown to
participate in the regulation of placental trophoblast differentia-
tion and invasion of the uterus during pregnancy (Caniggia,
Taylor, Ritchie, Lye, & Letarte, 1997). In PE, shallow tropho-
blast invasion of the maternal spiral arteries restricts conversion
of these arteries from small muscular vessels to large
low-resistance vessels via the replacement of smooth muscle
with fibrous tissue within the vessel wall. Without a sufficient
physiologic conversion, limited lumen diameter and distensibil-
ity of the spiral arteries subsequently leads to the reduction in
placental and fetal perfusion that is observed in PE (Brosens,
Robertson, & Dixon, 1972; Zhou, Damsky, & Fisher, 1997).
Conceptually, this process is referred to as Stage 1 in the
two-stage model of PE (Roberts & Hubel, 2009). Therefore,
an alteration inENG function during placental implantationmay
contribute to PE pathogenesis.
ENG is also expressed on vascular endothelial cells (Gougos
& Letarte, 1990) and is involved in the maintenance of vascular
tone through the regulation of nitric oxide–dependent vasodila-
tion (Jerkic et al., 2004; Toporsian et al., 2005). In PE, in addi-
tion to abnormal implantation, vascular endothelial function,
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including vasorelaxation and cell membrane permeability, is
disrupted (American College of Obstetricians and Gynecolo-
gists [ACOG], 2002). Conceptually, this is referred to as Stage
2 in the two-stage model of PE and is associated with reduced
organ perfusion, hypertension, proteinuria, and intravascular
fluid loss (Roberts & Gammill, 2005; Roberts & Hubel,
2009). Therefore, an alteration in ENG function in the vascula-
ture may contribute to PE pathogenesis.
Given the biologic plausibility of a role for ENG in PE
pathogenesis, a plethora of research reports addressing ENG’s
involvement in the disorder has recently inundated the scien-
tific literature. Despite the sizable amount of evidence being
generated, which has primarily targeted ENG protein levels
in PE, critical review and synthesis of the scientific literature
addressing ENG messenger RNA (mRNA) expression in
PE is lacking. We thus conducted this systematic review to
critique/synthesize scientific literature that addresses the role
of ENG expression in PE.
Data Collection Method
We used the PubMed and Ovid (MEDLINE) databases to iden-
tify articles addressing the role of ENG in PE from a human
gene expression standpoint. The keywords we used were pree-
clampsia, endoglin, and gene. In PubMed, we combined all
three keywords with the AND Boolean operator. Due to
differences in MeSH terms across the databases, we used the
following combination of keywords to retrieve articles in OVID
(Medline): endoglinAND (geneOR genes) AND (preeclampsia
OR pre-eclampsia). We limited the literature search, which
covered literature through January 2011, to theEnglish language
and articles involving human research.
After completing the literature search, we reviewed
abstracts of retrieved articles for relevance, excluding review
articles, duplicate articles, and articles not addressing ENG
expression in the context of PE. We also reviewed weekly
PubMed e-mail updates related to endoglin and PE, along with
reference lists of selected articles, to identify additional
articles. After independent review, we met to discuss findings
and synthesize results. We extracted from each study data
related to study objective, design/approach, setting, subject
information, phenotype, tissue type, data collection methods,
statistics, and results and summarized them in tabular format.
Results
We selected 9 of the14 articles we identified from the initial
literature search for inclusion. Of the excluded articles, 1 was
a review article, 1 addressed ENG expression at the DNA level
in PE, and 3 addressed ENG expression outside the context of
PE. We also selected for inclusion of six additional articles that
we identified from reference lists or PubMed e-mail updates.
Table 1 includes a summary of the results and characteristics
of the articles comparing ENG expression in human subjects
with PE to a control group/groups. Table 2 includes a summary
of the results and characteristics of the articles utilizing gene
expression methods to investigate mechanisms that may
explain the role of ENG in PE.
Discussion
Establishing a Role for ENG in PE via Gene Expression
Studies
We conducted this systematic review in order to critique and
synthesize scientific literature that addresses the role of ENG
in PE from a human gene expression standpoint. In reviewing
the 11 studies that compared gene expression levels of ENG
between women with and without PE, we consistently found
ENG expression to be significantly elevated in women
with PE regardless of definition of PE, ancestral background,
methods for gene expression analysis, tissue type, or time of
specimen collection (Table 1). Four of these studies (Purwosunu
et al., 2008; Purwosunu, Sekizawa, Okazaki, et al., 2009;
Purwosunu, Sekizawa, Yoshimura, et al., 2009; Sekizawa
et al., 2010), however, may represent one parent study instead
of independent replicates. Although the number of independent
studies would be reduced to eight, the support for ENG’s
involvement in PE remains strong.
Moreover, ENG expression was elevated throughout all
three trimesters of pregnancy in women who developed PE,
suggesting that ENG’s role in PE is initiated early in pregnancy
and sustained through delivery. Both first- and third-trimester
placental samples of women who developed PE had signifi-
cantly elevated levels of ENG expression (Farina et al., 2008;
Nishizawa et al., 2007; Sitras et al., 2009; Toft et al., 2008;
Venkatesha et al., 2006). Furthermore, the cellular and
cellular-free (plasma) components of blood in women who
developed PE had significantly elevated levels of ENG expres-
sion near the end of the first trimester and in the second and third
trimesters (Farina et al., 2010; Purwosunu et al., 2008; Purwo-
sunu, Sekizawa, Okazaki, et al., 2009; Purwosunu, Sekizawa,
Yoshimura, et al., 2009; Sekizawa et al., 2010).
Further research isneeded tounderstandwhyexpression levels
are altered and how these alterations are involved in the develop-
ment of PE. Two approaches that may provide insight into why
ENG expression is altered in PE are evaluating ENG at the mole-
cular level (DNA) and exploring it from an epigenetic point of
view. In the only study like it to date, Srinivas,Morrison,Andrela,
andElovitz (2010) examined the association betweenPEandalle-
lic variation in an angiogenic pathway among Black (N ¼ 184
cases andN¼ 305 controls) andWhite subjects (N¼ 32 cases and
N ¼ 85 controls) separately. Using the previously developed
ITMAT-Broad-CARe, version 2 (IBCv2) array, they evaluated
124 tagging single nucleotide polymorphisms (SNPs) across the
six candidate genes (vascular endothelial growth factor A, B, and
C; fms-like tyrosinekinase1 and 4; endoglin). Investigators failed
to demonstrate a significant association between variation in
ENG and PE; however, it is unclear if they fully evaluated the
entire ENG. Further research examining the association between
PE and allelic variation across the entire ENG in larger samples is
needed.
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Mechanisms Explaining the Role of ENG via Gene
Expression Studies
Using gene expression as a tool, research has identified poten-
tial mechanisms that may help to explain ENG’s role in PE
(Table 2). In the reviewed studies investigating mechanisms
that may explain ENG’s role in PE, investigators identified the
liver X receptor and the STOX1 transcription factor as poten-
tial regulators of ENG expression. Given that liver X receptors
and ENG have been shown to be involved in placental implan-
tation (Caniggia et al., 1997; Pavan et al., 2004), it is possible
that the abnormal implantation observed in PE could be attrib-
uted to altered regulation of ENG by liver X receptor. STOX1
may also be involved in PE despite inconsistent results
(Rigourd et al., 2008). Given that ENG expression is elevated
in PE (Table 1) and that overexpression of STOX1 in a chorio-
carcinoma cell line (Table 2) leads to the induction of ENG
expression (Rigourd et al.), it is plausible that STOX1 is
involved in the development of PE and may epistatically con-
tribute to ENG’s role in PE.
The two remaining studies investigated the effect of hypoxia
on ENG expression. Although one group of investigators did
not find hypoxia to modulate ENG expression in first-
trimester placental villous explants after 48 hr of incubation
(Munaut et al., 2008), another group found hypoxia to signifi-
cantly increase ENG expression in BeWo cells (choriocarci-
noma cell line) after 4 and 6 hr of incubation (Fujita et al.,
2010). These disparate results may be due to the different types
of cells used to assess hypoxia’s impact on ENG. Furthermore,
results by Fujita et al. (2010) suggest that 3-kinase-AKT-
MTOR-HIF-1a and ERK-HIF-1a signaling pathways influence
ENG expression under hypoxic conditions.
Limitations of Studies Comparing ENG Expression in
Subjects With PE Versus Control Group/Groups
Despite consistent findings, we did note limitations across stud-
ies and within individual studies that may impact the validity
and overall interpretation of the gene expression results. One
limitation that we found in all 11 studies is that they were cross
sectional in nature. Although the studies demonstrated that
ENG expression levels were elevated in all three trimesters
of pregnancy cross-sectionally, studies utilizing a prospective,
longitudinal approach have the ability to observe changes in
gene expression across pregnancy in the same subjects. Ulti-
mately, such information could provide further insight into
ENG’s role in PE throughout pregnancy. However, one must
consider that, although the longitudinal assessment of gene
expression from the blood is feasible, longitudinal assessment
of placental gene expression is neither feasible nor ethical
(e.g., second-trimester biopsies of pregnant women).
The variability in PE phenotype along with the variability in
inclusion/exclusion criteria utilized to classify cases and con-
trols among the reviewed studies represents another limitation
that impacts the ability to compare results across studies. Such
a limitation further hampers the ability to combine studies for
the purpose of conducting a meta-analysis, which can be
employed to estimate effect sizes.
Other noted limitations across studies were related to meth-
ods used to evaluate gene expression. Authors frequently failed
to report the following steps involved in gene expression anal-
ysis: (a) performance of RNA quality/quantity control checks
on extracted RNA prior to gene expression analysis, (b) use
of an RNA stabilizer to prevent RNA degradation in the tissue
until extraction and gene expression analysis, and (c) use of an
endogenous control when conducting real-time quantitative
reverse transcriptase–polymerase chain reaction (qRT-PCR).
Although these limitations may reflect editing to meet journal
page constraints, they may also represent methodological flaws
that could cause the validity of the findings to be in question.
Like the limitations noted across studies, limitations unique
to several individual studies may also impact validity and gen-
eralization of results. In the study by Sitras et al. (2009), we
noted two limitations that have the potential to impact placental
gene expression. First, gestational age at delivery (sample col-
lection) was significantly earlier in cases compared to controls.
Tsai et al. (2011) also noted this limitation; however, more in-
depth analysis by this group indicated that estimated gesta-
tional age had minimal independent contribution to their gene
expression data. Ultimately, the magnitude of observed differ-
ences in ENGmRNA expression of the placenta may have been
impacted by differences related to developmental stage of preg-
nancy. Although this issue may be mitigated through the
matching of healthy controls to cases for gestational age at
delivery, one must consider if a control who delivers preterm
truly represents a ‘‘healthy’’ control. Second, the study sample
included subjects who delivered via cesarean section prior to
labor onset and those who delivered vaginally. Because placen-
tal gene expression profiles may differ between laboring and
nonlaboring women, differences related to labor may influence
study results. Such limitations deserve consideration when
researchers are designing studies that evaluate relationships
between gene expression and disease/health outcomes.
In the study by Toft et al. (2008), the absence of a normoten-
sive control group and the use of a small sample size to conduct
targeted gene analysis via qRT-PCR represent potential limita-
tions. If the investigators had included a normotensive control
group, it would be possible to compare differences in ENG
expression between those with PE and those with an uncompli-
cated pregnancy within the study and across similar studies.
As for the issue related to small sample size, significant results
could ultimately indicate false-positive findings as opposed to
large effect sizes.
Limitations of Studies Investigating Mechanisms That
May Explain the Role of ENG in PE
We also noted several limitations in the studies investigating
mechanisms that may explain the role of ENG in PE. In the
study by Munaut et al. (2008), hypoxia did not modulate ENG
expression in first-trimester placental villi culture explants.
However, unlike the other candidate genes under study, authors
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did not report the effects of hypoxia on ENG expression in
human umbilical vein endothelial cells and immortalized
first-trimester extravillous trophoblast. It is unclear if the
authors simply omitted these results from the report or if they
did not study the effects of hypoxia on ENG expression in these
cell types. Because ENG is expressed on trophoblast and
vascular endothelial cells, study of its expression in these cell
types would have provided additional insight into hypoxia’s
effect on ENG’s role in PE.
The use of cell lines to conduct research concerning biolo-
gical processes in humans represents an additional limitation
of the mechanistic studies reviewed. Although the choriocarci-
noma cell lines utilized by Fujita et al. (2010), Henry-Berger
et al. (2008), and Rigourd et al. (2008) were human in origin,
the representativeness of an immortal cell line as ‘‘normal’’
decreases and the risk of genetic abnormalities increases with
each cell passage. As a result, study findings may not accu-
rately represent biological activities that are occurring in vivo.
Conclusion
PE represents a multisystem, hypertensive disorder of preg-
nancy that significantly contributes to maternal and fetal/neo-
natal morbidity and mortality worldwide. At present, the
etiology of PE remains unknown, but gene expression studies
included in this systematic review support ENG’s involvement
in the development of PE. Despite the methodological limita-
tions in these studies, ENG expression was consistently
elevated in women with PE. In addition, these studies showed
that ENG’s role in PE may be explained by several mechanisms
that may represent a variety of biological functions.
Investigators can utilize the findings of this review to design
future studies examining ENG’s role in PE. First, research
addressing methodological limitations found in the gene
expression studies is needed to validate previous findings.
Steps to mitigate such limitations include conducting and
reporting RNA quality/quantity control checks, using RNA
stabilizers to optimize RNA integrity of samples, using and
reporting endogenous controls when appropriate, and collect-
ing tissues of interest at comparable times (e.g., similar gesta-
tional age) between groups. Second, research that examines
why ENG expression levels are altered and how these altera-
tions are involved in PE development is needed. Ultimately,
such studies have the potential to increase overall understanding
of PE and to solve PE’s etiologic puzzle, which may include
ENG as one of its pieces.
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